

19.09.2020

11:15 - 12:15 **Type: Opening ceremony** **Channel 1**
Title: ESMO Virtual Congress 2020 Opening ceremony

11:15 - 11:28 **Welcome to the ESMO Virtual Congress 2020**

11:28 - 11:48 **COVID-19: Public health and scientific challenges**
A. Fauci, NIH - National Institutes of Health, Bethesda, US

11:48 - 11:55 **Highlights of the Science weekend**
J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

11:55 - 12:15 **How T cells induce cancer regressions**
A. Ribas, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

12:30 - 14:10 **Type: Proffered Paper session** **Channel 1**
Title: Proffered Paper - Non-metastatic NSCLC and other thoracic malignancies

Chair(s): Lyudmila Bazhenova, US

12:30 - 12:42 **12140 - Neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC): Preliminary results from a multicenter study (IFCT-1601 IONESCO)**
M. Wislez¹, J. Mazieres², A. Lavole¹, G. Zalcman³, O. Carre⁴, T. Egenod⁵, R. Caliandro⁶, R. Gervais⁷, G. Jeannin⁸, O. Molinier⁹, M.A. Massiani¹⁰, A. Langlais¹¹, F. Morin¹², F. Le Pimpec Barthes¹³, L. Brouchet², J. Assouad¹⁴, B. Milleron¹², D. Damotte¹⁵, M. Antoine¹, V. Westeel¹⁶, ¹Hopital Tenon, Paris, FR, ²CHU Toulouse - Hôpital Larrey, Toulouse, FR, ³Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Université Paris-Diderot, Paris, FR, ⁴Clinique de l'Europe Amiens, Amiens, FR, ⁵CHU Limoges - Hopital Dupuytren, Limoges, FR, ⁶Institut Mutualiste Montsouris, Paris, FR, ⁷Centre Francois Baclesse, Caen, FR, ⁸Centre Jean Perrin, Clermont-Ferrand, FR, ⁹Centre Hospitalier Du Mans, Le Mans, FR, ¹⁰Hopital René Huguenin - Institut Curie, Saint-Cloud, FR, ¹¹IFCT, Paris, FR, ¹²French Cooperative Thoracic Intergroup, Paris, FR, ¹³Hôpital Européen George Pompidou, Paris, FR, ¹⁴Hôpital Tenon, Paris, FR, ¹⁵Université Paris Descartes, Paris, FR, ¹⁶CHRU Besançon - Hopital Jean Minjoz, Besançon, FR

12:42 - 12:54 **12150 - Neoadjuvant atezolizumab (A) for resectable non-small cell lung cancer (NSCLC): results from the phase II PRINCEPS trial.**
B. Besse¹, J. Adam¹, N. Cozic², N. Chaput-Gras¹, D. Planchard¹, L. Mezquita³, J. Remon Masip⁴, P. Lavaud¹, C. Naltet¹, A. Gazzah¹, V. Thomas De Montpreville⁵, M.-R. Ghigna⁵, S. Mussot⁵, E. Fadel⁶, L. Mabille⁵, B. Duchemann⁷, F. Barlesi², J.-C. Soria¹, C. Caramella¹, O. Mercier⁶, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁴CIOCC- Centro Integral Oncológico Clara Campal, Barcelona, ES, ⁵Hospital Marie Lannelongue, Le Plessis Robinson, FR, ⁶Centre Chirurgical Marie Lannelongue, Le

Plessis-Robinson, FR, ⁷Hôpital Avicenne, Bobigny, FR

12:54 - 13:04 **Invited Discussant 12140 and 12150**

L. Bazhenova, Moores Cancer Center - UC San Diego Health, La Jolla, US

13:04 - 13:14 **Q&A and live discussion**

13:14 - 13:26 **LBA84 - Consolidation ipilimumab and nivolumab vs observation in limited stage SCLC after chemo-radiotherapy - results from the ETOP/IFCT 4-12 STIMULI trial**

S. Peters¹, J.-L. Pujol², U. Dafni³, M. Dómine⁴, A. Becker⁵, J. Andrade⁶, A. Curioni-Fontecedro⁷, O. Molinier⁸, D. Moro-Sibilot⁹, K. Nackaerts¹⁰, A. Insa Mollá¹¹, G. López Vivanco¹², J. Madelaine¹³, S. Popat¹⁴, M. Reck¹⁵, H. Roschitzki-Voser¹⁶, P. Mitchell¹⁷, D. De Ruyscher¹⁸, C. Le Pechoux¹⁹, R. Stahel⁷, ¹Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ²Hopital Arnaud de Villeneuve, Montpellier, FR, ³University of Athens, Athens, GR, ⁴Hospital Universitario Fundacion Jimenez Díaz, Madrid, ES, ⁵Amsterdam University Medical Center, Amsterdam, NL, ⁶Hospital Virgen De La Salud, Toledo, ES, ⁷University Hospital Zürich, Zürich, CH, ⁸Centre Hospitalier Du Mans, Le Mans, FR, ⁹CHU Grenoble-Alpes, Grenoble, FR, ¹⁰KU Leuven, Leuven, BE, ¹¹Hospital Clínico Universitario De Valencia, Valencia, ES, ¹²Hospital Universitario Cruces, Barakaldo,, ES, ¹³Centre Hospitalier Caen, Caen, FR, ¹⁴The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ¹⁵Krankenhaus Grosshansdorf, Grosshansdorf, DE, ¹⁶ETOP - European Thoracic Oncology Platform, Bern, CH, ¹⁷Austin Hospital (VIC), Melbourne, AU, ¹⁸Maastro Clinic, Maastricht, NL, ¹⁹Institut Gustave Roussy, Villejuif, FR

13:26 - 13:38 **17830 - Patient reported outcomes from a randomized phase II trial comparing standard-dose with high-dose twice daily (BID) thoracic radiotherapy (TRT) in limited stage small cell lung cancer (LS SCLC)**

B. Gronberg¹, K. Killingberg², K. Stokke³, T. Halvorsen¹, ¹NTNU - Norwegian University of Science and Technology, Trondheim, NO, ²Norwegian University of Science and Technology, Trondheim, NO, ³NTNU-Norwegian University of Science and Technology, Trondheim, NO

13:38 - 13:48 **Invited Discussant LBA84 and 17830**

C. Faivre-Finn, The Christie NHS Foundation Trust, Manchester, GB

13:48 - 13:58 **Q&A and live discussion**

12:30 - 14:10 Type: Proffered Paper session Channel 2
Title: Proffered Paper - Gynaecological cancers 1
Chair(s): Domenica Lorusso, IT; Andreas du Bois, DE

12:30 - 12:42 **LBA28 - A randomised double-blind placebo-controlled phase II trial of palbociclib combined with letrozole (L) in patients (pts) with oestrogen receptor-positive (ER+) advanced/recurrent endometrial cancer (EC): NSGO-PALEO / ENGOT-EN3 trial.**

M.R. Mirza¹, L. Bjørge², F. Marmé³, R. Depont Christensen⁴, M. Gil-Martin⁵, A. Auranen⁶, B. Ataseven⁷, M.J. Rubio⁸, V. Salutati⁹, B. Lund¹⁰, I. Runnebaum¹¹, A. Redondo¹², K. Lindemann¹³, F. Trillsch¹⁴, M.P. Barretina Ginesta¹⁵, H. Roed¹⁶, J. Løhndorf¹⁷, G.-B. Nyvang¹⁸, J. Sehouli¹⁹, ¹Copenhagen University Hospital - Rigshospitalet, Copenhagen, DK, ²Nordic Society of Gynaecological Oncology (NSGO-CTU) and Haukeland University Hospital and Center of Biomarkers CCBio, University of Bergen, Norway, Bergen, NO, ³UMM - Universitätsklinikum Mannheim - Medizinische Fakultät, Mannheim, DE, ⁴Nordic Society of Gynaecological Oncology (NSGO-CTU) and Institute of Public Health, University of Southern Denmark, Odense, DK, ⁵GEICO & Institut Català d'Oncologia-IDIBELL, L'Hospitalet-Barcelona, Spain, barcelona, ES, ⁶Tampere University Hospital (Tays), Tampere, FI, ⁷Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ⁸University Hospital Reina Sofia, Cordoba, ES, ⁹Policlinico Universitario A. Gemelli, Rome, IT, ¹⁰Nordic Society of Gynaecological Oncology (NSGO-CTU) and Aalborg university hospital, Aalborg, DK, ¹¹Klinik für Frauenheilkunde und Fortpflanzungsmedizin, 07747, DE, ¹²Hospital Universitario La Paz, Madrid, ES, ¹³Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO, ¹⁴Klinikum der Universität München, Munich, DE, ¹⁵ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta Hospital Universitari Josep Trueta), Girona, ES, ¹⁶Rigshospitalet, Copenhagen, DK, ¹⁷Nordic Society of Gynaecological Oncology - Rigshospitalet, Copenhagen, DK, ¹⁸NSGO-CTU & Odense University Hospital, Odense, DK, ¹⁹Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE

12:42 - 12:54

8060 - Radical hysterectomy in cervical cancer patients with intraoperatively detected positive lymph node: ABRAX multicentric retrospective cohort study (ENGOT-Cx3/CEGOG CX2)

D. Cibula¹, L. Dostalek², P. Hillemanns³, G. Scambia⁴, J. Persson⁵, F. Raspagliesi⁶, Z. Novak⁷, A. Jaeger⁸, M. Capilna⁹, V. Weinberger¹⁰, J. Klat¹¹, R. Schmidt¹², A. Lopez¹³, G. Scibilia¹⁴, R. Pareja¹⁵, A. Kucukmetin¹⁶, L. Kreitner¹⁷, A. El-Balat¹⁸, S. Laufhütte¹⁹, I. Runnenbaum²⁰, ¹Charles University First Faculty of Medicine, Prague, CZ, ²First Faculty of Medicine, Charles University and General University Hospital, Prague, CZ, ³Medizinische Hochschule Hannover, Hannover, DE, ⁴Policlinico Universitario A. Gemelli, Roma, IT, ⁵Skane University Hospital, Lund, SE, ⁶Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁷National Institute of Oncology, Budapest, HU, ⁸UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁹University of Medicine and Pharmacy Targu Mures, Targu Mures, RO, ¹⁰Faculty of Medicine, Masaryk University, Brno, CZ, ¹¹University Hospital Ostrava, Ostrava Poruba, CZ, ¹²Barretos Cancer Hospital, Barretos, BR, ¹³National Institute of Neoplastic Diseases, Lima, PE, ¹⁴Cannizzaro Hospital, Catania, IT, ¹⁵INC - Instituto Nacional de Cancerologia - ESE, Bogota, CO, ¹⁶Queen Elizabeth Hospital, Gateshead, GB, ¹⁷St. Franziskus Hospital Münster, Münster, DE, ¹⁸Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ¹⁹District Hospital Altötting, Altötting, DE, ²⁰Jena University Hospital, Friedrich Schiller University, Jena, DE

12:54 - 13:04

Invited Discussant LBA28 and 8060

D. Lorusso, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT

13:04 - 13:14

Q&A and live discussion

- 13:14 - 13:26 **LBA29 - Individualized Starting Dose of Niraparib in Chinese Patients with Platinum-Sensitive Recurrent Ovarian Cancer (PSROC): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial (NORA)**
- X. Wu¹, J. Zhu², R. Yin³, J. Yang⁴, J. Liu⁵, J. Wang⁶, L. Wu⁷, Z. Liu⁸, Y. Gao⁹, D. Wang¹⁰, G. Lou¹¹, H. Yang¹², Q. Zhou¹³, B. Kong¹⁴, Y. Huang¹⁵, L. Chen¹⁶, G. Li¹⁷, R. An¹⁸, K. Wang¹⁹, Y. Zhang²⁰, ¹Fudan University Shanghai Cancer Center, Shanghai, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN, ³West China Second University Hospital, Sichuan University, Chengdu, CN, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁵Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁶Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, CN, ⁷National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁸The First Hospital of Jilin University, Changchun, CN, ⁹Peking University School of Oncology, Beijing Cancer Hospital, Beijing Institute for Cancer Research, Beijing, CN, ¹⁰Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, CN, ¹¹Harbin Medical University Cancer Hospital, Harbin, CN, ¹²Yunnan Cancer Hospital/The Third Affiliated Hospital of Kunming Medical University, Kunming, CN, ¹³Chongqing university cancer hospital, Chongqing, CN, ¹⁴Qilu Hospital of Shandong University, Ji'nan, CN, ¹⁵Hubei Cancer Hospital, Wuhan, CN, ¹⁶Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, CN, ¹⁷Cancer Center, Union Hospital, Tongji Medical College, Wuhan, CN, ¹⁸The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ¹⁹Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ²⁰Xiangya Hospital, Central South University, Changsha, CN
- 13:26 - 13:38 **LBA30 - INOVATYON study: Randomized phase III international study comparing trabectedin/PLD followed by platinum at progression vs carboplatin/PLD in patients with recurrent ovarian cancer progressing within 6-12 months after last platinum line.**
- N. Colombo¹, A. Gadducci², J. Sehouli³, E. Biagioli⁴, G.-B. Nyvang⁵, S. Riniker⁶, A. Montes⁷, N. Ottevanger⁸, A. G. Zeimet⁹, I. Vergote¹⁰, G. Funari⁴, A. Baldoni¹¹, G. Tognon¹², A. De Censi¹³, C. Churrua Galaz¹⁴, R. Chekerov¹⁵, J. Maenpaa¹⁶, E. Rulli⁴, R. Fossati¹⁷, A. Poveda¹⁸, ¹IEO - Istituto Europeo di Oncologia, Milan, IT, ²University of Pisa, Pisa, IT, ³Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁴Istituto di Ricerche Farmacologiche Mario Negri - IRCCS, Milano, IT, ⁵NSGO-CTU & Odense University Hospital, Odense, DK, ⁶Kantonsspital St.Gallen, St.Gallen, CH, ⁷Guy's & St Thomas' NHS Foundation Trust, London, GB, ⁸Radboud university medical center, Nijmegen, NL, ⁹Innsbruck Medical University, Innsbruck, AT, ¹⁰University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹¹Istituto Oncologico Veneto, Padova, IT, ¹²ASST Spedali Civili-Università degli Studi di Brescia, Brescia, IT, ¹³E.O. Opsedali Galliera, Genova, IT, ¹⁴HU Donostia - Onkologikoa, Donostia, ES, ¹⁵Charité Comprehensive Cancer Center - CCCC Charité Medical University of Berlin, Berlin, DE, ¹⁶Tampere University Hospital (Tays), Tampere, FI, ¹⁷IRCCS-Istituto di Ricerche Farmacologiche, Milan, IT, ¹⁸Fundación Instituto Valenciano de Oncología, Valencia, ES
- 13:38 - 13:48 **Invited Discussant LBA29 and LBA30**
- A. Du Bois, Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE

13:48 - 13:58 **Q&A and live discussion**

12:30 - 14:10 **Type: Proffered Paper session** **Channel 3**
Title: Proffered Paper - Head & Neck cancer
Chair(s): Anthony T.C. Chan, HK; Sjoukje Oosting, NL

12:30 - 12:42 **LBA38 - Pembrolizumab versus cetuximab, concomitant with radiotherapy (RT) in locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results of the GORTEC 2015-01 "PembroRad" randomized trial**
Y. Tao¹, X. Sun², C. Sire³, L. Martin⁴, M. Alfonsi⁵, J.B. Prevost⁶, M. Rives⁷, C. Lafond⁸, J.M. Tourani⁹, J. Biau¹⁰, L. Geoffrois¹¹, A. Coutte¹², X. Liem¹³, E. Vauleon¹⁴, F. Drouet¹⁵, A. Pechery¹⁶, J. Guigay¹⁷, M. Wanneveich¹⁶, A. Aupérin¹, J. Bourhis¹⁸, ¹Institut Gustave Roussy, Villejuif, FR, ²Hôpital Nord Franche-Comté - HNFC, Belfort, FR, ³CHU Bretagne Sud, Lorient, FR, ⁴Clinique des Ormeaux, Le Havre, FR, ⁵Institut Sainte Catherine, Avignon, FR, ⁶Centre Pierre Curie, Beuvry, FR, ⁷Institut Claudius Regaud, Toulouse, FR, ⁸Clinique Victor Hugo, Le Mans, FR, ⁹CHU Poitiers, Jean Bernard Hôpital, Poitiers, FR, ¹⁰Centre de Lutte contre le Cancer J. Perrin, Clermont Ferrand, FR, ¹¹Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ¹²CHU Amiens-Picardie - Site Sud, Amiens, FR, ¹³Centre Oscar Lambret, Lille, FR, ¹⁴Centre Eugene - Marquis, Rennes, FR, ¹⁵Clinique Mutualiste de l'Estuaire, Saint-Nazaire, FR, ¹⁶GORTEC-CHU Bretonneau, Tours cedex, FR, ¹⁷Centre Anticancer Antoine Lacassagne, Nice, FR, ¹⁸CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

12:42 - 12:54 **9100 - Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN)**
E. Cohen¹, R. Ferris², A. Psyrri³, R. Haddad⁴, M. Tahara⁵, J. Bourhis⁶, K. Harrington⁷, P. Chang⁸, J.-C. Lin⁹, M. Razaq¹⁰, M. Teixeira¹¹, J. Lovey¹², J. Chamois¹³, A. Rueda Dominguez¹⁴, C. Hu¹⁵, M. Dvorkin¹⁶, S. De Beukelaer¹⁷, D. Pavlov¹⁸, H. Thurm¹⁹, N. Lee²⁰, ¹Moore's Cancer Center, University of California, San Diego, US, ²University of Pittsburgh, Eye and Ear Institute, Pittsburgh, US, ³Attikon University Hospital, Athens, GR, ⁴Dana Farber Cancer Institute, Boston, US, ⁵National Cancer Center Hospital East, Kashiwa, JP, ⁶CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ⁷ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB, ⁸Taipei Veterans General Hospital, Taipei City, TW, ⁹Changhua Christian Hospital, Changhua City, TW, ¹⁰University of Oklahoma Health Sciences Center, Oklahoma City, US, ¹¹Instituto Português Oncologia de Coimbra Francisco Gentil E. P. E. (IPO Coimbra), Coimbra, PT, ¹²National Institute of Oncology Hungary, Budapest, HU, ¹³CHP Saint-Grégoire, St. Grégoire, FR, ¹⁴Hospital Costa del Sol, Marbella, ES, ¹⁵Fudan University Shanghai Cancer Center, Shanghai, CN, ¹⁶Budgetary Institution of Healthcare of the Omsk region, Omsk, RU, ¹⁷Pfizer AG / Pfizer PFE Switzerland GmbH, Zurich, CH, ¹⁸Pfizer Inc., La Jolla, US, ¹⁹Pfizer Inc - USA, San Diego, US, ²⁰Memorial Sloan Kettering Cancer Center, New York, US

12:54 - 13:04 **LBA39 - 3-years follow-up of double-blind randomized phase II comparing concurrent high-dose cisplatin chemo-radiation plus Debio-1143 (Xevinapant) or**

placebo in high-risk patients with locally advanced squamous cell carcinoma of the head and neck

J. Bourhis¹, X. Sun², C. Le Tourneau³, Y. Pointreau⁴, C. Sire⁵, M.-C. Kaminsky-Forrett⁶, A. Coutte⁷, M. Alfonsi⁸, P. Boisselier⁹, L. Martin¹⁰, J.-P. Delord¹¹, F. Clatot¹², J. Biau¹³, F. Rolland¹⁴, K. Gollmer¹⁵, S. Szyldergemajn¹⁵, C. Even¹⁶, Y. Tao¹⁶, ¹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ²Hôpital Nord Franche-Comté - HNFC, Belfort, FR, ³Institut Curie, Paris, FR, ⁴Centre Jean Bernard, Le Mans, FR, ⁵CHU Bretagne Sud, Lorient, FR, ⁶Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre les Nancy, FR, ⁷CHU Amiens-Picardie - Site Sud, Amiens, FR, ⁸Institut Ste Catherine, Avignon, FR, ⁹ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹⁰Clinique des Ormeaux, Le Havre, FR, ¹¹Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ¹²Centre Henri Becquerel, Rouen, FR, ¹³Centre de Lutte contre le Cancer J. Perrin, Clermont Ferrand, FR, ¹⁴ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹⁵Debiopharm International S.A., Lausanne, CH, ¹⁶Institut Gustave Roussy, Villejuif, FR

13:04 - 13:14 **Invited Discussant LBA38, 9100 and LBA39**

S. Oosting, UMCG - University Medical Center Groningen, Groningen, NL

13:14 - 13:24 **Q&A and live discussion**

13:24 - 13:36 **LBA40 - Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma; the IMCISION trial.**

L. Zuur¹, J. Vos², J. Elbers², O. Krijgsman², X. Qiao², A. Van Der Leun³, L. Smit², M. Van Den Brekel², B. Tan⁴, B. Jasperse⁵, W. Vogel², S. Willems⁶, A. Al-Mamgani², D. Peeper⁷, T. Schumacher⁷, C. Blank⁸, J.P. De Boer², J. Haanen⁸, ¹The Netherlands Cancer Institute, Amsterdam, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴Maastrich University Medical Center +, Maastricht, NL, ⁵Amsterdam UMC, location VUmc, Amsterdam, NL, ⁶UMC-University Medical Center Utrecht, Utrecht, NL, ⁷Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁸Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

13:36 - 13:48 **9110 - Performance of dual p16 and HPV testing for determining prognosis in cancer of the oropharynx, the EPIC-OPC Study**

M. Taberna¹, H. Mehanna², S. Tous¹, J. Brooks², C. Von Buchwald³, M. Mena⁴, N. Batis², R. Brakenhoff⁵, R. Baatenburg De Jong⁶, J. Klussmann⁷, T. Dalianis⁸, H. Mirghani⁹, A. Schache¹⁰, J. James¹¹, S.H. Huang¹², M. Broglie¹³, M. Hoffmann¹⁴, L. Alemany¹, ¹Institut Català d'Oncologia-Hospital Duran i Reynals, Hospitalet de Llobregat, ES, ²The University of Birmingham Institute for Cancer Studies, Birmingham, GB, ³Faculty of Health and Medicine Sciences, University of Copenhagen, Copenhagen, DK, ⁴Institut Català d'Oncologia (ICO) - Bellvitge Biomedical Research Institute (IDIBELL), Hospitalet de Llobregat, ES, ⁵VUmc Cancer Center Amsterdam, Amsterdam, NL, ⁶ErasmusMC Cancer Center, Rotterdam, NL, ⁷University of Giessen, Giessen, DE, ⁸Cancer Center Karolinska, Stockholm, SE, ⁹Gustave Roussy Cancer Campus, Villejuif, FR, ¹⁰University

of Liverpool Cancer Research Centre Roy Castle Building, Liverpool, GB, ¹¹Queen's University Belfast, Belfast, GB, ¹²Princess Margaret Cancer Center, Toronto, CA, ¹³University Hospital Zurich, Zurich, CH, ¹⁴Christian-Albrechts-University Kiel, Kiel, DE

13:48 - 13:58 **Invited Discussant LBA40 and 9110**

C. Simon, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

13:58 - 14:08 **Q&A and live discussion**

14:25 - 16:05 Type: Proffered Paper session Channel 1
Title: Proffered Paper - GI, colorectal
Chair(s): Michel Ducreux, FR; Chiara Cremolini, IT

14:25 - 14:37 **3960 - Health-related quality of life (HRQoL) in patients (pts) treated with pembrolizumab (pembro) vs chemotherapy as first-line treatment in microsatellite instability-high (MSI-H) and/or deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC): Phase III KEYNOTE-177 study**

T. André¹, M. Amonkar², J. Norquist², K.-K. Shiu³, T.W. Kim⁴, B.V. Jensen⁵, L.H. Jensen⁶, C.J. Punt⁷, D. Smith⁸, R. Garcia-Carbonero⁹, I. Sevilla¹⁰, C. De La Fouchardiere¹¹, F. Rivera¹², E. Elez¹³, L. Diaz¹⁴, T. Yoshino¹⁵, E. Van Cutsem¹⁶, P. Yang², M. Farooqui¹⁷, D. Le¹⁸, ¹Hôpital Saint-Antoine, Paris, FR, ²Merck & Co., Inc., Kenilworth, US, ³University College London NHS Foundation Trust, London, GB, ⁴Asan Medical Center, Seoul, KR, ⁵Herlev og Gentofte Hospital, Herlev, DK, ⁶Vejle Hospital-Sygehus Lillebaelt, Vejle, DK, ⁷Academic Medical Center, Amsterdam, NL, ⁸CHU Bordeaux - Hopital St. André, Bordeaux, FR, ⁹University Hospital 12 De Octubre, Madrid, ES, ¹⁰Hospital Universitario Virgen de la Victoria, Málaga, ES, ¹¹Centre Léon Bérard, Lyon, FR, ¹²Hospital Universitario M de Valdecilla, Santander, ES, ¹³Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹⁴MSKCC, New York, US, ¹⁵National Cancer Center Hospital East, Kashiwa, JP, ¹⁶University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹⁷Merck & Co. Inc - MRL Labs - Upper Gwynedd Campus, North Wales, US, ¹⁸Sidney Kimmel Comprehensive Cancer Center, Baltimore, US

14:37 - 14:49 **3970 - Avelumab plus cetuximab in pre-treated RAS wild type metastatic colorectal cancer patients as a rechallenge strategy: The phase II CAVE (cetuximab-avelumab) mCRC study**

E. Martinelli¹, G. Martini¹, T. Troiani¹, F. Pietrantonio², A. Avallone³, N. Normanno³, A. Nappi³, E. Maiello⁴, A. Falcone⁵, G. Santabarbara⁶, C. Pinto⁷, D. Santini⁸, D. Ciardiello¹, M. Terminiello¹, C. Borrelli¹, S. Napolitano¹, D. Renato¹, V. Famiglietti¹, L. Esposito¹, F. Ciardiello¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Medical Oncology, Milano, IT, ³Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁴IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ⁵Azienda Ospedaliero Universitaria Pisana - Stabilimento di Santa Chiara, Pisa, IT, ⁶Azienda Ospedaliera di Rilievo Nazionale "S. G. Moscati", Avellino, IT, ⁷IRCCS Santa Maria Nuova, Reggio Emilia, Reggio Emilia, IT, ⁸Policlinico Universitario Campus Bio-Medico, Rome, IT

14:49 - 14:59 **Invited Discussant 3960 and 3970**

C. Cremolini, Azienda Ospedaliera Universitaria S.Chiera, Pisa, IT

14:59 - 15:09 **Q&A and live discussion**

15:09 - 15:21 **3980 - Effect of 5 years of imaging and CEA follow-up to detect recurrence of colorectal cancer (CRC) - PRODIGE 13 a FFCD phase III trial**

C. Lepage¹, J.M. Phelip², L. Cany³, E. Barbier⁴, S. Manfredi⁵, P. Deguiral⁶, R. Faroux⁷, M. Baconnier⁸, D. Pezet⁹, J. Duchmann¹⁰, E. Terrebonne¹¹, A. Adenis¹², M. Benabdelghani¹³, J. Ain¹⁴, G. Breysacher¹⁵, I. Boillot-Benedetto¹⁶, A. Pelaquier¹⁷, P. Prost¹⁸, A. Lievre⁵, O. Bouche¹⁹, ¹CHU Dijon, Dijon, FR, ²CHU Saint Etienne - Hopital Nord, Saint-Étienne, FR, ³Polyclinique Francheville, Perigueux, FR, ⁴Fédération Francophone de Cancérologie Digestive, Dijon, FR, ⁵CHU Rennes - Hôpital Pontchaillou, Rennes, FR, ⁶Clinique Mutualiste de l'Estuaire, Saint Nazaire, FR, ⁷Centre Hospitalier Les Oudairies, La Roche sur Yon, FR, ⁸Centre Hospitalier Annecy-Genevois, Annecy, FR, ⁹CHU Estaing, Clermont Ferrand, FR, ¹⁰CH Compiègne, Compiègne, FR, ¹¹Haut Lévêque Hospital, Pessac, FR, ¹²ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹³Centre Paul Strauss, Strasbourg, FR, ¹⁴polyclinique Val de Saône, Mâcon, FR, ¹⁵Hopital Louis Pasteur, Colmar, FR, ¹⁶CH St Joseph-St Luc, Lyon, FR, ¹⁷Centre Hospitalier Montelimar Service de Oncologie, Montelimar, FR, ¹⁸CH Fleyriat, Bourg en Bresse, FR, ¹⁹CHU de Reims - Hôpital Robert Debré, Reims, FR

15:21 - 15:33 **3990 - Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial**

S. Lonardi¹, G. Rosati², F. Galli³, K.F. Dotti⁴, M. Ronzoni⁵, M.G. Zampino⁶, M. Banzi⁷, V. Pusceddu⁸, F. Pasini⁹, S. Bozzarelli¹⁰, N. Pella¹¹, C. Codecà¹², V. Montesarchio¹³, A. Mambrini¹⁴, A. De Stefano¹⁵, L. Ciuffreda¹⁶, S.E. Rebutzi¹⁷, F. Galli³, D. Bilancia¹⁸, R. Labianca¹⁹, ¹IRCCS Istituto Oncologico Veneto, Padova, IT, ²Azienda Ospedaliera Regionale S. Carlo di Potenza, Potenza, IT, ³Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, IT, ⁴Fondazione IRCCS INT, Milan, IT, ⁵Ospedale San Raffaele, Milan, IT, ⁶IEO - Istituto Europeo di Oncologia, Milan, IT, ⁷Azienda Ospedaliera Arcispedale Santa Maria Nuova - IRCCS, Reggio Emilia, IT, ⁸University Hospital, Cagliari, IT, ⁹Ospedale Santa Maria della Misericordia, Rovigo, IT, ¹⁰Humanitas Clinical and Research Center-IRCCS, Rozzano, IT, ¹¹Azienda Ospedaliera Universitaria S. Maria della Misericordia, Udine, IT, ¹²Azienda Ospedaliera San Paolo, Milan, IT, ¹³Azienda Ospedaliera Dei Colli-Monaldi, Napoli, IT, ¹⁴Azienda USL Toscana Nord Ovest, Carrara, IT, ¹⁵Istituto Nazionale dei Tumori Pascale, Napoli, IT, ¹⁶Ospedale S. Giovanni Battista, Torino, IT, ¹⁷IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ¹⁸Ospedale S. Carlo, Potenza, IT, ¹⁹Cancer Center ASST Papa Giovanni XXIII, Bergamo, IT

15:33 - 15:43 **Invited Discussant 3980 and 3990**

T. Price, The Queen Elizabeth Hospital - Emergency Department, Woodville, AU

15:43 - 15:53 **Q&A and live discussion**

14:25 - 16:05	Type: Proffered Paper session Title: Proffered Paper - Translational research	Channel 2
Chair(s): Samra Turajlic, GB; Núria López-Bigas, ES		
14:25 - 14:37	19280 - Meta-analysis of tumour and T cell intrinsic mechanisms of sensitization to checkpoint inhibition	
<p><u>K. Litchfield</u>¹, J. Reading², N. Mcgranahan³, S. Quezada², C. Swanton¹, ¹Francis Crick Institute, London, GB, ²University College London, London, GB, ³UCL Cancer Institute/Paul O'Gorman Building, London, GB</p>		
14:37 - 14:49	19290 - Soluble PD-L1 and circulating CD8&#x2b;PD1&#x2b; and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients	
<p><u>G. Mazzaschi</u>¹, R. Minari¹, V. Ferri¹, P. Bordi¹, L. Gnetti¹, M. Bersanelli², A. Cavazzoni¹, S. Buti³, A. Leonetti¹, A. Zecca¹, A. Cosenza¹, L. Ferri¹, E. Rapacchi¹, C. Mori¹, P.G. Petronini¹, G. Missale¹, F. Quaini³, M. Tiseo⁴, ¹University Hospital of Parma, Parma, IT, ²Azienda Ospedaliera di Parma, Parma, IT, ³AOU di Parma, Parma, IT, ⁴Azienda Ospedaliero-Universitaria di Parma, Parma, IT</p>		
14:49 - 14:59	Invited Discussant 19280 and 19290	
<p><u>D. Thommen</u>, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL</p>		
14:59 - 15:09	Q&A and live discussion	
15:09 - 15:21	19300 - Genomic alterations in solid tumours according to ESMO scale for clinical actionability of molecular targets (ESCAT)	
<p><u>P. Martin Romano</u>¹, L. Mezquita², L. Lacroix³, E. Rouleau³, A. Varga², C. Baldini¹, S. Postel-Vinay², L. Friboulet³, A. Geraud², M. Aldea², A. Gazzah², Y. Lorient², J.-C. Soria², F. André², A. Hollebecque², B. Besse², C. Massard³, A. Italiano⁴, ¹Gustave Roussy, Villejuif, FR, ²Institut Gustave Roussy, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Institute Bergonié, Bordeaux, FR</p>		
15:21 - 15:33	820 - Genomic evolution of metastatic tumours under therapeutic pressure	
<p><u>J. Van De Haar</u>¹, L. Hoes², P. Roepman³, E. Cuppen³, L. Wessels⁴, E. Voest¹, ¹Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ²NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ³Hartwig Medical Foundation, Amsterdam, NL, ⁴Netherlands Cancer Institute, Amsterdam, NL</p>		
15:33 - 15:45	11890 - Validation of whole genome sequencing in routine clinical practice	
<p><u>K. Monkhorst</u>¹, K. Samsom¹, L. Schipper¹, P. Roepman², L. Bosch³, E. De Bruijn², L. Hoes¹, I. Riethorst², L. Schoenmaker², L. Van Der Kolk¹, T. Buffart¹, K. Van Der Hoeven², E. Voest⁴, E. Cuppen², G. Meijer¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²Hartwig Medical Foundation, Amsterdam, NL, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴Netherlands Cancer Institute/Antoni</p>		

van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

15:45 - 15:55 **Invited Discussant 19300, 820, and 11890**

N. López-Bigas, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, ES

15:55 - 16:05 **Q&A and live discussion**

14:25 - 16:05 Type: Proffered Paper session Channel 3
Title: Proffered Paper - SARS-CoV-2 and cancer 1
 Chair(s): Evandro de Azambuja, BE; Benjamin Solomon, AU

14:25 - 14:37 **LBA69 - Impact of the COVID-19 pandemic on management of medical cancer treatments and psychological consequence for the patients**

F. Joly¹, A. Leconte², J.-M. Grellard², J. Lequesne², G. Binarelli², M. Lange², L. Tron³, F. Gernier², C. Rieux², M. Fernet², E. Bastien¹, A. Morel¹, B. Legrand², D. Richard⁴, A. Faveyrial¹, R. Travers², L.-F. Pépin⁵, O. Rigal⁴, F. Jardin⁴, B. Clarisse², ¹Centre François Baclesse, Caen, FR, ²Centre Francois Baclesse, Caen, FR, ³Inserm U1086 Anticipe, Caen, FR, ⁴Centre Henri Becquerel, Rouen, FR, ⁵Cancer Centre Henri Becquerel, Rouen, FR

14:37 - 14:49 **LBA70_PR - The Impact of COVID-19 on Oncology Professionals: Initial Results of The ESMO Resilience Task Force Survey Collaboration**

S. Banerjee¹, K.H.J. Lim², K. Kamposioras², K. Murali³, C. Oing⁴, K. Punie⁵, M. O'Connor⁶, B. Devnani⁷, M. Lambertini⁸, C. Benedikt Westphalen⁹, P. Garrido Lopez¹⁰, T. Amaral¹¹, E. Thorne¹², G. Morgan¹³, J. Haanen¹⁴, C. Hardy¹², ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²The Christie NHS Foundation Trust, Manchester, GB, ³Austin Hospital, Heidelberg, AU, ⁴UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶University Hospital Waterford, Waterford, IE, ⁷All India Institute of Medical Sciences, Delhi, IN, ⁸IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁹Ludwig Maximilians University - Grosshadern, Munich, DE, ¹⁰Hospital Universitario Ramon y Cajal, Madrid, ES, ¹¹University Hospital Tübingen, Tübingen, DE, ¹²Lancaster University, Lancaster, GB, ¹³Skane University Hospital, Lund, SE, ¹⁴Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

14:49 - 14:59 **Invited Discussant LBA69 and LBA70_PR**

E. De Azambuja, Institute Jules Bordet, Brussels, BE

14:59 - 15:09 **Q&A and live discussion**

15:09 - 15:21 **LBA71 - Systemic cancer treatment-related outcomes in patients with SARS-CoV-2 infection: A CCC19 registry analysis.**

T. Wise-Draper¹, A. Desai², A. Elkrief³, B. Rini⁴, D. Flora⁵, D.W. Bowles⁶, D. Shah⁷, D. Rivera⁸, D. Johnson⁴, G. Lopes⁹, P. Grivas¹⁰, M. Thompson¹¹, S. Peters¹², N. Kuderer¹³,

N. Nock¹⁴, P. Grover¹⁵, X. Li¹⁶, S. Gulati¹⁷, T. Choueiri¹⁸, J. Warner¹⁹, ¹Vontz Center for Molecular Studies, Cincinnati, US, ²University of Connecticut, Farmington, US, ³McGill University Healthcare Centre, Montreal, CA, ⁴Vanderbilt University Medical Center, Nashville, US, ⁵St Elizabeth Healthcare, Edgewood, US, ⁶University of Colorado, Aurora, US, ⁷Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, US, ⁸National Cancer Institute, Washington, US, ⁹University of Miami, Miami, US, ¹⁰University of Washington Seattle Cancer Care Alliance, Seattle, US, ¹¹Advocate Aurora Health, Milwaukee, US, ¹²Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹³Advanced Cancer Research Group, Seattle, US, ¹⁴Case Western Reserve University, Cleveland, US, ¹⁵University of Cincinnati, Cincinnati, US, ¹⁶Vanderbilt University, Nashville, US, ¹⁷Institution/Organization University of Cincinnati, Cincinnati, US, ¹⁸Dana Farber Cancer Institute, Boston, US, ¹⁹Institution/Organization Vanderbilt University Medical Center, Nashville, US

15:21 - 15:33 **16700 - Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium**

C. Palmieri¹, L. Turtle², A. Docherty³, E. Harrison³, T. Drake³, B. Greenhalf⁴, P. Openshaw⁵, J. Baillie³, M. Malcolm G Semple⁶, ¹Royal Liverpool University Hospital, Liverpool, GB, ²Liverpool University Hospitals NHS Foundation Trust., Liverpool, GB, ³University of Edinburgh, Edinburgh, GB, ⁴University of Liverpool, Liverpool, GB, ⁵Imperial College London, London, GB, ⁶NIHR Health Protection Unit in Emerging and Zoonotic infections and Centre for Excellence in Infectious Disease Research, Liverpool, GB

15:33 - 15:43 **Invited Discussant LBA71 and 16700**

B. Solomon, Peter MacCallum Cancer Centre, Melbourne, AU

15:43 - 15:53 **Q&A and live discussion**

16:20 - 18:00 Type: Proffered Paper session Channel 1
Title: Proffered Paper 1 - Breast cancer, metastatic
Chair(s): Lisa Carey, US

16:20 - 16:32 **LBA15 - Primary results from IMpassion131, a double-blind placebo-controlled randomised phase 3 trial of first-line paclitaxel (PAC) +/- atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)**

D. Miles¹, J. Gligorov², F. André³, D. Cameron⁴, A. Schneeweiss⁵, C. Barrios⁶, B. Xu⁷, A. Wardley⁸, D. Kaen⁹, L. Andrade¹⁰, V. Semiglazov¹¹, M. Reinisch¹², M. Patre¹³, L. Morales¹³, K. Russell¹³, M. Donica¹³, J. O'Shaughnessy¹⁴, ¹Mount Vernon Cancer Centre, Northwood, GB, ²Hopital Tenon, Paris, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB, ⁵University Hospital Heidelberg, Heidelberg, DE, ⁶Hospital Sao Lucas da PUCRS, Porto Alegre, BR, ⁷National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁸The Christie NHS Foundation Trust, Manchester, GB,

⁹Centro Oncológico Riojano Integral and Universidad Nacional de La Rioja, La Rioja, AR, ¹⁰Santa Casa de Misericordia de Salvador, Salvador, BR, ¹¹N.N. Petrov National Medical Research Center of Oncology, Saint-Petersburg, RU, ¹²Kliniken Essen Mitte Evang. Huysens-Stiftung, Essen, DE, ¹³F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁴Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, US

16:32 - 16:44

LBA16 - IMpassion130: final OS analysis from the pivotal Phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer

L. Emens¹, S. Adams², C. Barrios³, V. Dieras⁴, H. Iwata⁵, S. Loi⁶, H. Rugo⁷, A. Schneeweiss⁸, E. Winer⁹, S. Patel¹⁰, V. Henschel¹⁰, A. Swat¹¹, M. Kaul¹², L. Molinero¹³, S. Chui¹³, P. Schmid¹⁴, ¹UPMC Hillman Cancer Center, Pittsburgh, US, ²NYU Langone Medical Center, New York, US, ³Hospital Sao Lucas da PUCRS, Porto Alegre, BR, ⁴Centre Eugene - Marquis, Rennes, FR, ⁵Aichi Cancer Center Hospital, Nagoya, JP, ⁶Peter MacCallum Cancer Center, Melbourne, AU, ⁷UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁸University Hospital Heidelberg, Heidelberg, DE, ⁹Harvard Medical School, Boston, US, ¹⁰Genentech, South San Francisco, US, ¹¹F. Hoffmann-La Roche AG, Basel, CH, ¹²F Hoffman Roche, Basel, CH, ¹³Genentech, Inc., South San Francisco, US, ¹⁴Barts Cancer Institute-Queen Mary University of London, London, GB

16:44 - 16:54

Invited Discussant LBA15 and LBA16

L. Carey, UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US

16:54 - 17:04

Q&A and live discussion

17:04 - 17:16

LBA17 - ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician's choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)

A. Bardia¹, S. Tolaney², D. Loirat³, K. Punie⁴, M. Oliveira⁵, H. Rugo⁶, A. Brufsky⁷, K. Kalinsky⁸, J. Cortés⁹, J. O'Shaughnessy¹⁰, V. Dieras¹¹, L. Carey¹², L. Gianni¹³, M. Piccart¹⁴, S. Loibl¹⁵, D. Goldenberg¹⁶, Q. Hong¹⁶, M. Olivo¹⁷, L. Itri¹⁶, S. Hurvitz¹⁸, ¹Massachusetts General Hospital Cancer Center, Boston, US, ²Dana Farber Cancer Institute, Boston, US, ³Institut Curie, Paris, FR, ⁴University Hospitals Leuven, Leuven, BE, ⁵Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁶UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US, ⁷University of Pittsburgh Cancer Center, Pittsburgh, US, ⁸University of Columbia Cancer Center, New York, US, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ¹¹Centre Eugene - Marquis, Rennes, FR, ¹²UNC - The University of North Carolina at Chapel Hill - School of Medicine, Chapel Hill, US, ¹³IRCCS Ospedale San Raffaele, Milan, IT, ¹⁴Institute Jules Bordet, Brussels, BE, ¹⁵German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ¹⁶Immunomedics, Inc., Morris Plains, US, ¹⁷Daiichi Sankyo Inc., Basking Ridge, US, ¹⁸UCLA Hematology/Oncology Santa Monica, Santa Monica, US

17:16 - 17:28

LBA18 - Overall Survival (OS) Results From SOLAR-1, a Phase 3 Study of

Alpelisib (ALP) + Fulvestrant (FUL) for Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced Breast Cancer (ABC)

F. André¹, E. Ciruelos², D. Juric³, S. Loibl⁴, M. Campone⁵, I. Mayer⁶, G. Rubovszky⁷, T. Yamashita⁸, B. Kaufman⁹, Y.-S. Lu¹⁰, K. Inoue¹¹, Z. Papai¹², M. Takahashi¹³, F. Ghaznawi¹⁴, D. Mills¹⁵, M. Kaper¹⁴, M. Miller¹⁶, P.F. Conte¹⁷, H. Iwata¹⁸, H. Rugo¹⁹,
¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²University Hospital 12 De Octubre, Madrid, ES, ³Massachusetts General Hospital, Boston, US, ⁴German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ⁵ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁶Vanderbilt Ingram Cancer Center, Nashville, US, ⁷National Institute of Oncology - Hungary, Budapest, HU, ⁸Kanagawa Cancer Centre, Yokohama, JP, ⁹Tel Aviv University, Tel Aviv-Yafo, IL, ¹⁰National Taiwan University Hospital, Taipei, TW, ¹¹Saitama Cancer Center, Ina, JP, ¹²MH Honvedkorhaz, Budapest, HU, ¹³NHO Hokkaido Cancer Center, Hokkaido, JP, ¹⁴Novartis Pharmaceuticals Corp., East Hanover, US, ¹⁵Novartis Pharma Services AG, Basel, CH, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁷Istituto Oncologico Veneto IRCCS, Padova, IT, ¹⁸Aichi Cancer Center Hospital, Nagoya, JP, ¹⁹UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, US

17:28 - 17:40 **2730 - nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+; HER2- metastatic breast cancer**

E. Hamilton¹, J. Cortés², O. Ozyilkan³, S.-C. Chen⁴, K. Petrakova⁵, A. Manikhas⁶, G. Jerusalem⁷, R. Hegg⁸, J. Huober⁹, S.C. Chapman¹⁰, Z. Yang¹⁰, Y. Chen¹⁰, E.L. Johnston¹⁰, M. Martin¹¹,
¹Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Baskent Universitesi Adana Uygulama Ve Arastirma Merkezi - Faculty of Medicine, Adana, TR, ⁴Chang Gung Memorial Hospital - Linkou, Taiwan, CN, ⁵Masaryk Memorial Cancer Institute, Brno, CZ, ⁶City Clinical Oncology Dispensary, Saint-Petersburg, RU, ⁷Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ⁸Gynecological Clinical Service School of Medicine, Univ. Sao Paulo, Sao Paulo, BR, ⁹Universitaetsfrauenklinik Ulm, Ulm, DE, ¹⁰Lilly Corporate Center, Indianapolis, US, ¹¹Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, ES

17:40 - 17:50 **Invited Discussant LBA17, LBA18 and 2730**

F. Cardoso, Champalimaud Foundation Cancer Center, Lisbon, PT

17:50 - 18:00 **Q&A and live discussion**

16:20 - 18:00 **Type: Proffered Paper session** **Channel 2**
Title: Proffered Paper - Melanoma and other skin tumours
 Chair(s): James Larkin, GB; Rodabe Amaria, US

16:20 - 16:32 **LBA43 - Spaltalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600-mutant unresectable or metastatic melanoma: results from the randomized part 3 of the Phase III COMBI-i trial**

P. Nathan¹, R. Dummer², G. Long³, P. Ascierto⁴, H. Tawbi⁵, C. Robert⁶, P. Rutkowski⁷, O.

Leonov⁸, C. Dutriaux⁹, M. Mandala¹⁰, P. Lorigan¹¹, P.F. Ferrucci¹², K. Flaherty¹³, J.C. Brase¹⁴, S. Green¹⁴, T. Haas¹⁴, A. Masood¹⁵, E. Gasal¹⁶, A. Ribas¹⁷, D. Schadendorf¹⁸,
¹Mount Vernon Cancer Centre - East and North Herts NHS Trust, Northwood, GB,
²Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ³Melanoma Institute Australia, Wollstonecraft, AU, ⁴Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ⁵The University of Texas M. D. Anderson Cancer Center, Houston, US,
⁶Institut Gustave Roussy, Villejuif, FR, ⁷The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, ⁸Clinical Oncological Dispensary, Omsk, RU, ⁹CHU Bordeaux - Hopital St. André, Bordeaux, FR, ¹⁰Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ¹¹The Christie NHS Foundation Trust, Manchester, GB, ¹²Istituto Europeo di Oncologia, Milan, IT, ¹³Massachusetts General Hospital, Harvard Medical School, Boston, US, ¹⁴Novartis Pharma AG, Basel, CH, ¹⁵Novartis Pharmaceuticals Corp., East Hanover, US, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, US, ¹⁷Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US, ¹⁸University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

16:32 - 16:44

LBA44 - Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of LEAP-004

A.M. Arance Fernandez¹, S. O'Day², L. De La Cruz Merino³, T. Petrella⁴, R. Jamal⁵, L. Ny⁶, A. Carneiro⁷, A. Berrocal⁸, I. Márquez-Rodas⁹, A. Spreafico¹⁰, V. Victoria Atkinson¹¹, F. Costa Svedman¹², A. Smith¹³, K. Chen¹⁴, S. Diede¹⁵, C. Krepler¹⁶, G. Long¹⁷,
¹Hospital Clinic of Barcelona, Barcelona, ES, ²John Wayne Cancer Institute, Santa Monica, US, ³Hospital Universitario Virgen Macarena, Sevilla, ES, ⁴Sunnybrook Health Sciences Centre - Odette Cancer Centre, Toronto, CA, ⁵Centre hospitalier de l'Université de Montréal, Montreal, CA, ⁶University of Gothenburg & Sahlgrenska University Hospital, Gothenburg, SE, ⁷Skanes universitetssjukhus - Onkologiska Klinik, Lund, SE, ⁸Hospital General Universitario Valencia, Valencia, ES, ⁹General University Hospital Gregorio Marañón, Madrid, ES, ¹⁰Princess Margaret Cancer Centre, University of Toronto, Toronto, CA, ¹¹University of Queensland, Brisbane, AU, ¹²Karolinska University Hospital-Solna, Solna, SE, ¹³Eisai Ltd., Hatfield, GB, ¹⁴Merck Research Laboratories, Kenilworth, US, ¹⁵Merck & Co., Inc., Kenilworth, US, ¹⁶Merck & Co, North Wales, US, ¹⁷Melanoma Institute Australia, Wollstonecraft, AU

16:44 - 16:56

LBA45 - First report of efficacy and safety from the phase II study SECOMBIT (SEquential COMBo Immuno and Targeted therapy study)

P. Ascierto¹, M. Mandala², P.F. Ferrucci³, P. Rutkowski⁴, M. Guidoboni⁵, A.M. Arance Fernandez⁶, V. Ferraresi⁷, E. Maiello⁸, M. Guida⁹, M. Del Vecchio¹⁰, M.T. Fierro¹¹, P. Queirolo¹², C. Lebbé¹³, H. Helgadottir¹⁴, I. Melero¹⁵, G. Palmieri¹⁶, D. Giannarelli¹⁷, A. Grimaldi¹⁸, R. Dummer¹⁹, V. Chiarion Sileni²⁰,
¹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ²Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ³Istituto Europeo di Oncologia, Milan, IT, ⁴The Maria Sklodowska Curie Memorial Cancer Centre and Institute of Oncology (MCMCC), Warsaw, PL, ⁵Istituto Tumori della Romagna I.R.S.T., Meldola, IT, ⁶Hospital Clinic of Barcelona, Barcelona, ES, ⁷Istituto Nazionale Tumori Regina Elena, Rome, IT, ⁸IRCCS Fondazione Casa Sollievo della Sofferenza, San Giovanni Rotondo, IT, ⁹Istituto Tumori Giovanni Paolo II, Bari, IT, ¹⁰Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹¹Oncologia Medica, Torino, IT, ¹²IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ¹³Saint-Louis Hospital, Paris, FR, ¹⁴Karolinska Institutet and Karolinska University Hospital Solna, Stockholm, SE, ¹⁵Clinica Universitaria de Navarra, Pamplona, ES, ¹⁶Istituto

Chimica Biomolecolare, Sassari, IT, ¹⁷IFO- Istituto Nazionale Tumori Regina Elena, Rome, IT, ¹⁸Istituto Nazionale Tumori - I.R.C.C.S - Fondazione Pascale, Napoli, IT, ¹⁹Universitätsspital Zürich - Klinik für Dermatologie, Zurich, CH, ²⁰Veneto Oncology Institute-IRCCS, Padova, IT

16:56 - 17:06

Invited Discussant LBA43, LBA44 and LBA45

B. Chmielowski, UCLA - David Geffen School of Medicine, Los Angeles, US

17:06 - 17:16

Q&A and live discussion

17:16 - 17:28

LBA46 - Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase 3 trial

A. Eggermont¹, C. Blank², M. Mandala³, G. Long⁴, V. Victoria Atkinson⁵, S. Dalle⁶, A. Haydon⁷, A. Meshcheryakov⁸, A. Khattak⁹, M. Carlino¹⁰, S. Sandhu¹¹, S. Puig Sarda¹², P. Ascierto¹³, A. Van Akkooi², C. Krepler¹⁴, N. Ibrahim¹⁵, S. Marreaud¹⁶, M. Kicinski¹⁷, S. Suci¹⁷, C. Robert¹⁸, ¹Princess Máxima Center, Utrecht, NL, ²Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, ³Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, IT, ⁴Melanoma Institute Australia, Wollstonecraft, AU, ⁵University of Queensland, Brisbane, AU, ⁶Lyon Sud Hospital Center, Pierre Benite, FR, ⁷Alfred Hospital, Melbourne, AU, ⁸N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, ⁹Fiona Stanley Hospital, Murdoch, AU, ¹⁰The Crown Princess Mary Cancer Centre, Westmead, AU, ¹¹Peter MacCallum Cancer Centre, Melbourne, AU, ¹²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹³Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁴Merck & Co, North Wales, US, ¹⁵Merck & Co., Inc., Keilworth, US, ¹⁶EORTC - European Organisation for Research and Treatment of Cancer, Brussels, BE, ¹⁷European Organisation for Research and Treatment of Cancer, Brussels, BE, ¹⁸Institut Gustave Roussy, Villejuif, FR

17:28 - 17:40

10760 - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 4-y recurrence-free and overall survival (OS) results from CheckMate 238

J. Weber¹, M. Del Vecchio², M. Mandala³, H. Gogas⁴, A.M. Arance Fernandez⁵, S. Dalle⁶, C. Cowey⁷, M. Schenker⁸, J.-J. Grob⁹, V. Chiarion Sileni¹⁰, I. Márquez-Rodas¹¹, M. Butler¹², M. Maio¹³, M. Middleton¹⁴, L. De La Cruz Merino¹⁵, M. Lobo¹⁶, V. De Pril¹⁶, J. Larkin¹⁷, P. Ascierto¹⁸, ¹NYU Langone Perlmutter Cancer Center, New York, US, ²Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, ³Papa Giovanni XIII Hospital, Bergamo, IT, ⁴National and Kapodistrian University of Athens, Athens, GR, ⁵Hospital Clinic of Barcelona, Barcelona, ES, ⁶Hospices Civils de Lyon, Pierre Bénite, FR, ⁷Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, US, ⁸Oncology Center Sf Nectarie Ltd., Craiova, RO, ⁹Hôpital de la Timone, Marseille, FR, ¹⁰Veneto Institute of Oncology IOV - IRCCS, Padua, IT, ¹¹General University Hospital Gregorio Marañón, Madrid, ES, ¹²Princess Margaret Cancer Center, Toronto, CA, ¹³Azienda Ospedaliera Universitaria Senese - Santa Maria delle Scotte, Siena, IT, ¹⁴University of Oxford, Oxford, GB, ¹⁵Hospital Universitario Virgen Macarena, Sevilla, ES, ¹⁶Bristol Myers Squibb, Princeton, US, ¹⁷Royal Marsden NHS Foundation Trust, London, GB,

¹⁸Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

17:40 - 17:50 **Invited Discussant LBA46 and 10760**
R. Amaria, The M. D. Anderson Cancer Center, Houston, US

17:50 - 18:00 **Q&A and live discussion**

16:20 - 18:00 Type: Proffered Paper session Channel 3
Title: Proffered Paper - GU, non prostate 1
Chair(s): Richard Cathomas, CH; Lisa Pickering, GB

16:20 - 16:32 **LBA23 - Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361**
A. Alva¹, T. Csőszi², M. Ozguroglu³, N. Matsubara⁴, L. Geczi⁵, S.Y.-S. Cheng⁶, Y. Fradet⁷, S. Oudard⁸, C. Vulsteke⁹, R. Morales Barrera¹⁰, A. Fléchon¹¹, S. Gunduz¹², Y. Loriot¹³, A. Rodriguez-Vida¹⁴, R. Mamtani¹⁵, E. Yu¹⁶, K. Nam¹⁷, K. Imai¹⁸, B.H. Moreno¹⁷, T. Powles¹⁹, ¹University of Michigan, Ann Arbor, US, ²Hetenyi G Korhaz Onkologiai Kozpont, Szolnok, HU, ³University Of Istanbul Cerrahpasa Medical Faculty, Istanbul, TR, ⁴National Cancer Center Hospital East, Kashiwa, JP, ⁵National Institute of Oncology - Hungary, Budapest, HU, ⁶Sunnybrook Odette Cancer Centre, Toronto, CA, ⁷CHU de Québec-Université Laval, Québec City, CA, ⁸Hopital European George Pompidou, Paris, FR, ⁹AZ Maria Middelaes AZMMSJ, Gent, BE, ¹⁰Vall d'Hebron University Hospital, Barcelona, ES, ¹¹Centre Léon Bérard, Rhones-Alpes, FR, ¹²Memorial Antalya Hospital, Antalya, TR, ¹³Institut Gustave Roussy, Villejuif, FR, ¹⁴Hospital del Mar, Barcelona, ES, ¹⁵Abramson Cancer Center, University of Pennsylvania, Philadelphia, US, ¹⁶University of Washington, Seattle, US, ¹⁷Merck & Co., Inc., Kenilworth, US, ¹⁸Merck & Co., Inc., North Wales, US, ¹⁹St. Bartholomew's Hospital, London, GB

16:32 - 16:44 **6970 - A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)**
T. Powles¹, M. Van Der Heijden², D. Castellano Gauna³, Y. Loriot⁴, M. Galsky⁵, D. Petrylak⁶, O. Ogawa⁷, S.H. Park⁸, A. Necchi⁹, J.-L. Lee¹⁰, U. De Giorgi¹¹, M. Bögemann¹², A. Bamias¹³, A. Fay¹⁴, I. Duran¹⁵, N. Angra¹⁶, A. Gupta¹⁶, P. He¹⁶, W. Levin¹⁶, J. Bellmunt¹⁷, ¹St. Bartholomew's Hospital, London, GB, ²Netherlands Cancer Institute, Amsterdam, NL, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Institut Gustave Roussy, Villejuif, FR, ⁵Icahn School of Medicine at Mount Sinai Hospital, New York City, US, ⁶Yale University School of Medicine, New heaven, US, ⁷Kyoto University, Kyoto, JP, ⁸Samsung Medical Center, Seoul, KR, ⁹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹⁰University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, ¹¹Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, IT, ¹²Universitätsklinikum Münster, Münster, DE, ¹³Attikon University Hospital, Athens, GR, ¹⁴Roche Brazil, Sao Paulo, BR, ¹⁵Hospital Universitario Marques de Valdecilla, Santander, ES, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷Harvard Medical School, Boston, US

- 16:44 - 16:54 **Invited Discussant LBA23 and 6970**
R. Cathomas, Kantonsspital Graubünden, Chur, CH
- 16:54 - 17:04 **Q&A and live discussion**
- 17:04 - 17:16 **LBA24 - TROPHY-U-01 Cohort 1 Final Results: A Phase 2 Study of Sacituzumab Govitecan (SG) in Metastatic Urothelial Cancer (mUC) That Has Progressed After Platinum (PLT) and Checkpoint Inhibitors (CPI)**
Y. Loriot¹, A. Balar², D. Petrylak³, S. Tagawa⁴, A. Rezazadeh⁵, A. Fléchon⁶, R. Jain⁷, N. Agarwal⁸, M. Bupathi⁹, P. Barthélémy¹⁰, P. Beuzeboc¹¹, P. Palmbos¹², C. Kyriakopoulos¹³, D. Pouessel¹⁴, C. Sternberg¹⁵, Q. Hong¹⁶, T. Goswami¹⁶, L. Itri¹⁶, P. Grivas¹⁷, ¹Institut Gustave Roussy, Villejuif, FR, ²New York University Langone Health, New York, US, ³Yale University School of Medicine, New heaven, US, ⁴NewYork-Presbyterian Hospital/ Weill Cornell Medical Center, New York, US, ⁵Norton Cancer Institute, Louisville, US, ⁶Centre Léon Bérard, Rhones-Alpes, FR, ⁷University of South Florida H. Lee Moffitt Cancer Center and Research Institute, Tampa, US, ⁸Huntsman Cancer Hospital, Salt Lake City, US, ⁹Rocky Mountain Cancer Centers, Littleton, US, ¹⁰Les Hôpitaux Universitaires de Strasbourg/ Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹¹Hôpital Foch, Suresnes, FR, ¹²University of Michigan Comprehensive Cancer Center, Ann Arbor, US, ¹³University of Wisconsin Carbone Cancer Center, Madison, US, ¹⁴Institut Claudius Regaud / Cancer Comprehensive Center, Midi-Pyrénées, FR, ¹⁵Weill Cornell Medicine - The Blenis Lab, New York, US, ¹⁶Immunomedics, Inc., Morris Plains, US, ¹⁷University of Washington Seattle Cancer Care Alliance, Seattle, US
- 17:16 - 17:28 **6980 - Patient-reported outcomes (PROs) from IMvigor130: A global, randomised, partially blinded phase III study of atezolizumab (atezo) + platinum-based chemotherapy (PBC) vs placebo (PBO) + PBC in previously untreated locally advanced or metastatic urothelial carcinoma (mUC)**
A. Bamias¹, M. De Santis², J.Á. Arranz³, E. Grande⁴, M.D. Galsky⁵, E. Kikuchi⁶, S.H. Park⁷, U. De Giorgi⁸, X. Garcia Del Muro⁹, M. Mencinger¹⁰, B. Alekseev¹¹, J. Puente¹², K. Izumi¹³, M. Gumus¹⁴, B. Mellado Gonzalez¹⁵, J.-R. Li¹⁶, C. Quach¹⁷, B. Ding¹⁸, S. Bernhard¹⁹, I.D. Davis²⁰, ¹Attikon University Hospital, Athens, GR, ²Charité - Universitätsmedizin Berlin, Berlin, DE, ³Gregorio Marañon Hospital, Madrid, ES, ⁴MD Anderson Cancer Center Madrid, Madrid, ES, ⁵Mount Sinai Hospital, New York, US, ⁶St. Marianna University School of Medicine, Kawasaki, JP, ⁷Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁸IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRCCS S.r.l., Meldola, IT, ⁹Institut Català D'Oncologia Hospitalet, Barcelona, ES, ¹⁰Institute of Oncology Ljubljana, Ljubljana, SI, ¹¹Research Oncology Institute, Tomsk, RU, ¹²Hospital Clinico Universitario San Carlos, Madrid, ES, ¹³Kanazawa University Hospital, Kanazawa, JP, ¹⁴Istanbul Medeniyet University, Istanbul, TR, ¹⁵Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic i Provincial, Barcelona, ES, ¹⁶Taichung Veterans General Hospital, Taichung City, TW, ¹⁷Genentech, South San Francisco, US, ¹⁸Genentech, Inc., South San Francisco, US, ¹⁹F. Hoffmann-La Roche, Ltd., Welwyn, GB, ²⁰Monash University, Victoria, AU
- 17:28 - 17:40 **6990 - Avelumab first-line (1L) maintenance + best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma (UC): Association between**

clinical outcomes and exploratory biomarkers

S. Sridhar¹, T. Powles², Y. Loriot³, J. Bellmunt⁴, C. Sternberg⁵, D. Petrylak⁶, R. Tambaro⁷, L.M. Dourthe⁸, C. Alvarez-Fernandez⁹, M. Aarts¹⁰, X.J. Mu¹¹, K. Ching¹¹, J. Pu¹¹, S. Roychoudhury¹¹, C. Davis¹¹, A. Di Pietro¹², P. Grivas¹³, ¹Princess Margaret Cancer Centre, Toronto, CA, ²St. Bartholomew's Hospital, London, GB, ³Institut Gustave Roussy, Villejuif, FR, ⁴Harvard Medical School, Boston, US, ⁵Weill Cornell Medicine - The Blenis Lab, New York, US, ⁶Yale University School of Medicine, New heaven, US, ⁷Istituto Nazionale per lo Studio e la Cura dei Tumori, IRCCS Fondazione Giovanni Pascale, Naples, IT, ⁸Clinique de l'Orangerie, Strasbourg, FR, ⁹Hospital Universitario Central de Asturias, Oviedo, ES, ¹⁰Atrium Medisch Centrum, Maastricht, NL, ¹¹Pfizer, La Jolla, US, ¹²Pfizer SRL, Milan, IT, ¹³University of Washington Seattle Cancer Care Alliance, Seattle, US

17:40 - 17:50 **Invited Discussant LBA24, 6980 and 6990**

J. Gschwend, TUM - Technical University of Munich, Munich, DE

17:50 - 18:00 **Q&A and live discussion**

16:20 - 17:50	Type: EONS session Title: EONS13: Oncology care during Covid-19: How does it affect our patients Chair(s): Wendy Oldenmenger, NL	Channel 4
16:20 - 16:40	Patient experience according to a patient advocate B. Ryll, Melanoma Patient network Europe, Uppsala, SE	
16:40 - 16:52	CN26 - Patient-reported experiences of cancer care related to the COVID-19 pandemic in Switzerland: A qualitative study S. Colomer-Lahiguera ¹ , K. Ribi ² , C. Witt ³ , M. Eicher ⁴ , ¹ Institute of Higher Education and Research in Healthcare - IUFERS, CHUV, Lausanne, CH, ² IBCSG International Breast Cancer Study Group, Bern, CH, ³ University Hospital Zürich, Zurich, CH, ⁴ CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
16:52 - 17:04	CN29 - SARS-CoV-2 and the perspectives of people living with cancer: The AIIO survey on the Italian lockdown V. Biagioli ¹ , S. Belloni ² , B. Albanesi ¹ , A. Piredda ³ , R. Caruso ⁴ , ¹ Sapienza - Università di Roma, Rome, IT, ² Tor Vergata University, Rome, IT, ³ European Institute of Oncology, Milan, IT, ⁴ IRCCS Policlinico San Donato, San Donato Milanese (Mi), IT	
17:04 - 17:16	Nursing aspects on the transformation of cancer care during the Covid-19 pandemic H. Ullgren, Karolinska University Hospital-Solna, Solna, SE	
17:16 - 17:46	Q&A live discussion	
18:30 - 20:10	Type: Proffered Paper session Title: Presidential Symposium I Chair(s): Solange Peters, CH; John Haanen, NL	Channel 1
18:30 - 18:42	LBA1 - Osimertinib adjuvant therapy in patients (pts) with resected EGFR mutated (EGFRm) NSCLC (ADAURA): central nervous system (CNS) disease recurrence M. Tsuboi ¹ , Y.-L. Wu ² , J. He ³ , T. John ⁴ , C. Grohe ⁵ , M. Majem ⁶ , J. Goldman ⁷ , K. Laktionov ⁸ , S.-W. Kim ⁹ , T. Kato ¹⁰ , H.V. Vu ¹¹ , C. Akewanlop ¹² , C.-J. Yu ¹³ , F. De Marinis ¹⁴ , M. Domine ¹⁵ , F. Shepherd ¹⁶ , C. Yan ¹⁷ , A. Atasoy ¹⁷ , R. Herbst ¹⁸ , ¹ National Cancer Center Hospital East, Kashiwa, JP, ² Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ³ National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁴ Austin Health, Melbourne, AU, ⁵ Evangelische Lungenklinik, Berlin, DE, ⁶ Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁷ University of California Los Angeles, Los Angeles, US, ⁸ N.N Blokhin Russian Cancer Center, Russian Academy of Medical Sciences, Moscow, RU, ⁹ Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ¹⁰ Kanagawa Cancer Center, Asahi Ward, Yokohama, JP, ¹¹ Choray Hospital, Ho Chi Minh City, VN, ¹² Siriraj	

Hospital, Mahidol University, Bangkok Noi, TH, ¹³National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, TW, ¹⁴European Institute of Oncology (IEO), IRCCS, Milan, IT, ¹⁵Instituto de Investigacion Sanitaria-Fundación Jimenez Diaz (IIS- FJD), Madrid, ES, ¹⁶University Health Network, Princess Margaret Cancer Centre and the University of Toronto, Toronto, CA, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸Yale School of Medicine and Yale Cancer Center, New Haven, US

18:42 - 18:52 **Invited Discussant LBA1**

J. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

18:52 - 19:02 **Q&A and live discussion**

19:02 - 19:14 **LBA2 - Lorlatinib vs Crizotinib in the First-line Treatment of Patients (pts) with Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC): Results of the Phase 3 CROWN Study**

B. Solomon¹, T. Bauer², F. De Marinis³, E. Felip⁴, Y. Goto⁵, G. Liu⁶, J. Mazieres⁷, D.-W. Kim⁸, T. Mok⁹, A. Polli¹⁰, H. Thurm¹¹, A.M. Calella¹², G. Peltz¹³, A. Shaw¹⁴, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, US, ³European Institute of Oncology, IRCCS, Milan, IT, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵National Cancer Center Hospital, Tokyo, JP, ⁶University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁷CHU Toulouse - Hôpital Larrey, Toulouse, FR, ⁸Seoul National University Hospital, Seoul, KR, ⁹State Key Laboratory of South China, Chinese University of Hong Kong, Hong Kong, HK, ¹⁰Pfizer Italy, Milan, IT, ¹¹Pfizer Inc., La Jolla, US, ¹²Pfizer Inc., Milan, IT, ¹³Pfizer Inc., Boston, US, ¹⁴Massachusetts General Hospital Cancer Center, Boston, US

19:14 - 19:24 **Invited Discussant LBA2**

C. Lovly, Vanderbilt University, Nashville, US

19:24 - 19:34 **Q&A and live discussion**

19:34 - 19:46 **6960_PR - Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: first results from the randomized phase 3 CheckMate 9ER trial**

T. Choueiri¹, T. Powles², M. Burotto³, M. Bourlon⁴, B. Zurawski⁵, V.M. Oyervides Juárez⁶, J. Hsieh⁷, U. Basso⁸, A. Shah⁹, C. Suarez¹⁰, A. Hamzaj¹¹, C. Barrios¹², M. Richardet¹³, D. Pook¹⁴, Y. Tomita¹⁵, B. Escudier¹⁶, J. Zhang¹⁷, B. Simsek¹⁸, A. Apolo¹⁹, R. Motzer²⁰, ¹Dana Farber Cancer Institute, Boston, US, ²Barts Cancer Institute, London, GB, ³Centro de Investigación Clínica Bradford Hill, Santiago, CL, ⁴Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MX, ⁵Centrum Onkologii, Bydgoszcz, PL, ⁶Centro Universitario contra el Cáncer Hospital Universitario "Dr. José Eleuterio González" Universidad Autónoma de Nuevo León, Nuevo León, MX, ⁷Washington University School of Medicine, St. Louis, US, ⁸ISTITUTO ONCOLOGICO VENETO IOV IRCCS, Padova, IT, ⁹The University of Texas M. D. Anderson Cancer Center, Houston, US, ¹⁰Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, ES,

¹¹Ospedale San Donato, Arezzo, IT, ¹²Hospital Sao Lucas da PUCRS, Porto Alegre, BR, ¹³Instituto Oncologico de Cordoba, Cordoba, AR, ¹⁴Cabrini Monash University, Malvern, AU, ¹⁵Graduate School of Medical and Dental Sciences, Niigata University, Niigata, JP, ¹⁶Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁷Bristol Myers Squibb, Princeton, US, ¹⁸Bristol Myers Squibb, Princetone, US, ¹⁹Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, US, ²⁰Memorial Sloan-Kettering Cancer Center, New York, US

19:46 - 19:56

Invited Discussant 696O_PR

C.G. Porta, IRCCS Istituti Clinici Scientifici Maugeri, Pavia, IT

19:56 - 20:06

Q&A and live discussion

20.09.2020

11:15 - 12:15 **Type: Educational session** **Channel 1**
Title: Cancer policy: What it is and why you cannot work without it
Chair(s): Rosa Giuliani, GB

11:15 - 11:30 **Connecting the dots: The EU plan to beat cancer**

11:30 - 11:45 **The ESMO vision for European cancer policy**
P.G. Casali, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

11:45 - 12:00 **This is what we need to achieve globally**
R. Giuliani, The Clatterbridge Cancer Centre, Liverpool, GB

12:00 - 12:12 **Q&A and live discussion**

11:15 - 12:15 **Type: Special session** **Channel 2**
Title: Challenges in the development and real-world use of the ESMO-MCBS
Chair(s): E.G. Elisabeth de Vries, NL; Nathan Cherny, IL

11:15 - 11:27 **ESMO-MCBS: What is new and how are we expanding**
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

11:27 - 11:39 **How can the ESMO-MCBS contribute to a higher QoL for patients?**
A. Bottomley, European Organisation for Research and Treatment of Cancer, Brussels, BE

11:39 - 11:51 **Prioritising cancer systemic therapies using the ESMO-MCBS: The Israeli experience**
R. Leibowitz-Amit, Chaim Sheba Medical Center, Ramat Gan, IL

11:51 - 12:03 **Shortcomings in study design: Implementation that can skew the ESMO-MCBS results**
B. Gyawali, Queen's University, Kingston, CA

12:03 - 12:11 **Q&A and live discussion, all Speakers online Chairs to moderate Q&A**

11:15 - 12:15 **Type: Special session** **Channel 3**
Title: Are women underrepresented in cancer research published in scientific oncology journals?
 Chair(s): Pilar Garrido Lopez, ES

11:15 - 11:25 **Introduction and presentation of data from W40 authorship study**
P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES

11:25 - 11:55 **Women in science**
J. Clark, The Lancet, London, GB

11:55 - 12:15 **Q&A and live discussion**

12:30 - 14:10 **Type: Proffered Paper session** **Channel 1**
Title: Proffered Paper - GI, non colorectal
 Chair(s): Salah-Eddin Al-Batran, DE; Lorenza Rimassa, IT

12:30 - 12:42 **9810 - Hepatic arterial infusion chemotherapy (HAIC) with oxaliplatin, fluorouracil, and leucovorin (FOLFOX) versus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma (HCC): A randomised phase III trial**
M. Shi, Q. Li, M. He, R. Guo, Sun Yat-sen University Cancer Center, Guangzhou, CN

12:42 - 12:52 **Invited Discussant 9810**
L. Rimassa, Istituto Clinico Humanitas, Rozzano, IT

12:52 - 13:02 **Q&A and live discussion**

13:02 - 13:14 **LBA65 - The Canadian Cancer Trials Group PA.7 Trial: Results of a Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)**

D. Renouf¹, J. Knox², P. Kavan³, D. Jonker⁴, S. Welch⁵, F. Couture⁶, F. Lemay⁷, M. Tehfe⁸, M. Harb⁹, N. Aucoin⁹, Y.-J. Ko¹⁰, P. Tang¹¹, R. Ramjeesingh¹², B. Meyers¹³, C. Kim¹⁴, D. Schaeffer¹⁵, J. Loree¹⁶, S. Gill¹⁶, D. Tu¹⁷, C. O'Callaghan¹⁷, ¹BC Cancer Agency - Vancouver, Vancouver, CA, ²Princess Margaret Cancer Centre, Toronto, CA, ³Jewish General Hospital, Montreal, CA, ⁴Ottawa Hospital Cancer Centre, Ottawa, CA, ⁵London Health Sciences Centre, London, CA, ⁶CHUQ- Hote-Dieu de Quebec, Quebec, CA, ⁷Centre hospitalier universitaire de Sherbrooke, Sherbrooke, CA, ⁸Centre Hospitalier de l'Université de Montréal, Montréal, CA, ⁹Hopital de la Cite-de-la-Sante, Laval, CA, ¹⁰Sunnybrook Odette Cancer Centre, Toronto, CA, ¹¹Tom Baker Cancer Centre, Calgary, CA, ¹²Queen Elizabeth II Health Sciences Centre, Halifax, CA, ¹³Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, CA, ¹⁴CancerCare Manitoba, Winnipeg, CA, ¹⁵Vancouver General Hospital, Vancouver, CA, ¹⁶BC Cancer - Vancouver, Vancouver, CA, ¹⁷Canadian Cancer Trials Group, Kingston, CA

13:14 - 13:26 **15250 - The QOLIXANE trial - Real life QoL and efficacy data in 1st line pancreatic cancer from the prospective platform for outcome, quality of life, and translational research on pancreatic cancer (PARAGON) registry**

T. Götze¹, R.D. Hofheinz², A. Reichart¹, C. Pauligk³, R. Schlag⁴, G. Siegler⁵, H.-G. Hoeffkes⁶, W. Blau⁷, N. Homann⁸, J. Trojan⁹, O. Waidmann⁹, D. Pink¹⁰, H. Messmann¹¹, V. Kunzmann¹², A. Vogel¹³, T. Ettrich¹⁴, C. Schönherr³, M. Schaaf¹⁵, G. Zur Hausen¹, S.-E. Al-Batran¹, ¹Nordwest-Krankenhaus, Frankfurt am Main, DE, ²UMM - Universitaetsklinikum Mannheim, Mannheim, DE, ³IKF Klinische Krebsforschung GmbH am Krankenhaus Nordwest, Frankfurt am Main, DE, ⁴Hämatonkologische Praxis Dr. R. Schlag, Berlin, DE, ⁵Klinikum Nuernberg Nord, Nürnberg, DE, ⁶Klinikum Fulda gAG, Fulda, DE, ⁷Universitätsklinik Giessen, Giessen, DE, ⁸Klinikum Wolfsburg, Wolfsburg, DE, ⁹Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE, ¹⁰HELIOS Klinikum Bad Saarow, Bad Saarow, DE, ¹¹Klinikum Augsburg, Augsburg, DE, ¹²University Clinic Würzburg-Medizinische Klinik und Poliklinik II Zentrum fuer Innere Medizin (ZIM), Wuerzburg, DE, ¹³Hannover Medical School, Hannover, DE, ¹⁴University of Ulm, Ulm, DE, ¹⁵Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt am Main, DE

13:26 - 13:36 **Invited Discussant LBA65 and 15250**

13:36 - 13:46 **Q&A and live discussion**

12:30 - 14:10 Type: Proffered Paper session Channel 2
Title: Proffered Paper - CNS tumours
Chair(s): Emilie Le Rhun, CH; Simone Niclou, LU

12:30 - 12:42 **3600 - Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?**

M. Weller¹, D. Gramatzki², J. Felsberg³, B. Hentschel⁴, M. Wolter³, G. Schackert⁵, M. Westphal⁶, L. Regli⁷, N. Thon⁸, M. Tatagiba⁹, W. Wick¹⁰, U. Schlegel¹¹, D. Krex⁵, P. Roth¹, E. Rushing⁷, T. Pietsch¹², A. Von Deimling¹⁰, M. Sabel³, M. Loeffler⁴, G. Reifenberger¹³, ¹Universitätsspital Zürich - Klinik für Neurologie, Zurich, CH, ²University Hospital Zürich, Zurich, CH, ³Heinrich Heine University Düsseldorf, Düsseldorf, DE, ⁴University of Leipzig, Leipzig, DE, ⁵Universitaetsklinikum Carl Gustav Carus Dresden, Dresden, DE, ⁶UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ⁷University Hospital Zurich, Zurich, CH, ⁸Ludwig-Maximilians-University Munich, Munich, DE, ⁹University of Tübingen, Tübingen, DE, ¹⁰University of Heidelberg, Heidelberg, DE, ¹¹University Hospital Knappschaftskrankenhaus, Bochum, DE, ¹²University Hospital Bonn, Bonn, DE, ¹³Universitätsklinikum Düsseldorf, Düsseldorf, DE

12:42 - 12:54 **3610 - Defining the prognostic role of MGMT methylation value by pyrosequencing assay in glioblastoma patients: A large Italian multicenter study**

M. Caccese¹, M. Simonelli², L. Bellu³, V. Villani⁴, S. Rizzato⁵, T. Ius⁶, F. Pasqualetti⁷, M. Russo⁸, F. Franchino⁹, R. Amoroso¹⁰, R. Bertorelle³, F. Cavallin¹¹, A. Dipasquale¹², M. Carosi⁴, S. Pizzolitto⁵, D. Cesselli⁵, M.P. Gardiman¹³, M. Padovan¹, V. Zagonel¹⁴, G. Lombardi¹⁴, ¹IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ²Humanitas University, Milan, IT, ³Veneto Institute of Oncology IOV-IRCCS, Padova, IT, ⁴Regina Elena National Cancer Institute, Rome, IT, ⁵Azienda Sanitaria Universitaria Friuli Centrale, Udine, IT, ⁶University Hospital of Udine, Udine, IT, ⁷Pisa University Hospital, Pisa, IT, ⁸Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, IT, ⁹University of Turin and City of Health and Science Hospital, Turin, IT, ¹⁰Azienda Sanitaria Alto Adige-Comprensorio Sanitario di Bolzano, Bolzano, IT, ¹¹Independent Statistician, Solagna, IT, ¹²Humanitas Cancer Center, Milan, IT, ¹³University Hospital of Padua, Padova, IT, ¹⁴Veneto Institute of Oncology - IRCCS, Padova, IT

12:54 - 13:04 **Invited Discussant 3600 and 3610**

S. Niclou, Luxembourg Institute of Health, Luxembourg, LU

13:04 - 13:14 **Q&A and live discussion**

13:14 - 13:26 **3620 - Perifocal edema volume correlates with density of tumour-infiltrating cytotoxic T cells in newly diagnosed glioblastoma**

M. Mair¹, K. Haller¹, G. Kuhrer¹, K. Feldmann¹, B. Kiesel¹, A. Wohrer¹, G. Widhalm², J. Furtner-Srajter³, M. Preusser¹, A.S. Berghoff⁴, ¹Vienna General Hospital (AKH) - Medizinische Universitat Wien, Vienna, AT, ²Department of Neurosurgery, Vienna, AT, ³Medical University of Vienna, Vienna, AT, ⁴Medizinische Universitat Wien (Medical University of Vienna), Vienna, AT

13:26 - 13:38 **3630 - Clinical characterization of a real-life cohort of 6001 patients with brain metastases from solid cancers treated between 1986-2020**

A. Steindl¹, J. Kreminger², E. Moor², A. Starzer², K. Dieckmann³, B. Gatterbauer⁴, G. Widhalm⁴, M. Preusser³, A.S. Berghoff², ¹Medizinische Universitat Wien, Vienna, AT, ²Medizinische Universitat Wien (Medical University of Vienna), Vienna, AT, ³Vienna General Hospital (AKH) - Medizinische Universitat Wien, Vienna, AT, ⁴Department of Neurosurgery, Vienna, AT

13:38 - 13:50 **3640 - Intracranial efficacy of entrectinib in patients with NTRK fusion-positive solid tumours and baseline CNS metastases**

T. John¹, C.-H. Chiu², B.C. Cho³, M. Fakhri⁴, A.F. Farago⁵, G.D. Demetri⁶, K. Goto⁷, R.C. Doebele⁸, S. Siena⁹, A. Drilon¹⁰, M.R. Patel¹¹, S.V. Liu¹², M.-J. Ahn¹³, L. Bazhenova¹⁴, T.R. Overbeck¹⁵, J. Nieva¹⁶, S.-W. Kim¹⁷, L. Veronese¹⁸, B.-M. Day¹⁹, F. De Braud²⁰, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Taipei Veterans General Hospital, Taipei City, TW, ³Yonsei Cancer Center, Seoul, KR, ⁴City of Hope, Duarte, US, ⁵Massachusetts General Hospital Cancer Center, Boston, US, ⁶Dana-Farber Cancer Institute, Boston, US, ⁷National Cancer Center Hospital East, Kashiwa, JP, ⁸University of Colorado, Aurora, US, ⁹ASST Grande Ospedale Metropolitano Niguarda, Milan, IT, ¹⁰Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ¹¹Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, US, ¹²Georgetown University, Washington, US, ¹³Samsung Medical Center (SMC)-Sungkyunkwan University

School of Medicine, Seoul, KR, ¹⁴Moore's Cancer Center - UC San Diego Health, La Jolla, US, ¹⁵University of Göttingen, Göttingen, DE, ¹⁶University of Southern California, Los Angeles, US, ¹⁷University of Ulsan College of Medicine, Seoul, KR, ¹⁸F. Hoffmann-La Roche AG - Switzerland, Basel, CH, ¹⁹Genentech, South San Francisco, US, ²⁰Università degli Studi di Milano, Milan, IT

13:50 - 14:00 **Invited Discussant 3620, 3630 and 3640**
E. Le Rhun, University Hospital Zürich, Zurich, CH

14:00 - 14:10 **Q&A and live discussion**

12:30 - 14:10 Type: Proffered Paper session Channel 3
Title: Proffered Paper - Breast cancer, early stage
Chair(s): Javier Cortés, ES; Sherko Kümmel, DE

12:30 - 12:42 **LBA11 - IMpassion031: results from a Ph 3 study of neoadjuvant (neoadj) atezolizumab + chemotherapy in early triple-negative breast cancer (TNBC)**
N. Harbeck¹, H. Zhang², C. Barrios³, S. Saji⁴, K.H. Jung⁵, R. Hegg⁶, A. Koehler⁷, J. Sohn⁸, H. Iwata⁹, M. Telli¹⁰, C. Ferrario¹¹, K. Punie¹², F. Penault-Llorca¹³, S. Patel¹⁴, A. Nguyen Duc¹⁵, M. Liste-Hermoso¹⁵, V. Maiya¹⁶, L. Molinero¹⁴, S. Chui¹⁴, E. Mittendorf¹⁷,
¹Ludwig Maximilians University - Grosshadern, Munich, DE, ²Memorial Sloan Kettering Cancer Center, New York, US, ³Hospital Sao Lucas da PUCRS, Porto Alegre, BR, ⁴Fukushima Medical University Hospital, Fukushima, JP, ⁵Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁶Gynecological Clinical Service School of Medicine, Univ. Sao Paulo, Sao Paulo, BR, ⁷Gemeinschaftspraxis für Haematologie und Onkologie Langen, Langen, DE, ⁸Yonsei University, Seoul, KR, ⁹Aichi Cancer Center Hospital, Nagoya, JP, ¹⁰Stanford University School of Medicine, Stanford, US, ¹¹Jewish General Hospital McGill University, Montreal, CA, ¹²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹³Jean Perrin Center, Clermont-Ferrand, FR, ¹⁴Genentech, Inc., South San Francisco, US, ¹⁵F. Hoffmann-La Roche, Ltd., Basel, CH, ¹⁶Genentech, Inc. - Member of the Roche Group, South San Francisco, US, ¹⁷Brigham and Women's Hospital, Boston, US

12:42 - 12:54 **1590 - Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group**
V. De Jong¹, Y. Wang¹, M. Opdam¹, N. Ter Hoeve², K. Józwiak³, M. Hauptmann³, N. Stathonikos², H. Horlings¹, A. Broeks⁴, S. Michiels⁵, E. Van Der Wall², P. Van Diest⁶, S. Siesling⁷, M. Schmidt⁴, S. Loi⁸, M. Kok⁹, S. Linn⁴, R. Salgado¹⁰, G. Dackus¹, ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²UMC-University Medical Center Utrecht, Utrecht, NL, ³Brandenburg Medical School Theodor Fontane, Neuruppin, DE, ⁴Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL, ⁵Gustave Roussy, Villejuif, FR, ⁶UMCU, Utrecht, NL, ⁷Comprehensive Cancer Organization, Utrecht, NL, ⁸Peter MacCallum Cancer Center, Melbourne, AU, ⁹Netherlands Cancer Institute, Amsterdam, NL, ¹⁰St-Augustinus Ziekenhuis, Wilrijk, BE

- 12:54 - 13:06 **1600 - Survival analysis of the randomized phase III GeparOcto trial comparing neoadjuvant chemotherapy (NACT) of iddEPC versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer, TNBC) (PM(Cb)) for patients (pts) with high-risk early breast cancer (BC)**
A. Schneeweiss¹, V. Möbus², H. Tesch³, P. Klare⁴, C. Denkert⁵, K. Kast⁶, C. Hanusch⁷, T. Link⁶, M. Untch⁸, C. Jackisch⁹, J.-U. Blohmer¹⁰, P.A. Fasching¹¹, C. Solbach², J. Huober¹², K. Rhiem¹³, V. Nekljudova¹⁴, K. Lübbe¹⁵, S. Loibl¹⁴, ¹University Hospital Heidelberg, Heidelberg, DE, ²University Hospital Frankfurt, Frankfurt, DE, ³Private practice - Dr. Hans Tesch, Frankfurt am Main, DE, ⁴Medical Center, Berlin, DE, ⁵Uniklinikum Giessen und Marburg, Marburg, DE, ⁶Medical Faculty and University Hospital Carl Gustav Carus, Dresden, DE, ⁷Rotkreuzklinikum, München, DE, ⁸Helios Klinikum Berlin Buch, Berlin, DE, ⁹Klinikum Offenbach GmbH, Offenbach am Main, DE, ¹⁰St. Gertrauden-Krankenhaus, Berlin, DE, ¹¹Universitätsklinikum Erlangen, Erlangen, DE, ¹²Universitätsfrauenklinik Ulm, Ulm, DE, ¹³University Hospital Cologne, Köln, DE, ¹⁴German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ¹⁵Frauenklinik Hannover, Hannover, DE
- 13:06 - 13:16 **Invited Discussant LBA11, 1590 and 1600**
S. Kümmel, Kliniken Essen Mitte Evang. Huysdens-Stiftung, Essen, DE
- 13:16 - 13:26 **Q&A and live discussion**
- 13:26 - 13:38 **LBA12 - PALLAS: A randomized phase III trial of adjuvant palbociclib with endocrine therapy versus endocrine therapy alone for HR+/HER2- early breast cancer**
E. Mayer¹, M. Gnant², A. Demichele³, M. Martin⁴, H. Burstein¹, A. Prat⁵, G. Rubovszky⁶, K. Miller⁷, G. Pfeiler⁸, E. Winer⁹, N. Zdenkowski¹⁰, D. Anderson¹¹, Z. Nowecki¹², S. Loibl¹³, H. Fohler¹⁴, O. Metzger¹, D. Fumagalli¹⁵, K. Puyana Theall¹⁶, C. Fesl¹⁷, A. Dueck¹⁸, ¹Dana Farber Cancer Institute, Boston, US, ²Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT, ³University of Pennsylvania-Perelman Center for Advanced Medicine, Philadelphia, US, ⁴Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁵Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ⁶National Institute of Oncology - Hungary, Budapest, HU, ⁷Indiana University School of Medicine, Indianapolis, US, ⁸Medical University of Vienna, Vienna, AT, ⁹Harvard Medical School, Boston, US, ¹⁰Lake Macquarie Private Hospital, Gateshead, AU, ¹¹Regions Hospital Cancer Care Center, St Paul, US, ¹²Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ¹³German Breast Group (GBG) Forschungs GmbH, Neu-Isenburg, DE, ¹⁴Austrian Breast and Colorectal Cancer Study Group, Vienna, AT, ¹⁵BIG Against Breast Cancer, Brussels, BE, ¹⁶Pfizer Inc, Cambridge, US, ¹⁷ABCSG - Austrian Breast Cancer Study Group, Vienna, AT, ¹⁸Mayo Clinic, Scottsdale, US
- 13:38 - 13:50 **1610 - Randomized preoperative window of opportunity (WOO) study with the CDK4/6 inhibitor abemaciclib in early breast cancer (EBC) patients and differential gene expression pathway analyses with palbociclib**
M. Arnedos¹, D. Chaltiel¹, B. Cheaib¹, D. Drubay¹, D. Gentien², A. Vieillefon², V. Scott¹, I. Bouakka¹, J. Adam¹, I. Garberis¹, F. Rimareix¹, N. Leymarie¹, A.A. Viansone¹, M. Lacroix-Triki¹, S. Michiels³, F. André⁴, ¹Institut Gustave Roussy, Villejuif, FR, ²Institut Curie,

Paris, FR, ³Gustave Roussy, Villejuif, FR, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR

13:50 - 14:00 **Invited Discussant LBA12 and 1610**

S. Di Cosimo, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

14:00 - 14:10 **Q&A and live discussion**

14:25 - 16:05 Type: Proffered Paper session Channel 1
Title: Proffered Paper - NSCLC metastatic 1
Chair(s): Lecia Sequist, US

14:25 - 14:37 **12570 - Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib)**

D. Hong¹, Y.-J. Bang², F. Barlesi³, G. Durm⁴, G. Falchook⁵, R. Govindan⁶, G. Dy⁷, K. Park⁸, J. Strickler⁹, T. Burns¹⁰, J. Kim¹¹, A. Ang¹¹, J.R. Lipford¹¹, G. Ngarmchamnanrith¹¹, A. Anderson¹¹, B. Li¹², ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Seoul National University Hospital, Seoul, KR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴Indiana University School of Medicine, Indianapolis, US, ⁵Sarah Cannon Research Institute, New York, US, ⁶Washington University School of Medicine, St. Louis, US, ⁷Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁸Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, Seoul, KR, ⁹Duke Cancer Center, Durham, US, ¹⁰University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, US, ¹¹Amgen Inc., Thousand Oaks, US, ¹²MSKCC - Memorial Sloan Kettering Cancer Center, New York, US

14:37 - 14:49 **12580 - Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC**

B.C. Cho¹, K.H. Lee², E.K. Cho³, D.-W. Kim⁴, J.-S. Lee⁵, J.-Y. Han⁶, S.-W. Kim⁷, A. Spira⁸, E. Haura⁹, J. Sabari¹⁰, R. Sanborn¹¹, J. Bauml¹², J. Gomez¹³, P. Lorenzini¹⁴, J. Infante¹⁵, J. Xie¹⁵, N. Haddish-Berhane¹⁶, M. Thayu¹⁵, R. Knoblauch¹⁵, K. Park¹⁷, ¹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ²Chungbuk National University Hospital, Chungcheongbuk-Do, KR, ³Gil Medical Center, Gachon University College of Medicine, Incheon, KR, ⁴Seoul National University Hospital, Seoul, KR, ⁵Seoul National University Bundang Hospital, Seongnam, KR, ⁶National Cancer Center, Goyang, KR, ⁷Asan Medical Center, Seoul, KR, ⁸Virginia Cancer Specialist, Fairfax, US, ⁹H. Lee Moffitt Cancer Center & Research Institute, Tampa, US, ¹⁰New York University School of Medicine, New York, US, ¹¹Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, ¹²Perelman School of Medicine at the University of Pennsylvania, Philadelphia, US, ¹³Icahn School of Medicine at Mount Sinai, New York, US, ¹⁴Janssen R&D, Spring House, US, ¹⁵Janssen Research & Development, Spring House, US, ¹⁶Janssen Research and Development, Spring House, PA, USA, Spring House, US, ¹⁷Samsung Medical Center, Seoul, KR

14:49 - 14:59 **Invited Discussant 12570 and 12580**

C. Lindsay, The Christie NHS Foundation Trust, Manchester, GB

14:59 - 15:09 **Q&A and live discussion**

15:09 - 15:21 **LBA50 - ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer (NSCLC): a multicentered, randomized, double-blind, placebo-controlled phase III trial (CTONG1706)**

L. Zhang¹, H. Zhao², Z. Zhang², W. Yao³, X. Min⁴, K. Gu⁵, G. Yu⁶, C. Cheng⁷, J. Cui⁸, L. Miao⁹, X. Song¹⁰, L. Zhang¹¹, X. Yuan¹², Y. Fang¹³, X. Fu¹⁴, C. Hu¹⁵, X. Zhu¹⁶, Y. Fan¹⁷, Q. Yu¹⁸, ¹State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Sun Yat-sen University Cancer Center, Guangzhou, CN, ³Sichuan Cancer Hospital, Chengdu, CN, ⁴Anhui Chest Hospital, Hefei, CN, ⁵The First Affiliated Hospital of Anhui Medical University, Hefei, CN, ⁶Weifang People's Hospital, Weifang, CN, ⁷the First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Guangzhou, CN, ⁸First Hospital of Jilin University, Changchun, CN, ⁹The Affiliated Hospital of Nanjing University Medical School, Nanjing, CN, ¹⁰Shanxi Tumor Hospital, Taiyuan, CN, ¹¹Peking Union Medical College Hospital of Chinese Academy of Medical Sciences, Beijing, CN, ¹²Huizhou Municipal Central Hospital, Huizhou, CN, ¹³Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, CN, ¹⁴The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, CN, ¹⁵Xiangya Hospital Central South University, Changsha, CN, ¹⁶Zhongda Hospital Southeast University, Nanjing, CN, ¹⁷Zhejiang Cancer Hospital, Hangzhou, CN, ¹⁸Guangxi Medical University Affiliated Tumor Hospital, Nanjing, CN

15:21 - 15:33 **12590 - A randomized phase II study of osimertinib with or without bevacizumab in advanced lung adenocarcinoma patients with EGFR T790M mutation (West Japan Oncology Group 8715L)**

Y. Toi¹, H. Hayashi², D. Fujimoto³, M. Tachihara⁴, N. Furuya⁵, S. Otani⁶, J. Shimizu⁷, N. Katakami⁸, K. Azuma⁹, N. Miura¹⁰, K. Nishino¹¹, S. Hara¹², S. Teraoka¹³, S. Morita¹⁴, K. Nakagawa¹⁵, N. Yamamoto¹³, ¹Sendai Kousei Hospital, Sendai, JP, ²Kindai University Faculty of Medicine, Osakasayama, JP, ³Kobe City Medical Center General Hospital, Kobe, JP, ⁴Kobe University Graduate School of Medicine, Kobe, JP, ⁵St. Marianna University School of Medicine, Kawasaki, JP, ⁶Kitasato University School of Medicine, Sagami-hara, JP, ⁷Aichi Cancer Center Hospital, Nagoya, JP, ⁸Takarazuka City Hospital, Takarazuka, JP, ⁹Department of Internal Medicine, Kurume University School of Medicine, Kurume, JP, ¹⁰National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ¹¹Osaka International Cancer Center, Osaka, JP, ¹²Itami City Hospital, Itami, JP, ¹³Wakayama Medical University, Wakayama, JP, ¹⁴Kyoto University Graduate School of Medicine, Kyoto, JP, ¹⁵Kindai University School of Medicine, Osaka, JP

15:33 - 15:43 **Invited Discussant LBA50 and 12590**

L. Sequist, Massachusetts General Hospital, Boston, US

15:43 - 15:53 **Q&A and live discussion**

- 14:25 - 16:05** **Type: Proffered Paper session** **Channel 2**
Title: Proffered Paper - Investigational immunotherapy
Chair(s): Silvia Formenti, US; Ignacio Melero, ES
- 14:25 - 14:37 **LBA41 - LEAP-005: Phase 2 Study of Lenvatinib (Len) Plus Pembrolizumab (Pembro) in Patients (Pts) With Previously Treated Advanced Solid Tumors**
Z. Lwin¹, C. Gomez-Roca², E. Saada-Bouزيد³, E. Yanez⁴, F. Longo Muñoz⁵, S.-A. Im⁶, E. Castanon⁷, H. Senellart⁸, D. Graham⁹, M. Voss¹⁰, M. Doherty¹¹, J. Lopez¹², R. Ghori¹³, P. Kubiak¹⁴, F. Jin¹³, K. Norwood¹³, H.C. Chung¹⁵, ¹Royal Brisbane and Women's Hospital, Herston, AU, ²Institut Claudius Regaud, Toulouse, FR, ³Centre de Lutte Contre le Cancer Antoine Lacassagne, Nice, FR, ⁴School of Medicine, Universidad de la Frontera, Temuco, CL, ⁵IRYCIS, CIBERONC, Madrid, ES, ⁶Seoul National University Hospital, Seoul, KR, ⁷Clínica Universitaria de Navarra, Pamplona, ES, ⁸Centre René Gauducheau ICO, Saint-Herblain, FR, ⁹The Christie NHS Foundation Trust, Manchester, GB, ¹⁰Universitätsklinikum Frankfurt, Frankfurt, DE, ¹¹Sunnybrook Health Sciences Centre, University of Toronto, Toronto, CA, ¹²The Royal Marsden Foundation Trust and the Institute of Cancer Research, London, GB, ¹³Merck & Co., Inc., Kenilworth, US, ¹⁴Eisai Inc., Woodcliff Lake, US, ¹⁵Yonsei University College of Medicine, Seoul, KR
- 14:37 - 14:49 **10190 - Phase I studies of Sym021, an anti-PD-1 antibody, alone and in combination with Sym022 (anti-LAG-3) or Sym023 (anti-TIM-3)**
N. Lakhani¹, A. Spreafico², A. Tolcher³, J. Rodon⁴, F. Janku⁴, S. Chandana¹, M. Oliva⁵, M. Sharma¹, R. Abdul-Karim⁶, U. Hansen⁷, L. Hansen⁷, N.J. Skartved⁷, T. Poulsen⁷, R. Nadal⁷, J. Lantto⁷, D. Wood⁸, P. Nadler⁸, L. Siu⁹, ¹START Midwest, Grand Rapids, US, ²Princess Margaret Cancer Centre, University of Toronto, Toronto, CA, ³NEXT OncologyTM, San Antonio, US, ⁴The University of Texas M. D. Anderson Cancer Center, Houston, US, ⁵Princess Margaret Cancer Center, Toronto, CA, ⁶NEXT Oncology, San Antonio, US, ⁷Symphogen A/S, Ballerup, DK, ⁸Nadler Pharma Associates, Randolph, US, ⁹Princess Margaret Cancer Centre, Toronto, CA
- 14:49 - 14:59 **Invited Discussant LBA41 and 10190**
I. Melero, Clinica Universitaria de Navarra, Pamplona, ES
- 14:59 - 15:09 **Q&A and live discussion**
- 15:09 - 15:21 **10200 - A phase I, first-in-human, open-label, dose escalation study of MGD019, an investigational bispecific PD-1 x CTLA-4 DART molecule in patients with advanced solid tumours**
M. Sharma¹, R. Sanborn², G. Cote³, J. Bendell⁴, S. Kaul⁵, F. Chen⁶, A. Berezchnoy⁷, P. Moore⁷, E. Bonvini⁷, B. Sumrow⁷, J. Luke⁸, ¹START Midwest, Grand Rapids, US, ²Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Portland, US, ³Massachusetts General Hospital, Boston, US, ⁴Sarah Cannon Research Institute, Nashville, US, ⁵Bio-ClinPharm Consulting, LLC, Cranbury, US, ⁶MacroGenics, Inc., Brisbane, US, ⁷MacroGenics, Inc., Rockville, US, ⁸UPMC Hillman Cancer Center, Pittsburgh, US
- 15:21 - 15:33 **10210 - Safety and antitumor activity of AK104, a bispecific antibody targeting**

PD-1 and CTLA-4, in patients with mesothelioma which is relapsed or refractory to standard therapies

M. Millward¹, S. Frentzas², H. Gan³, A. Prawira⁴, B. Tran⁵, J. Coward⁶, X. Jin⁷, B. Li⁷, M. Wang⁷, K.Y. Kwek⁸, Y. Xia⁷, J. Desai⁵, ¹School of Medicine and Pharmacology Sir Charles Gairdner Hospital, Nedlands, AU, ²Monash Health and Monash University, Melbourne, AU, ³Austin Hospital, Heidelberg, AU, ⁴St Vincent's Hospital, Sydney, AU, ⁵Peter MacCallum Cancer Centre, Melbourne, AU, ⁶Icon Cancer Centre, South Brisbane, AU, ⁷Akeso Biopharma Co. Ltd., Zhongshan, CN, ⁸IQVIA-Science Park Office, Singapore, SG

15:33 - 15:43 **Invited Discussant 10200 and 10210**

M. Rescigno, Humanitas University, Milan, IT

15:43 - 15:53 **Q&A and live discussion**

**14:25 - 16:05 Type: Proffered Paper session
Title: Proffered Paper - NETs**

Channel 3

Chair(s): Eva Segelov, AU; Jonathan Strosberg, US

14:25 - 14:37 **11560 - Surufatinib (S) for patients (Pts) with advanced pancreatic neuroendocrine tumours (SANET-p): A randomized, double-blind, placebo (P)-controlled phase III trial (NCT02589821)**

J. Xu¹, L. Shen², C. Bai³, J. Li², Z. Zhou⁴, X. Yu⁵, Z. Li⁶, E. Li⁷, X. Yuan⁸, Y. Chi⁹, Y. Yin¹⁰, W. Lou¹¹, N. Xu¹², Y. Bai¹³, T. Zhang¹⁴, D. Xiu¹⁵, X. Wang¹⁶, J. Li¹⁷, S. Fan¹⁷, W. Su¹⁷, ¹The Fifth Medical Center, General Hospital of the People's Liberation Army, Beijing, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³Peking Union Medical College Hospital, Beijing, CN, ⁴Sun Yat-sen University Cancer Center, Guangzhou, CN, ⁵Fudan University Shanghai Cancer Center, Shanghai, CN, ⁶West China Hospital, Sichuan University, Chengdu, CN, ⁷The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, CN, ⁸Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ⁹Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ¹⁰The First Affiliated Hospital of Nanjing Medical University, Nanjing, CN, ¹¹Zhongshan Hospital of Fudan University, Shanghai, CN, ¹²The First Affiliated Hospital of Zhejiang University, Hangzhou, CN, ¹³Harbin Medical University Cancer Hospital, Harbin, CN, ¹⁴Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ¹⁵Peking University Third Hospital, Beijing, CN, ¹⁶Qilu Hospital of Shandong University, Jinan, CN, ¹⁷Hutchison MediPharma Limited, Shanghai, CN

14:37 - 14:49 **11600 - An international open-label study on safety and efficacy of 177Lu-satoreotide tetraxetan in somatostatin receptor positive neuroendocrine tumours (NETs): An interim analysis**

G. Nicolas¹, C. Ansquer², N. Lenzo³, H. Grønbaek⁴, A. Haug⁵, S. Navalkisoor⁶, J.-M. Beauregard⁷, N. Germann⁸, S. Mcewan⁹, D. Wild¹⁰, R. Hicks¹¹, ¹University Hospital Basel - Institute of Pathology and Medical Genetics, Basel, CH, ²CHU-Hôtel Dieu, Nantes, FR, ³GenesisCare, East Fremantle, AU, ⁴Aarhus Universitetshospital, Aarhus, DK, ⁵Medical University of Vienna, Vienna, AT, ⁶Royal Free London, London, GB, ⁷CHU de Québec-Université Laval, Quebec, CA, ⁸Ipsen Innovation France, Les Ulis, FR, ⁹Ipsen,

Mississauga, CA, ¹⁰University Hospital Basel, Basel, CH, ¹¹Peter MacCallum Cancer Centre, Melbourne, AU

14:49 - 14:59 **Invited Discussant 11560 and 11600**

E. Segelov, Monash Medical Centre, Clayton, AU

14:59 - 15:09 **Q&A and live discussion**

15:09 - 15:21 **11570 - A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)**

J. Capdevila¹, A. Teule², C. López³, R. García-Carbonero⁴, M. Benavent⁵, A. Custodio⁶, A. Cubillo⁷, V. Alonso⁸, T. Alonso Gordo⁹, A. Carmona-Bayonas¹⁰, G. Crespo¹¹, M. Blanco-Codesido¹², P. Jimenez-Fonseca¹³, A. Viúdez¹⁴, A. La Casta Muñoa¹⁵, I. Sevilla¹⁶, M. Llanos¹⁷, A. Segura¹⁸, J. Hernando-Cubero¹⁹, J.L. Manzano²⁰, ¹Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES, ²Catalan Institute of de Oncology, Barcelona, ES, ³Hospital Universitario Marqués de Valdecilla, Santander, ES, ⁴Hospital Universitario 12 de Octubre, Madrid, ES, ⁵Hospital Virgen del Rocío, Sevilla, ES, ⁶Hospital Universitario La Paz, Madrid, ES, ⁷Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, ⁸Hospital Universitario Miguel Servet, Zaragoza, ES, ⁹Hospital Universitario Ramon y Cajal, Madrid, ES, ¹⁰Hospital Universitario Morales Meseguer, Murcia, ES, ¹¹Hospital Universitario de Burgos, Burgos, ES, ¹²Hospital General Universitario Gregorio Marañón, Madrid, ES, ¹³Hospital Universitario Central de Asturias, Oviedo, ES, ¹⁴Complejo Hospitalario de Navarra, Pamplona, ES, ¹⁵Hospital Universitario de Donostia, Donostia, ES, ¹⁶Hospital Universitario Virgen de la Victoria, Málaga, ES, ¹⁷Hospital Universitario de Canarias, San Cristóbal de la Laguna, ES, ¹⁸Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹⁹Vall Hebron University Hospital, Vall Hebron Institute of Oncology (VHIO), Barcelona, Barcelona, ES, ²⁰Hospital Germans Trias i Pujol, Badalona, ES

15:21 - 15:33 **19130 - Results from the registrational phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET mutation-positive medullary thyroid cancer (RET⁺; MTC)**

M. Hu¹, V. Subbiah¹, L. Wirth², M. Schuler³, A. Mansfield⁴, M. Brose⁵, G. Curigliano⁶, S. Leboulleux⁷, V. Zhu⁸, B. Keam⁹, I. Matos¹⁰, C.-C. Lin¹¹, D. Adkins¹², C. Baik¹³, G. Lopes¹⁴, Y. Godbert¹⁵, D. Sarker¹⁶, H. Zhang¹⁷, C. Turner¹⁸, M. Taylor¹⁹, ¹The University of Texas M. D. Anderson Cancer Center, Houston, US, ²Massachusetts General Hospital, Harvard Medical School, Boston, US, ³University Duisburg-Essen & German Cancer Consortium (DKTK), Partner site University Hospital Essen, Essen, DE, ⁴Mayo Clinic, Rochester, US, ⁵University of Pennsylvania- Clinical Research Building, Philadelphia, US, ⁶IEO - Istituto Europeo di Oncologia, Milan, IT, ⁷Gustave Roussy, Villejuif, FR, ⁸University of California - Irvine, Orange, US, ⁹Seoul National University Hospital, Seoul, KR, ¹⁰Vall d'Hebron Institute of Oncology, Barcelona, ES, ¹¹National Taiwan University Hospital, Taipei City, TW, ¹²Washington University School of Medicine, St Louis, US, ¹³Seattle Cancer Care Alliance, Seattle, US, ¹⁴University of miami, Miami, US, ¹⁵Institut Bergonie, Bordeaux, FR, ¹⁶Guy's Hospital, King's College London, London, GB, ¹⁷Blueprint Medicine Corporation, Cambridge, US, ¹⁸Blueprint Medicines

Corporation, Cambridge, US, ¹⁹OHSU Knight Cancer Institute - Northwest Portland, Portland, US

15:33 - 15:43 **Invited Discussant 11570 and 19130**

N. Fazio, IEO - Istituto Europeo di Oncologia, Milan, IT

15:43 - 15:53 **Q&A and live discussion**

16:20 - 18:00 Type: Proffered Paper session Channel 1
Title: Proffered Paper - Sarcoma

Chair(s): Winette Van Der Graaf, NL; Suzanne George, US

16:20 - 16:32 **16190 - High clinical benefit rates of single agent pembrolizumab in selected rare sarcoma histotypes: First results of the AcS#xe9; Pembrolizumab study**

J.-Y. Blay¹, S. Chevret², N. Penel³, F. Bertucci⁴, E. Bompas⁵, E. Saada-Bouزيد⁶, J.-C. Eymard⁷, J.-P. Lotz⁸, E. Coquan⁹, R. Schott¹⁰, P. Soulié¹¹, C. Linassier¹², A. Le Cesne¹³, M. Brahmi¹, N. Hoog-Labouret¹⁴, F. Legrand¹⁵, C. Simon¹⁶, A. Lamrani-Ghaouti¹⁶, I. Ray-Coquard¹, C. Massard¹³, ¹Centre Léon Bérard, Lyon, FR, ²Hopital St Louis, Paris, FR, ³Centre Oscar Lambret, Lille, FR, ⁴Institut Paoli Calmettes, Marseille, FR, ⁵ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁶Centre Anticancer Antoine Lacassagne, Marseille, FR, ⁷Institut Jean Godinot, Reims, FR, ⁸Hospital Tenon Ap-Hp, Paris, FR, ⁹Centre Francois Baclesse, Caen, FR, ¹⁰Centre Paul Strauss Centre de Lutte contre le Cancer, Strasbourg, FR, ¹¹Centre Paul Papin, Angers, FR, ¹²CHRU Bretonneau, Tours, FR, ¹³Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁴institut national du cancer, boulogne, FR, ¹⁵Institut national du cancer, boulogne, FR, ¹⁶UNICANCER, Paris, FR

16:32 - 16:44 **LBA67 - TRAMUNE, a phase Ib study combining Trabectedin and Durvalumab, Results of the expansion cohort in patients with advanced pretreated Soft Tissue Sarcomas**

M. Toulmonde¹, M. Brahmi², A. Giraud³, A. Bessedé⁴, M. Kind⁵, E. Toulza³, M. Pulido³, S. Cousin⁶, K. Bourcier¹, S. Albert³, S. Mothes³, C. Chakiba⁵, I. Ray-Coquard², A. Floquet¹, S. Croce³, S. Mathoulin-Pélissier³, R. Perret³, J.-Y. Blay², A. Italiano¹, ¹Institute Bergonié, Bordeaux, FR, ²Centre Léon Bérard, Lyon, FR, ³Institut Bergonie, Bordeaux, FR, ⁴Immusmol, Bordeaux, FR, ⁵Institut Bergonié, Bordeaux, FR, ⁶Centre Oscar Lambret, Lille, FR

16:44 - 16:54 **Invited Discussant 16190 and LBA67**

J. Martin Broto, Hospital Universitario Virgen del Rocio, Seville, ES

16:54 - 17:04 **Q&A and live discussion**

17:04 - 17:16 **LBA68 - Results of the randomized, Placebo (PL)-controlled Phase II study evaluating the efficacy and safety of Regorafenib (REG) in patients (pts) with metastatic relapsed Ewing sarcoma (ES), on behalf of the French Sarcoma Group**

(FSG) and Unicancer

F. Duffaud¹, J.-Y. Blay², O. Mir³, C. Chevreau⁴, P. Boudou Rouquette⁵, E. Kalbacher⁶, N. Penel⁷, C. Perrin⁸, V. Laurence⁹, E. Bompas¹⁰, E. Saada-Bouzid¹¹, C. Delcambre¹², F. Bertucci¹³, M. Cancel¹⁴, C. Schiffler², L. Monard¹⁵, C. Bouvier¹⁶, V. Vidal¹⁶, N. Gaspar³, S. Chabaud², ¹CHU La Timone Adultes, Marseille, FR, ²Centre Léon Bérard, Lyon, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ⁵Hopital Cochin - Site Port-Royal AP-HP, Paris, FR, ⁶CHRU Besancon - Hopital Jean Minjot, Besançon, FR, ⁷Centre Oscar Lambret, Lille, FR, ⁸Centre Eugene - Marquis, Rennes, FR, ⁹Institut Curie, Paris, FR, ¹⁰ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹¹Centre Anticancer Antoine Lacassagne, Marseille, FR, ¹²Centre Francois Baclesse, Caen, FR, ¹³Institut Paoli Calmettes, Marseille, FR, ¹⁴CHU Bretonneau Centre, Tours University, Tours, FR, ¹⁵UNICANCER, Paris, FR, ¹⁶CHU La Timone, Marseille, FR

17:16 - 17:28 **16200 - Phase I study of TK216, a novel anti-ETS agent for Ewing sarcoma**

J. Ludwig¹, N. Federman², P. Anderson³, M. Macy⁴, L. Davis⁵, R. Riedel⁶, J. Muscal⁷, N. Daw⁸, R. Ratan⁸, J. Toretsky⁹, X. Ianopoulos¹⁰, F. Hsu¹⁰, J. Breitmeyer¹¹, P. Meyers¹², ¹University of Texas MD Anderson cancer Center, Houston, US, ²David Geffen School of Medicine, University of California, Los Angeles, US, ³Cleveland Clinic, Cleveland, US, ⁴Children's Hospital Colorado, Aurora, US, ⁵Oregon Health and Science University, Knight Cancer Institute, Portland, US, ⁶Duke Cancer Institute, Duke University Medical Center, Duke, US, ⁷Texas Children's Hospital, Houston, US, ⁸University of Texas M.D. Anderson Cancer Center, Houston, US, ⁹Georgetown University, Washington, US, ¹⁰Oncternal Therapeutics, San Diego, US, ¹¹Oncternal Therapeutics, san Diego, US, ¹²Memorial Sloan-Kettering Cancer Center, New York, US

17:28 - 17:38 **Invited Discussant LBA68 and 16200**

S. Strauss, University College London Hospital - University College London Hospitals NHS Foundation Trust, London, GB

17:38 - 17:48 **Q&A and live discussion**

16:20 - 18:00 **Type: Proffered Paper session** **Channel 2**
Title: Proffered Paper - SARS-CoV-2 and cancer 2
Chair(s): Antonio Passaro, IT; Emanuela Romano, FR

16:20 - 16:32 **LBA72 - Assessment of clinical and laboratory prognostic factors in patients with cancer and SARS-CoV-2 infection: The COVID-19 and Cancer Consortium (CCC19)**

P. Grivas¹, J. Warner², Y. Shyr², D. Shah³, S. Rubinstein⁴, N. Kuderer⁵, T. Choueiri⁶, D. Rivera⁷, C. Painter⁸, M. Thompson⁹, S. Peters¹⁰, A. Desai¹¹, A. Khaki¹², N. Pennell¹³, J. Hawley¹⁴, B. Halmos¹⁵, M. Puc¹⁶, G. Lyman¹⁷, B. Rini⁴, G. Lopes¹⁸, ¹University of Washington Seattle Cancer Care Alliance, Seattle, US, ²Institution/Organization Vanderbilt University Medical Center, Nashville, US, ³Mays Cancer Center at UT Health San Antonio MD Anderson, San Antonio, US, ⁴Vanderbilt University Medical Center,

Nashville, US, ⁵Advanced Cancer Research Group, Seattle, US, ⁶Dana Farber Cancer Institute, Boston, US, ⁷National Cancer Institute, Washington, US, ⁸Broad Institute, Cambridge, US, ⁹Advocate Aurora Health, Milwaukee, US, ¹⁰Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹¹University of Connecticut, Farmington, US, ¹²University of Washington, Seattle, US, ¹³Cleveland Clinic, Cleveland, US, ¹⁴Columbia University Irving Medical Center, New York City, US, ¹⁵Montefiore/Albert Einstein Cancer Center, Bronx, US, ¹⁶Virtua Health, Marlton, US, ¹⁷Fred Hutchinson Cancer Research Center, Seattle, US, ¹⁸University of Miami, Miami, US

- 16:32 - 16:44 **LBA73 - The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01**
P. Kvistborg¹, A. Gangaev¹, S. Ketelaars¹, S. Patiweal¹, A. Dopler¹, O. Isaeva¹, K. Hoefakker¹, S. De Biasi², C. Mussini², G. Guaraldi², M. Girardis², C. Talavera Ormeno³, P. Hekking³, N. Lardy⁴, M. Toebes¹, R. Balderas⁵, T. Schumacher⁶, H. Ovaa³, A. Cossarizza², ¹NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ²University of Modena, Modena, IT, ³Leiden University Medical Center, Leiden, NL, ⁴Sanquin Diagnostics, Amsterdam, NL, ⁵BD Bioscience, San Jose, US, ⁶Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL
- 16:44 - 16:54 **Invited Discussant LBA72 and LBA73**
E. Romano, Institut Curie, Paris, FR
- 16:54 - 17:04 **Q&A and live discussion**
- 17:04 - 17:16 **LBA74 - Disparities in Cancer during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study (CCOS)**
D. Doroshov¹, A. Schmidt², Z. Bakouny³, S. Bhalla⁴, J. Steinharter², D. Tremblay⁵, M. Awad², A. Kessler⁵, G. Bouchard², M. Evans⁵, F. Busser², B. Zimmerman⁵, C. Curran², T. Jun⁶, R. Haddad², Q. Qin⁵, P.V. Nuzzo⁷, J. Feld⁸, M. Galsky⁸, T. Choueiri², ¹Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, US, ²Dana Farber Cancer Institute, Boston, US, ³Saint Joseph University - Faculty of Medicine, Beirut, LB, ⁴Mount Sinai Hospital, New York, US, ⁵Icahn School of Medicine at Mount Sinai Hospital, New York, US, ⁶Icahn School of Medicine at Mount Sinai, New York, US, ⁷IRCCS AOU San Martino - IST-Istituto Nazionale per la Ricerca sul Cancro, Genova, IT, ⁸Icahn School of Medicine at Mount Sinai Hospital, New York City, US
- 17:16 - 17:28 **LBA75 - Defining COVID-19 outcomes in thoracic cancer patients: TERA-VOLT (Thoracic cancer international COVID-19 collaboration)**
J. Baena Espinar¹, V. Torri², J. Whisenant³, F.R. Hirsch⁴, J. Rogado⁵, J. De Castro Carpeño⁶, B. Halmos⁷, G.L. Ceresoli⁸, A. Gomez Rueda⁹, M. Tiseo¹⁰, E. Felip¹¹, M. Majem Tarruella¹², I. Monnet¹³, U. Tapan¹⁴, L. Horn³, L.-C. Huang³, M. Garassino¹⁵, S. Peters¹⁶, H. Wakelee¹⁷, M. Hellmann¹⁸, ¹Hospital Universitario 12 Octubre, Madrid, ES, ²Istituto Di Ricerche Farmacologiche Mario Negri, Milan, IT, ³Vanderbilt University of Medicine, Nashville, US, ⁴Mount Sinai Pediatric Associates Practice, New York, US, ⁵Hospital Universitario de La Princesa, Madrid, ES, ⁶Hospital Universitario La Paz,

Madrid, ES, ⁷Montefiore/Albert Einstein Cancer Center, Bronx, US, ⁸Medical Oncology, Cliniche Humanitas Gavazzeni Bergamo, Italy, bergamo, IT, ⁹Hospital Universitario Ramon y Cajal, Madrid, ES, ¹⁰Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ¹¹Vall d'Hebron University Hospital, Barcelona, ES, ¹²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹³CHI de Créteil,, Créteil, FR, ¹⁴Boston Medical Center, Boston, US, ¹⁵Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ¹⁶Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH, ¹⁷Stanford Cancer Institute, Stanford University, Stanford, US, ¹⁸Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

17:28 - 17:38

Invited Discussant LBA74 and LBA75

A. Passaro, IEO - Istituto Europeo di Oncologia, Milan, IT

17:38 - 17:48

Q&A and live discussion

16:20 - 18:00

Type: Proffered Paper session

Channel 3

Title: Proffered Paper - Developmental therapeutics

Chair(s): Christophe Massard, FR; Giulio Draetta, US

16:20 - 16:32

5240 - Initial results of a phase I study of MK-4830, a first-in-class anti-ILT4 myeloid-specific antibody in patients (pts) with advanced solid tumours

L. Siu¹, D. Wang², J. Hilton³, R. Geva⁴, D. Rasco⁵, A.K. Abraham⁶, J.F. Markensohn⁶, L. Suttner⁶, S. Siddiqi⁶, R.A. Altura⁶, C. Maurice-Dror⁷, ¹Princess Margaret Cancer Centre, Toronto, CA, ²Henry Ford Hospital, Detroit, US, ³University of California San Francisco, San Francisco, US, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, IL, ⁵START Center for Cancer Care, San Antonio, US, ⁶Merck & Co., Inc., Kenilworth, US, ⁷Rambam Health Care Center, Haifa, IL

16:32 - 16:44

5250 - A phase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, in patients with HER2-positive malignancies

G. Ku¹, J. Bendell², A. Tolcher³, S. Hurvitz⁴, A. Krishnamurthy⁵, A. El-Khoueiry⁶, A. Patnaik⁷, R. Shroff⁸, A. Noonan⁹, N. Hahn¹⁰, M. Matrana¹¹, M. Zettl¹², K. Aviano¹³, L. Mar¹³, P. Jolicoeur¹³, S. Olwill¹², I. Bruns¹⁴, S. Piha-Paul¹⁵, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Sarah Cannon Research Institute, Nashville, US, ³NEXT OncologyTM, San Antonio, US, ⁴UCLA Hematology/Oncology Santa Monica, Santa Monica, US, ⁵University of Pittsburgh Hillman Cancer Center, Pittsburgh, US, ⁶USC Norris Comprehensive Cancer Center, Los Angeles, US, ⁷South Texas Accelerated Research Therapeutics, San Antonio, US, ⁸University of Arizona Cancer Center, Tucson, US, ⁹The Ohio State University, Ohio, US, ¹⁰Indiana University Simon Cancer Center, Indianapolis, US, ¹¹Ochsner Medical Center, New Orleans, US, ¹²Pieris Pharmaceuticals, Hallbergmoss, DE, ¹³PIERIS, Boston, US, ¹⁴PIERIS, Freising, DE, ¹⁵The University of Texas MD Anderson Cancer Center, Houston, TX, Houston, US

16:44 - 16:56

5260 - High activity of nivolumab in patients with pathogenic exonucleasic domain POLE (edPOLE) mutated Mismatch Repair proficient (MMRp) advanced tumours

B. Rousseau¹, I. Bieche², E. Pasmant³, V. Simmet⁴, N. Hamzaoui³, J. Masliah-Planchon², D. Pouessel⁵, A. Bruyas⁶, P. Augereau⁴, J.-J. Grob⁷, F. Rolland⁸, E. Saada-Bouزيد⁹, R. Cohen¹⁰, O. Bouche¹¹, N. Hoog-Labouret¹², F. Legrand¹³, C. Simon¹⁴, A. Lamrani-Ghaouti¹⁴, S. Chevret¹⁵, A. Marabelle¹⁶, ¹Centre hospitalier universitaire Henri-Mondor, Créteil, FR, ²Institut Curie, Paris, FR, ³Cochin Hospital, Paris, FR, ⁴Centre Paul Papin, Angers, FR, ⁵Institut Claudius Regaud / Cancer Comprehensive Center, Midi-Pyrénées, FR, ⁶Hôpital de la Croix-Rousse, Lyon, FR, ⁷Hôpital de la Timone, Marseille, FR, ⁸ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ⁹Centre Anticancer Antoine Lacassagne, Marseille, FR, ¹⁰Hôpital Saint-Antoine, Paris, FR, ¹¹CHU de Reims - Hôpital Robert Debré, Reims, FR, ¹²institue national du cancer, boulogne, FR, ¹³Institut national du cancer, boulogne, FR, ¹⁴UNICANCER, Paris, FR, ¹⁵Hopital St Louis, Paris, FR, ¹⁶Institut Gustave Roussy, Villejuif, FR

16:56 - 17:06 **Invited Discussant 5240, 5250 and 5260**

A. Italiano, Institute Bergonié, Bordeaux, FR

17:06 - 17:16 **Q&A and live discussion**

17:16 - 17:28 **5270 - CC-90010, a reversible, oral bromodomain and extra-terminal (BET) inhibitor in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory (R/R) non-Hodgkin lymphoma: Updated results of a phase I study**

V. Moreno Garcia¹, I. Braña², J. Sepulveda Sanchez³, M. Vieito⁴, T. Hernández-Guerrero⁵, B. Doger⁶, O. Saavedra⁴, C. Carlo-Stella⁷, J.-M. Michot⁸, A. Italiano⁹, G. Musuraca¹⁰, R. Sarmiento¹¹, B. Amoroso¹², S. Mora¹², T. Sánchez-Pérez¹², I. Aronchik¹³, E. Filvaroff¹³, B. Hanna¹³, Z. Nikolova¹², A. Pinto¹⁴, ¹University Hospital Fundacion Jimenez Diaz, Madrid, ES, ²Vall d'Hebron University Hospital, Barcelona, ES, ³University Hospital 12 De Octubre, Madrid, ES, ⁴Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁵Hospital Universitario Fundación Jimenez Diaz, Madrid, ES, ⁶Fundación Jiménez Díaz, Madrid, ES, ⁷Humanitas Clinical and Research Center, Milan, IT, ⁸Institut Gustave Roussy, Villejuif, FR, ⁹Institute Bergonié, Bordeaux, FR, ¹⁰Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori (IRST), Meldola, IT, ¹¹Celgene Institute Translational Research Europe-CITRE, Sevilla, ES, ¹²Celgene Institute for Translational Research Europe, A Bristol Myers Squibb Company, Sevilla, ES, ¹³Bristol Myers Squibb, Princeton, US, ¹⁴IRCCS, Naples, IT

17:28 - 17:40 **5280 - CC-90011 in patients (Pts) with advanced solid tumours (STs) and relapsed/refractory non-Hodgkin lymphoma (R/R NHL): Updated results of a phase I study**

A. Hollebecque¹, J. De Bono², S. Salvagni³, R. Plummer⁴, P. Niccoli⁵, J. Capdevila⁶, G. Curigliano⁷, V. Moreno Garcia⁸, F. De Braud⁹, M. López-Brea¹⁰, P. Martin-Romano¹, E. Baudin¹¹, M. Arias¹², J. De Alvaro¹², J. Parra-Palau¹², T. Sánchez-Pérez¹², I. Aronchik¹³, E. Filvaroff¹³, M. Lamba¹³, Z. Nikolova¹², ¹Institut Gustave Roussy, Villejuif, FR, ²The Institute of Cancer Research (ICR), London, GB, ³Policlinico S. Orsola-Malpighi, Bologna, IT, ⁴Sir Bobby Robson Cancer Trials Research Centre, Northern Institute for Cancer Research, Newcastle, GB, ⁵Insitut Paoli-Calmettes, Marseille, FR, ⁶Vall d'Hebron University Hospital, Barcelona, ES, ⁷IEO - Istituto Europeo di Oncologia, Milan, IT,

⁸University Hospital Fundacion Jimenez Diaz, Madrid, ES, ⁹Istituto Nazionale Tumori Milano, Milan, IT, ¹⁰H.U. Marqués de Valdecilla, Santander, ES, ¹¹Gustave Roussy - Cancer Campus, Villejuif, FR, ¹²Celgene Institute for Translational Research Europe, A Bristol Myers Squibb Company, Sevilla, ES, ¹³Bristol Myers Squibb, Princeton, US

17:40 - 17:50 **Invited Discussant 5270 and 5280**

G. Draetta, The University of Texas M. D. Anderson Cancer Center, Houston, US

17:50 - 18:00 **Q&A and live discussion**

18:30 - 20:25 Type: Proffered Paper session Channel 1
Title: Presidential Symposium II
Chair(s): Solange Peters, CH

18:30 - 18:42 **LBA3_PR - An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small cell lung cancer (NSCLC) and mediastinal N2 involvement. Primary end-point analysis of Lung ART (IFCT-0503, UK NCRI, SAKK) NCT00410683.**

C. Le Pechoux¹, N. Pourel², F. Barlesi³, C. Faivre-Finn⁴, D. Lerouge⁵, G. Zalcman⁶, D. Antoni⁷, B. Lamezec⁸, U. Nestle⁹, P. Boisselier¹⁰, F. Thillays¹¹, A. Paumier¹², E. Dansin¹³, K. Peignaux¹⁴, J. Madelaine¹⁵, E. Pichon¹⁶, A. Larrouy¹⁷, O. Riesterer¹⁸, A. Lavole¹⁹, A. Bardet¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Institut Sainte Catherine, Avignon, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR, ⁴The Christie NHS Foundation Trust, Manchester, GB, ⁵Centre Baclesse, Caen, FR, ⁶Hôpital Bichat-Claude Bernard, Assistance Publique Hôpitaux de Paris, Université Paris-Diderot, Paris, FR, ⁷Institut de Cancerologie Strasbourg Europe, Strasbourg, FR, ⁸Clinique Armoricaine de Radiologie, St. Briec, FR, ⁹Universitätsklinikum Freiburg Klinik für Innere Medizin Hämatologie, Onkologie und Stammzelltransplantation, Freiburg im Breisgau, DE, ¹⁰ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ¹¹Institut de Cancérologie de l'ouest, Rouen, FR, ¹²ICO Site Paul Papin, Angers, FR, ¹³Centre Oscar Lambret, Lille, FR, ¹⁴Centre Georges Francois Leclerc, Dijon, FR, ¹⁵Centre Hospitalier Caen, Caen, FR, ¹⁶CHRU Bretonneau, Tours, FR, ¹⁷Centre de Cancerologie Paris Nord, Sarcelles, FR, ¹⁸University Hospital Zürich, Zurich, CH, ¹⁹Hopital Tenon, Paris, FR

18:42 - 18:52 **Invited Discussant LBA3_PR**

R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL

18:52 - 19:02 **Q&A and live discussion**

19:02 - 19:14 **LBA4 - IPATential150: Phase III study of ipatasertib (ipat) plus abiraterone (abi) vs placebo (pbo) plus abi in metastatic castration-resistant prostate cancer (mCRPC)**

J. De Bono¹, S. Bracarda², C. Sternberg³, K. Chi⁴, D. Olmos⁵, S. Sandhu⁶, C. Massard⁷, N. Matsubara⁸, B. Alekseev⁹, R. Gafanov¹⁰, F. Parnis¹¹, G.L. Buchsacher Jr¹², L. Corrales¹³, M. Borre¹⁴, G. Vasconcelos Alves¹⁵, J. Garcia¹⁶, M.-L. Harle-Yge¹⁶, G.

Chen¹⁷, M. Wongchenko¹⁷, C. Sweeney¹⁸, ¹The Institute of Cancer Research (ICR), London, GB, ²Azienda Ospedaliera Sta Maria, Terni, IT, ³Weill Cornell Medicine - The Blenis Lab, New York, US, ⁴BC Cancer Agency - Vancouver, Vancouver, CA, ⁵Spanish National Cancer Research Center (CNIO), Madrid, ES, ⁶Peter MacCallum Cancer Centre, Melbourne, AU, ⁷Gustave Roussy - Cancer Campus, Villejuif, FR, ⁸National Cancer Center Hospital East, Kashiwa, JP, ⁹P.A. Herzen Research Institute, Moscow, RU, ¹⁰Russian Scientific Center of Roentgenoradiology, Moscow, RU, ¹¹Adelaide Cancer Centre, Adelaide, AU, ¹²Southern California Permanente Medical Group, Los Angeles, US, ¹³Centro de Investigación y Manejo del Cáncer CIMCA, San José, CR, ¹⁴Aarhus University Hospital, Aarhus, DK, ¹⁵Hospital Nossa Senhora da Conceicao, Porto Alegre, BR, ¹⁶F. Hoffmann-La Roche, Ltd., Basel, CH, ¹⁷Genentech, Inc., South San Francisco, US, ¹⁸Dana-Farber Cancer Institute, Boston, US

19:14 - 19:26

6100 - Final overall survival (OS) analysis of PROfound: Olaparib vs physician's choice of enzalutamide or abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations

J. De Bono¹, J. Mateo², K. Fizazi³, F. Saad⁴, N. Shore⁵, S. Sandhu⁶, K. Chi⁷, O. Sartor⁸, N. Agarwal⁹, D. Olmos¹⁰, A. Thiery-Vuillemin¹¹, P. Twardowski¹², G. Roubaud¹³, M. Ozguroglu¹⁴, J. Kang¹⁵, J. Burgents¹⁶, C. Gresty¹⁷, C. Corcoran¹⁷, C. Adelman¹⁷, M. Hussain¹⁸, ¹The Institute of Cancer Research (ICR), London, GB, ²Vall d'Hebron University Hospital, Barcelona, ES, ³Institut Gustave Roussy, Villejuif, FR, ⁴Centre Hospitalier de l'Université de Montréal/CHUM, Montreal, CA, ⁵Atlantic Urology Clinics, Myrtle Beach, US, ⁶Peter MacCallum Cancer Centre, Melbourne, AU, ⁷BC Cancer Agency, Vancouver, CA, ⁸Tulane University School of Medicine, New Orleans, US, ⁹Huntsman Cancer Hospital, Salt Lake City, US, ¹⁰Spanish National Cancer Research Centre (CNIO), Madrid and Hospitales Universitarios Virgen de la Victoria y Regional de Málaga, Málaga, ES, ¹¹CHRU Besancon - Hopital Jean Minjoz, Besancon, FR, ¹²John Wayne Cancer Institute, Santa Monica, US, ¹³Institute Bergonié, Bordeaux, FR, ¹⁴University Of Istanbul Cerrahpasa Medical Faculty, Istanbul, TR, ¹⁵AstraZeneca, Gaithersburg, US, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷AstraZeneca, Cambridge, GB, ¹⁸Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, US

19:26 - 19:36

Invited Discussant LBA4 and 6100

H. Grönberg, Karolinska Institute, Stockholm, SE

19:36 - 19:51

Q&A live discussion

19:51 - 20:03

LBA5_PR - Abemaciclib in high risk early breast cancer

S. Johnston¹, N. Harbeck², R. Hegg³, M. Toi⁴, M. Martin⁵, Z. Shao⁶, M. Campone⁷, E. Hamilton⁸, J. Sohn⁹, V. Guarneri¹⁰, J. Cortés¹¹, P. Neven¹², F. Boyle¹³, I. Smith¹⁴, D. Headley¹⁵, R. Wei¹⁶, M. Frenzel¹⁷, J. Cox¹⁶, J. O'Shaughnessy¹⁸, P. Rastogi¹⁹, ¹Royal Marsden Hospital NHS Foundation Trust, London, GB, ²Ludwig Maximilians University - Grosshadern, Munich, DE, ³Gynecological Clinical Service School of Medicine, Univ. Sao Paulo, Sao Paulo, BR, ⁴Kyoto University-Graduate school of medicine, Kyoto, JP, ⁵Hospital General Universitario Gregorio Marañón, Madrid, ES, ⁶Fudan University Shanghai Cancer Center, Shanghai, CN, ⁷ICO Institut de Cancerologie de l'Ouest René Gauducheau,

Saint-Herblain, FR, ⁸Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁹Yonsei University, Seoul, KR, ¹⁰Istituto Oncologico Veneto IRCCS, Padova, IT, ¹¹Vall d'Hebron University Hospital, Barcelona, ES, ¹²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ¹³Mater Hospital, North Sydney, North Sydney, AU, ¹⁴Artios Pharma Ltd, Cambridge, GB, ¹⁵Eli Lilly, Indianapolis, US, ¹⁶Eli Lilly and Company, Indianapolis, US, ¹⁷Eli Lilly and Company - Global Headquarters, Indianapolis, US, ¹⁸Texas Oncology - Baylor Sammons Cancer Center, Dallas, US, ¹⁹NSABP Foundation, Pittsburgh, US

20:03 - 20:13 **Invited Discussant LBA5_PR**
G. Sledge, Stanford University, Stanford, US

20:13 - 20:23 **Q&A and live discussion**

21.09.2020

11:15 - 12:15 **Type: Young Oncologist session** **Channel 3**
Title: Quality or quantity: What is the best publication strategy? The Editors' voice
Chair(s): Teresa Amaral, DE; Matteo Lambertini, IT

11:15 - 11:20 **Annals of Oncology**
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR

11:20 - 11:25 **ESMO Open**
M. Preusser, Vienna General Hospital (AKH) - Medizinische Universität Wien, Vienna, AT

11:25 - 11:30 **IO Tech**
J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

11:30 - 12:10 **Q&A and live discussion, all Speakers online Chairs to moderate Q&A**

12:30 - 14:10 **Type: Proffered Paper session** **Channel 1**
Title: Proffered Paper - Breast cancer, metastatic 2
Chair(s): Lesley Fallowfield, GB; Olivia Pagani, CH

12:30 - 12:42 **2740 - Health-related quality of life (HRQoL) changes with veliparib in patients (pts) with metastatic or locally advanced breast cancer in the phase III BROCADE 3 study**
M. Friedlander¹, V. Dieras², B. Arun³, H.S. Han⁴, H. Wildiers⁵, J.P. Ayoub⁶, S. Puhalla⁷, S. Hudgens⁸, L. Floden⁸, N. Khandelwal⁹, K. Benjamin⁹, R. Kamalakar⁹, D. Maag⁹, ¹The Prince of Wales Hospital, Sydney, AU, ²Centre Eugène Marquis Rennes, Institut Curie, Paris, FR, ³The University of Texas MD Anderson Cancer Center, Houston, US, ⁴Moffitt Cancer Center and Research Institute, Tampa, US, ⁵UZ Leuven, Leuven, BE, ⁶CHUM-Notre Dame Hospital, Montreal, CA, ⁷University of Pittsburgh Medical Center, Pittsburgh, US, ⁸Clinical Outcomes Solutions, Tucson, US, ⁹AbbVie Inc, North Chicago, US

12:42 - 12:54 **2750 - Impact of tucatinib on health-related quality of life (HRQoL) in patients with HER2-positive; metastatic breast cancer (MBC) with and without brain metastases (BM)**
V. Mueller¹, E. Paplomata², E. Hamilton³, A. Zelnak⁴, L. Fehrenbacher⁵, E. Jakobsen⁶, E. Curtit⁷, F. Boyle⁸, E.H. Brix⁹, A. Brenner¹⁰, C. Ferrario¹¹, M. Munoz-Mateu¹², T. Arkenau¹³, K. Gelmon¹⁴, D. Cameron¹⁵, G. Curigliano¹⁶, K. Debusk¹⁷, J. Ramos¹⁸, X. An¹⁹, A. Wardley²⁰, ¹UKE Universitätsklinikum Hamburg-Eppendorf KMTZ, Hamburg, DE, ²Winship Cancer Institute of Emory University, Atlanta, US, ³Sarah Cannon Research Institute-Cancer Centre, Nashville, US, ⁴Northside Hospital, Sandy Springs, US, ⁵Kaiser Foundation Research Institute, Oakland, CA, Oakland, US, ⁶Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, Vejle, DK, ⁷CHU Besançon, Hôpital Jean Minjoz, Besançon, FR, ⁸Mater Hospital, North Sydney, North Sydney, AU, ⁹Herlev and Gentofte Hospital, Herlev,

DK, ¹⁰Institute for Drug Development Cancer Therapy Research Center, San Antonio, US, ¹¹Jewish General Hospital McGill University, Montreal, CA, ¹²Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹³Sarah Cannon Research Institute, London, GB, ¹⁴BC Cancer Agency - Vancouver, Vancouver, CA, ¹⁵Edinburgh Cancer Centre Western General Hospital, Edinburgh, GB, ¹⁶IEO - Istituto Europeo di Oncologia, Milan, IT, ¹⁷Seattle Genetics Inc, Bothell, US, ¹⁸Seattle Genetics, Inc., Seattle, US, ¹⁹Seattle Genetics, Inc., Bothell, US, ²⁰The Christie NHS Foundation Trust, Manchester, GB

12:54 - 13:06

2760 - Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC)

P.A. Fasching¹, A. Bardia², A. Nusch³, G. Jerusalem⁴, A. Chan⁵, N. El Saghir⁶, E. Alba⁷, S.-A. Im⁸, W. Janni⁹, D. Chandiwana¹⁰, B. Lanoue¹⁰, A. Thuerigen¹⁰, A. Gaur¹¹, N. Harbeck¹², ¹Universitätsklinikum Erlangen, Erlangen, DE, ²Massachusetts General Hospital Cancer Center, Boston, US, ³Practice for Hematology and Internal Oncology, Velbert, DE, ⁴Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ⁵Breast Cancer Research Centre-WA and School of Medicine, Perth, AU, ⁶American University of Beirut Medical Center, Beirut, LB, ⁷Hospital Clínico Universitario Virgen de la Victoria, Málaga, ES, ⁸Seoul National University Hospital, and Cancer Research Institute, Seoul National University College of Medicine, Seoul, KR, ⁹Ulm Medical University, Ulm, DE, ¹⁰Novartis Pharmaceuticals Corporation, East Hanover, US, ¹¹Novartis Healthcare Pvt Ltd, Hyderabad, IN, ¹²Ludwig Maximilians University - Grosshadern, Munich, DE

13:06 - 13:16

Invited Discussant 2740, 2750 and 2760

L. Fallowfield, Brighton and Sussex Medical School, University of Sussex, Brighton, GB

13:16 - 13:26

Q&A and live discussion

13:26 - 13:38

LBA19 - GEICAM/2014-12 (FLIPPER) study: First analysis from a randomized phase II trial of fulvestrant (F)/palbociclib (P) versus (vs.) F/placebo (PL) as first-line therapy in postmenopausal women with HR (Hormone Receptor)+/HER2- endocrine sensitive advanced breast cancer (ABC)

J. Albanell¹, M.T. Martinez², M. Ramos³, M. O' Connor⁴, L. Merino De La Cruz⁵, A. Santaballa Bertran⁶, N. Martínez-Jáñez⁷, F. Moreno⁸, I. Fernández Pérez⁹, J. Alarcon Company¹⁰, J.A. Virizuela Echaburu¹¹, J. De La Haba Rodríguez¹², P. Sánchez-Rovira¹³, L. González-Cortijo¹⁴, M. Margeli Vila¹⁵, A. Sánchez Muñoz¹⁶, I. Garau Llinas¹⁷, M. Casas¹⁸, S. Bezares Montes¹⁹, F. Rojo Todo²⁰, ¹Hospital del Mar, Barcelona, ES, ²Hospital Clínico Universitario de Valencia, Valencia, ES, ³Centro oncológico de Galicia. GEICAM Spanish Breast Cancer Group., A Coruna, ES, ⁴University Hospital Waterford. Cancer Trials Ireland., Waterford, IE, ⁵7 Hospital Virgen de la Macarena. GEICAM Spanish Breast Cancer Group., Sevilla, ES, ⁶Hospital Universitario y Politécnico de la Fe. GEICAM Spanish Breast Cancer Group., Valencia, ES, ⁷Hospital Universitario Ramón y Cajal. GEICAM Spanish Breast Cancer Group., Madrid, ES, ⁸Hospital Clínico Universitario San Carlos. GEICAM Spanish Breast Cancer Group., Madrid, ES, ⁹Complejo Hospitalario de Vigo Hospital Álvaro Cunqueiro. GEICAM Spanish Breast Cancer Group., VIGO, ES, ¹⁰Hospital Son Espases. GEICAM Spanish Breast Cancer Group., Palma de Mallorca, ES, ¹¹Hospital Quirón Sagrado Corazón. GEICAM Spanish Breast Cancer

Group. SEOM Sociedad Española de Oncología Médica, Sevilla, ES, ¹²Hospital Reina Sofía. Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII. GECAM Spanish Breast Cancer Group., Córdoba, ES, ¹³Complejo Hospitalario de Jaén. GEICAM Spanish Breast Cancer Group, Jaén, ES, ¹⁴Hospital Universitario Quirosalud. GEICAM Spanish Breast Cancer Group, Madrid, ES, ¹⁵B-ARGO Group, Catalan Institut of Oncology, Hospital Universitari Germans Trias i Pujol. GEICAM Spanish Breast Cancer Group., Badalona, ES, ¹⁶Hospital Universitario Virgen de la Victoria. GEICAM Spanish Breast Cancer Group., Málaga, ES, ¹⁷Hospital Son Llàtzer. GEICAM Spanish Breast Cancer Group., Palma de Mallorca, ES, ¹⁸GEICAM Spanish Breast Cancer Group, San Sebastian de los Reyes, ES, ¹⁹GEICAM Spanish Breast Cancer Group, Madrid, ES, ²⁰Hospital Universitario Fundacion Jimenez Diaz. GEICAM Spanish Breast Cancer Group. Centro de Investigación Biomédica en Red de Oncología, CIBERONC-ISCIII, Madrid, ES

13:38 - 13:48 **Invited Discussant LBA19**

J. Gligorov, Hopital Tenon, Paris, FR

13:48 - 13:58 **Q&A and live discussion**

12:30 - 14:10 Type: Proffered Paper session Channel 2
Title: Proffered Paper - Supportive and palliative care
Chair(s): Stein Kaasa, NO; Jayne Wood, GB

12:30 - 12:42 **LBA87 - A Pragmatic Cluster-Randomized Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer (AToM)**

M. Krzyzanowska¹, J. Julian², C.-S. Gu³, M. Powis⁴, Q. Li⁵, K. Enright⁶, D. Howell⁴, C. Earle⁷, S. Gandhi⁸, S. Rask⁹, C. Brezden-Masley¹⁰, S. Dent¹¹, L. Hajra¹², O. Freedman¹³, S. Spadafora¹⁴, C. Hamm¹⁵, N. Califaretti¹⁶, M. Trudeau⁸, M. Levine³, E. Grunfeld¹⁷,
¹University Health Network - Princess Margaret Cancer Center, Toronto, CA, ²Ontario Clinical Oncology Group, Hamilton, CA, ³Hamilton Health Sciences Centre, Hamilton, CA, ⁴Princess Margaret Cancer Centre, Toronto, CA, ⁵Institute for Clinical Evaluative Sciences, Toronto, CA, ⁶Trillium Health Partners, Mississauga, CA, ⁷ICES Central, Toronto, CA, ⁸Sunnybrook Health Sciences Centre, Toronto, CA, ⁹Royal Victoria Hospital, Barrie, CA, ¹⁰St. Michael's Hospital, Toronto, CA, ¹¹The Ottawa Hospital Regional Cancer Centre, Ottawa, CA, ¹²Markham Stouffville Hospital, Markham, CA, ¹³Durham Regional Cancer Centre, Oshawa, CA, ¹⁴Sault Area Hospital, Sault Ste Marie, CA, ¹⁵Windsor Regional Hospital, Windsor, CA, ¹⁶Grand River Regional Cancer Centre, Waterloo, CA, ¹⁷University of Toronto, Toronto, CA

12:42 - 12:54 **18090 - TRheuMa registry provides real world data on rheumatic immune-related adverse events**

K. Benesova¹, L. Diekmann¹, H.-M. Lorenz¹, J. Leipe², J. Kunz³, J. Hassel⁴, K. Jordan⁵,
¹Medizinische Universitaetsklinik (Neue Kreb-Klinik), Heidelberg, DE, ²University Hospital Mannheim, Mannheim, DE, ³Thoraxklinik, University Hospital Heidelberg, Heidelberg, DE, ⁴NCT - Nationales Zentrum für Tumorerkrankungen, Heidelberg, DE, ⁵University of Heidelberg, Heidelberg, DE

- 12:54 - 13:06 **15680 - Quality of life in cancer patients treated with immune checkpoint inhibitors: A meta-analysis**
B. Gonzalez¹, S. Eisel², K. Bowles², A. Hoogland², B. James³, B. Small³, S. Sharpe², K. Hyland³, H. Bulls², S. Christy², J. Mansfield³, A. Nelson², R. Alla³, K. Maharaj³, B. Kennedy², E. Lafranchise³, N. Williams⁴, M. Postow⁵, A. Dicker⁶, H. Jim², ¹H. Lee Moffitt Cancer Center University of South Florida, Tampa, US, ²Moffitt Cancer Center, Tampa, US, ³University of South Florida, Tampa, US, ⁴Levine Cancer Institute at Atrium Health, Charlotte, US, ⁵Memorial Sloan Kettering 60th Street Outpatient Center, New York, US, ⁶Thomas Jefferson University, Philadelphia, US
- 13:06 - 13:16 **Invited Discussant LBA87, 18090 and 15680**
M. Hjermstad, Oslo University Hospital, Ullevål, Oslo, NO
- 13:16 - 13:26 **Q&A and live discussion**
- 13:26 - 13:38 **18100 - Impact of malnutrition according to the GLIM criteria in cancer patients admitted to hospital**
M. Nunez Abad¹, J. Garrido Gallego¹, V. Iranzo², C. Caballero Diaz¹, A. Fernandez Diaz¹, I. Shaheen¹, M. Meri Abad¹, M. Franco La Rosa¹, C. Garcia Gonzalez¹, V. Ruiz Cordero¹, L. Sanz Monge¹, A. Jimenez Portilla³, A. Artero Fullana¹, N. Prieto Colodrero³, B. Voltas Arribas¹, Y. Ruiz Berjaga¹, M. Llamas Montero¹, C. Sanchez Juan¹, C. Camps Herrero¹, B.T. Muresan¹, ¹Hospital General Universitario Valencia, Valencia, ES, ²Hospital General Universitario de Valencia, Valencia, ES, ³Fundación de Investigación Hospital General Universitario de Valencia, Valencia, ES
- 13:38 - 13:50 **15040 - Relationship between sarcopenia and anthracycline related cardiotoxicity in patients with cancer**
O. Dizdar¹, O. Bas², A. Erdemir², R. Onur², G. Guner¹, D.C. Guven³, S. Aksu⁴, N. Kertmen⁴, S. Aksoy⁴, I. Barista¹, A. Turker¹, ¹Hacettepe University Cancer Institute, Ankara, TR, ²Hacettepe University - Faculty of Medicine, Ankara, TR, ³Hacettepe University Oncology Hospital, Ankara, TR, ⁴Hacettepe University Faculty of Medicine, Ankara, TR
- 13:50 - 14:00 **Invited Discussant 18100 and 15040**
J. Wood, The Royal Marsden Hospital - NHS Foundation Trust, London, GB
- 14:00 - 14:10 **Q&A and live discussion**
- 14:25 - 16:05 Type: Proffered Paper session Channel 1**
Title: Proffered Paper - GU, prostate
 Chair(s): Silke Gillessen, CH
- 14:25 - 14:37 **6090 - Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE) immune therapy for**

metastatic castration-resistant prostate cancer (mCRPC)

B. Tran¹, L. Horvath², T. Dorff³, M. Rettig⁴, M. Lolkema⁵, J.-P. Machiels⁶, S. Rottey⁷, K. Autio⁸, R. Greil⁹, N. Adra¹⁰, C. Lemech¹¹, M. Minocha¹², F.-C. Cheng¹², H. Kouros-Mehr¹², K. Fizazi¹³, ¹Peter MacCallum Cancer Centre, Melbourne, AU, ²Chris O'Brien Lifehouse, Camperdown, AU, ³City of Hope, Duarte, US, ⁴UCLA, Los Angeles, US, ⁵Erasmus University Medical Center, Rotterdam, NL, ⁶Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE, ⁷Ghent University, Ghent, BE, ⁸Memorial Sloan Kettering Cancer Center, New York, US, ⁹Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT and Cancer Cluster, Salzburg, AT, ¹⁰Indiana University School of Medicine, Indianapolis, US, ¹¹Scientia Clinical Research, Randwick, AU, ¹²Amgen Inc., Thousand Oaks, US, ¹³Institut Gustave Roussy, Villejuif, FR

14:37 - 14:47 **Invited Discussant 6090**

C. Sternberg, Weill Cornell Medicine - The Blenis Lab, New York, US

14:47 - 14:57 **Q&A and live discussion**

14:57 - 15:09 **6110 - Abiraterone acetate plus prednisolone for hormone-naïve prostate cancer (PCa): Long-term results from metastatic (M1) patients in the STAMPEDE randomised trial (NCT00268476)**

N. James¹, H. Rush², N. Clarke², G. Attard³, A. Cook⁴, D. Dearnaley⁵, S. Gillessen⁶, A. Hoyle⁷, R. Jones⁸, R. Millman², A. Birtle⁹, S. Chowdhury¹⁰, J. Gale¹¹, Z. Malik¹², J. O'Sullivan¹³, C. Pezaro¹⁴, D. Sheehan¹⁵, J. Tanguay¹⁶, M. Parmar⁴, M. Sydes¹⁷, ¹ICR - Institute of Cancer Research, London, GB, ²University College London NHS Foundation Trust, London, GB, ³UCL Cancer Institute - UCL - London's Global University, London, GB, ⁴Institute of Clinical Trials and Methodology-UCL, London, GB, ⁵Institute of Cancer Research, London, GB, ⁶EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH, ⁷The Christie and Salford Royal NHS Foundation Trusts, Manchester, GB, ⁸Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁹Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, Preston, GB, ¹⁰Guy's and St. Thomas' Hospital NHS Trust, London, GB, ¹¹Princess Alexandra Hospital, Portsmouth, GB, ¹²The Clatterbridge Cancer Centre NHS Foundation Trust, Wirral, GB, ¹³The Northern Ireland Cancer Centre, Belfast, GB, ¹⁴Sheffield teaching hospital, Sheffield, GB, ¹⁵RD&E Hospital, Devon, GB, ¹⁶Velindre Cancer Centre, Cardiff, GB, ¹⁷Medical Research Council Clinical Trials Unit, London, GB

15:09 - 15:19 **Invited Discussant 6110**

M. De Santis, Charité - Universitätsmedizin Berlin, Berlin, DE

15:19 - 15:29 **Q&A and live discussion**

14:25 - 16:05	Type: Proffered Paper session Title: Proffered Paper - Public Policy Chair(s): Rosa Giuliani, GB; Jose Martin-Moreno, ES	Channel 2
---------------	--	------------------

- 14:25 - 14:37 **15810_PR - Estimation of European cancer burden for the year 2020**
T. Dyba¹, G. Randi¹, M.D.C. Martos¹, F. Giusti¹, J. Ferlay², F. Bray², N. Dimitrova¹, L. Neamtiu³, N. Nicholson¹, R. Carvalho¹, M. Bettio¹, ¹European Commission - Joint Research Centre, Ispra, IT, ²International Agency for Research on Cancer, Lyon, FR, ³European Commission, Ispra, IT
- 14:37 - 14:49 **LBA66_PR - Disparities in access to oncology clinical trials in Europe in the period 2009-2019**
A. Carneiro¹, T. Amaral², M. Brandao³, M. Scheffler⁴, K. Bol⁵, R. Ferrara⁶, M. Jalving⁷, G. Lo Russo⁸, I. Marquez-Rodas⁹, A. Matikas¹⁰, L. Mezquita¹¹, G. Morgan¹², C.E. Onesti¹³, S. Pilotto¹⁴, E. Saloustros¹⁵, D. Trapani¹⁶, ¹Skanes universitetssjukhus - Onkologiska Klinik, Lund, SE, ²University Hospital Tubingen, Tuebingen, DE, ³Institute Jules Bordet, Brussels, BE, ⁴Uniklinik Köln, Cologne, DE, ⁵Herlev Hospital - National Center for Cancer Immune Therapy, Herlev, DK, ⁶Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, IT, ⁷University Medical Center Groningen, Groningen, NL, ⁸Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, ⁹Hospital General Universitario Gregorio Marañon - Fundación Investigación Biomedica, Madrid, ES, ¹⁰Karolinska University Hospital-Solna, Stockholm, SE, ¹¹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹²Skane University Hospital, Lund, SE, ¹³Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ¹⁴Ospedale Borgo Roma - AOU Integrata di Verona, Verona, IT, ¹⁵University Hospital of Larissa, Larissa, GR, ¹⁶Istituto Europeo di Oncologia, Milan, IT
- 14:49 - 14:59 **Invited Discussant 15810_PR and LBA66_PR**
R. Giuliani, The Clatterbridge Cancer Centre, Liverpool, GB
- 14:59 - 15:09 **Q&A and live discussion**
- 15:09 - 15:21 **15820 - Developing a real-world outcomes forecast model using matched oncology clinical trials and real world evidence to inform policy-making and reimbursement approaches**
J. Hinkel¹, T. Gorman², A. Ray², S. Brar², ¹University of Oxford, Oxford, GB, ²Lydion Research, Los Angeles, US
- 15:21 - 15:33 **15830 - Clinical benefit of cancer drugs approved in Switzerland during the last decade**
R. Adam¹, A. Tibau², C. Molto Valiente², B. Seruga³, A. Ocaña⁴, E. Amir⁵, A. Templeton⁶, ¹Kantonsspital St. Gallen, St. Gallen, CH, ²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ³Institute of Oncology Ljubljana, Ljubljana, SI, ⁴Hospital Clinico Universitario San Carlos, Madrid, ES, ⁵University Health Network - Princess Margaret Cancer Center, Toronto, CA, ⁶St. Claraspital AG, Basel, CH
- 15:33 - 15:45 **15840 - Health technology assessment (HTA) in England, France and Germany: What do we know about variations in cancer-related HTA outcomes?**
R. Schaefer, D. Hernández, M. Schlander, German Cancer Research Center, Heidelberg,

DE

15:45 - 15:55 **Invited Discussant 15820, 15830 and 15840**

C. Le Tourneau, Institut Curie, Paris, FR

15:55 - 16:05 **Q&A and live discussion**

14:25 - 16:05 Type: Proffered Paper session Channel 3

Title: Proffered Paper - NSCLC metastatic 2

Chair(s): Roy Herbst, US; Fiona Blackhall, GB

14:25 - 14:37 **LBA51 - KEYNOTE-024 5-year OS update: first-line (1L) pembrolizumab (pembro) vs platinum-based chemotherapy (chemo) in patients (pts) with metastatic NSCLC and PD-L1 tumor proportion score (TPS) $\geq 50\%$**

J. Brahmer¹, D. Rodriguez-Abreu², A.G. Robinson³, R. Hui⁴, T. Cs szi⁵, A. F l p⁶, M. Gottfried⁷, N. Peled⁸, A. Tafreshi⁹, S. Cuffe¹⁰, M. O'Brien¹¹, S. Rao¹², K. Hotta¹³, T.A. Leal¹⁴, J.W. Riess¹⁵, E. Jensen¹⁶, B. Zhao¹⁶, M.C. Pietanza¹⁷, M. Reck¹⁸, ¹Johns Hopkins Hospital, Baltimore, US, ²Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES, ³Westmead Hospital and the University of Sydney, Sydney, AU, ⁴Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead, AU, ⁵Hetenyi G Korhaz Onkologiai Kozpont, Szolnok, HU, ⁶Orsz gos Kor nyi Pulmonol giai Int zet, Budapest, HU, ⁷Meir Medical Center, Kfar-Saba, IL, ⁸Soroka University Medical Center, Beer Sheva, IL, ⁹Consulting Suites, Wollongong, AU, ¹⁰St. James's Hospital and Cancer Trials Ireland (formerly ICORG - All Ireland Cooperative Oncology Research Group), Dublin, IE, ¹¹The Royal Marsden Hospital, Sutton, Surrey, GB, ¹²MedStar Franklin Square Hospital, Baltimore, US, ¹³Okayama University Hospital, Okayama, JP, ¹⁴Carbone Cancer Center, University of Wisconsin, Madison, US, ¹⁵UC Davis Comprehensive Cancer Center, Sacramento, US, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Merck Sharp & Dohme Corp. USA, Whitehouse Station, US, ¹⁸Krankenhaus Grosshansdorf, Grosshansdorf, DE

14:37 - 14:49 **LBA52 - EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) $\geq 50\%$**

A. Sezer¹, S. Kilickap², M. G m s ³, I. Bondarenko⁴, M.  zg ro lu⁵, M. Gogishvili⁶, H.M. Turk⁷,  .  i in⁸, D. Bentsion⁹, O. Gladkov¹⁰, P. Clingan¹¹, V. Sriuranpong¹², N. Rizvi¹³, S. Li¹⁴, S. Lee¹⁵, G. Gullo¹⁶, I. Lowy¹⁶, P. Rietschel¹⁶, ¹Baskent University Faculty of Medicine Adana Uygulama Ve Arastirma Mer., Adana, TR, ²Hacettepe University - Faculty of Medicine, Ankara, TR, ³Istanbul Medeniyet University Hospital, Istanbul, TR, ⁴Municipal Institution City Clinical Hospital, Dnipropetrovsk Oblast, UA, ⁵Istanbul University-Cerrahpasa, Istanbul, TR, ⁶University Clinic Ltd, Tbilisi, GE, ⁷Bezmialem Vakif University, Medical Faculty, Istanbul, TR, ⁸Trakya University School of Medicine, Edirne, TR, ⁹Oncology Centre, Sverdlovsk, RU, ¹⁰"EVIMED", Chelyabinsk, RU, ¹¹University of Wollongong/Illawarra Cancer Centre, Wollongong Hospital, Wollongong, AU, ¹²King Chulalongkorn Memorial Hospital, Bangkok, TH, ¹³Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US, ¹⁴Regeneron Pharmaceuticals, Inc., Basking Ridge, US, ¹⁵Regeneron Pharmaceuticals

Inc., Basking Ridge, US, ¹⁶Regeneron Pharmaceuticals, Inc., Tarrytown, US

- 14:49 - 15:01 **LBA53 - Precision Immuno-Oncology for advanced Non-Small Cell Lung Cancer (NSCLC) patients (pts) treated with PD1/L1 immune checkpoint inhibitors (ICIs): a first analysis of the PIONeer Study**
F. Barlesi¹, L. Greillier², F. Monville³, C. Foa⁴, J. Le Treut⁵, C. Audigier-Valette⁶, F. Vély⁷, S. Garcia⁸, F. Sabatier⁹, J. Ciccolini¹⁰, M. Fabre⁷, M. Le Ray¹¹, N. Resseguier⁸, P. Outters³, M. Roumieux¹², J. Mazieres¹³, M. Pérol¹⁴, E. Vivier¹⁰, P. Auquier⁸, J. Fieschi³, ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ²Hopital St. Marguerite Assistance Publique Hopitaux de Marseille, Marseille, FR, ³HalioDx, Marseille Cedex, FR, ⁴Hopital Privé de Versailles - Les Franciscaines - Ramsay Générale de Santé, Versailles, FR, ⁵hopital européen Marseille, marseille, FR, ⁶Hospital Sainte Musse, Toulon, FR, ⁷APHM, Marseille cedex, FR, ⁸APHM, Marseille, FR, ⁹APHM Hôpital Conception, Marseille, FR, ¹⁰Aix-Marseille University - Faculté de Médecine Nord, Marseille, FR, ¹¹APHM Hôpital de La Timone, Marseille, FR, ¹²Aix Marseille Université - CRCM, Marseille, FR, ¹³CHU Toulouse - Hôpital Larrey, Toulouse, FR, ¹⁴Centre Léon Bérard, Lyon, FR
- 15:01 - 15:11 **Invited Discussant LBA51, LBA52 and LBA53**
R. Herbst, Yale University School of Medicine, Yale Comprehensive Cancer Center, New Haven, US
- 15:11 - 15:21 **Q&A live discussion**
- 15:21 - 15:33 **LBA54 - Randomized phase III trial of nivolumab in combination with carboplatin, paclitaxel, and bevacizumab as first-line treatment for patients with advanced or recurrent non-squamous NSCLC**
J.-S. Lee¹, S. Sugawara², J.H. Kang³, H.R. Kim⁴, N. Inui⁵, T. Hida⁶, K.H. Lee⁷, T. Yoshida⁸, H. Tanaka⁹, C.T. Yang¹⁰, M. Nishio¹¹, Y. Ohe¹², T. Tamura¹³, N. Yamamoto¹⁴, C.-J. Yu¹⁵, H. Akamatsu¹⁴, Y. Namba¹⁶, N. Sumiyoshi¹⁷, K. Nakagawa¹⁸, ¹Seoul National University Bundang Hospital, Seongnam, KR, ²Sendai Kousei Hospital, Sendai, JP, ³Seoul St. Mary's Hospital, of the Catholic University, Seoul, KR, ⁴Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁵HamHamatsu University Hospital, Hamamatsu, JP, ⁶Aichi Cancer Center Hospital, Nagoya, JP, ⁷Chungbuk National University Hospital, Chungcheongbuk-Do, KR, ⁸National Cancer Center Hospital, Tokyo, JP, ⁹Niigata Cancer Center Hospital, Niigata, JP, ¹⁰Chang Gung Memorial Hospital-Taipei, New Taipei city, TW, ¹¹Cancer Institute Hospital of JFCR, Tokyo, JP, ¹²National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, ¹³St. Luke's International Hospital, Tokyo, JP, ¹⁴Wakayama Medical University, Wakayama, JP, ¹⁵National Taiwan University Hospital, Taipei, TW, ¹⁶Ono Pharmaceutical Co., Ltd. - Headquarters, Osaka, JP, ¹⁷Ono Pharmaceutical Co., Ltd.-Headquarters, Osaka, JP, ¹⁸Kindai University School of Medicine, Osaka, JP
- 15:33 - 15:45 **LBA55 - WJOG @Be Study: A Phase II Study of Atezolizumab (Atez) With Bevacizumab (Bev) for Non-Squamous (Sq) Non-Small-Cell Lung Cancer (NSCLC) with High PD-L1 Expression**
T. Seto¹, K. Nosaki², M. Shimokawa³, R. Toyozawa¹, S. Sugawara⁴, H. Hayashi⁵, H.

Murakami⁶, T. Kato⁷, S. Niho², H. Saka⁸, M. Oki⁸, H. Yoshioka⁹, I. Okamoto¹⁰, H. Daga¹¹, K. Azuma¹², H. Tanaka¹³, K. Nishino¹⁴, M. Satouchi¹⁵, N. Yamamoto¹⁶, K. Nakagawa¹⁷,
¹National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ²National Cancer Center Hospital East, Kashiwa, JP, ³Yamaguchi University Graduate School of Medicine, Ube, JP, ⁴Sendai Kousei Hospital, Sendai, JP, ⁵Kindai University Faculty of Medicine, Osakasayama, JP, ⁶Shizuoka Cancer Center, Shizuoka, JP, ⁷Kanagawa Cancer Center, Yokohama, JP, ⁸National Hospital Organization Nagoya Medical Center, Nagoya, JP, ⁹Kansai Medical University Hospital, Hirakata, JP, ¹⁰National Kyushu Cancer Center, Fukuoka, JP, ¹¹Osaka City General Hospital, Osaka, JP, ¹²Department of Internal Medicine, Kurume University School of Medicine, Kurume, JP, ¹³Niigata Cancer Center Hospital, Niigata, JP, ¹⁴Osaka International Cancer Center, Osaka, JP, ¹⁵Hyogo Cancer Center, Akashi, JP, ¹⁶Wakayama Medical University, Wakayama, JP, ¹⁷Kindai University School of Medicine, Osaka, JP

- 15:45 - 15:55 **Invited Discussant LBA54 and LBA55**
A. Sacher, Princess Margaret Cancer Center, Toronto, CA
- 15:55 - 16:05 **Q&A live discussion**

16:20 - 18:00 **Type: Proffered Paper session** **Channel 1**
Title: Proffered Paper - Basic Science
Chair(s): Daniel Peeper, NL

16:20 - 16:32 **10 - A study of cancer dissemination from metastatic intermediates of hypermethylated colorectal patients reveals a new mode of collective migration**

E. Dornier¹, D.-L. Pagès¹, M. Ducreux², D. Malka³, F. Jaulin¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy - Cancer Campus, Villejuif, FR, ³Institut de Cancérologie Gustave Roussy, Villejuif, FR

16:32 - 16:44 **19770 - Functional inactivation of E-cadherin drives EMT-less metastasis**

S. Alberti¹, E. Guerra², R. Lattanzio², M. Ceci², K. Boujnah¹, S. Briguori¹, V. Garbo¹, A. Moschella¹, D. Altomare³, R. Depalo³, M.T. Rotelli³, A. Picciariello³, M. Trerotola², ¹AOU Policlinico G. Martino - Università di Messina, Messina, IT, ²University of Chieti, Chieti Scalo, IT, ³University of Bari, Bari, IT

16:44 - 16:54 **Invited Discussant 10 and 19770**

16:54 - 17:04 **Q&A and live discussion**

17:04 - 17:16 **20 - Growth differentiation factor 15 (GDF-15) neutralization reverses cancer cachexia, restores physical performance and mitigates emesis associated with platinum-based chemotherapy**

Z. Wu¹, D. Bennett¹, J. Brosnan¹, R. Calle¹, S. Collins², R. Esquejo¹, S. Joaquim¹, A. Joyce³, H. Kim¹, B. Lacarubba¹, L. Lin¹, J.Y. Kim-Muller¹, M. Peloquin¹, B. Pettersen¹, S. Qiao¹, M. Rossulek¹, G. Weber¹, B. Zhang¹, M. Birnbaum¹, D. Breen¹, ¹Pfizer, Cambridge, US, ²Pfizer, Sandwich, Kent, GB, ³Pfizer, Andover, US

17:16 - 17:28 **30 - Efficacy of the triple combination of Estrogen Receptor, CDK4/6 and PI3K pathway inhibitors in ex-vivo models of breast cancer**

A. Diana¹, C.M. Della Corte¹, F. Carlino¹, V. Ciaramella¹, E. Franzese¹, S. Centonze¹, C. Trovato¹, I. Vassallo², F. Iovino¹, E. Procaccini¹, F. Ciardiello¹, F. Morgillo¹, M. Orditura¹, ¹Università degli Studi della Campania Luigi Vanvitelli, Napoli, IT, ²Università degli studi della Campania Luigi Vanvitelli, Napoli, IT

17:28 - 17:38 **Invited Discussant 20 and 30**

17:38 - 17:48 **Q&A and live discussion**

16:20 - 18:00 **Type: Proffered Paper session** **Channel 2**

Title: Proffered Paper - GU, non prostate 2

Chair(s): Manuela Schmidinger, AT; Viktor Grünwald, DE

- 16:20 - 16:32 **7000 - Kidney ccRCC immune classification (KIC) enhances the predictive value of T effector (Teff) and angiogenesis (Angio) signatures in response to nivolumab (N)**
M. Meylan¹, B. Beuselinck², C. Dalban³, Y. Vano⁴, N. Rioux Leclercq⁵, C. Sautès-Fridman¹, E. Roussel⁶, A. Verbiest⁷, N. Chaput⁸, S. Terry⁹, C. Chevreau¹⁰, M. Gross Goupil¹¹, A. Fléchon¹², B. Laguerre¹³, S. Chabaud³, F. Tantot¹⁴, D. Lambrechts², B. Escudier¹⁵, W.-H. Fridman¹, L. Albiges¹⁶, ¹Centre de Recherche des Cordeliers, Paris, FR, ²University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ³Centre Léon Bérard, Lyon, FR, ⁴Hopital European George Pompidou, Paris, FR, ⁵Inserm U1085-IRSET, University Hospital, Rennes, FR, ⁶University Hospitals Leuven,, Leuven, BE, ⁷University Hospitals Leuven, Leuven, BE, ⁸Gustave Roussy, Villejuif, FR, ⁹Gustave Roussy - Université Paris-Saclay, Villejuif, FR, ¹⁰INSTITUT CLAUDIUS REGAUD, Toulouse, FR, ¹¹CHU Bordeaux - Hopital St. André, Bordeaux, FR, ¹²Centre Léon Bérard, Rhones-Alpes, FR, ¹³Centre Eugene - Marquis, Rennes, FR, ¹⁴Unicancer, Le Kremlin Bicêtre, FR, ¹⁵Gustave Roussy - Cancer Campus, Villejuif, FR, ¹⁶Institut Gustave Roussy, Villejuif, FR
- 16:32 - 16:44 **7010 - Assessment of circulating cell-free tumor DNA (ctDNA) in 847 patients (pts) with metastatic renal cell carcinoma (mRCC) and concordance with tissue-based testing**
Z. Zengin¹, C. Weipert², J. Hsu¹, N. Salgia¹, J. Saam², T. Choueiri³, N. Agarwal⁴, S. Pal¹, ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²Guardant Health, Inc., Redwood City, US, ³Dana Farber Cancer Institute, Boston, US, ⁴University of Utah Health - Huntsman Cancer Institute, Salt Lake City, US
- 16:44 - 16:54 **Invited Discussant 7000 and 7010**
W. Berger, Medizinische Universitaet Wien, Vienna, AT
- 16:54 - 17:04 **Q&A and live discussion**
- 17:04 - 17:16 **7020 - Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from the COSMIC-021 study**
S. Pal¹, C.-K. Tsao², C. Suarez³, W. Kelly⁴, L. Pagliaro⁵, U. Vaishampayan⁶, Y. Loriot⁷, S. Srinivas⁸, B. Mcgregor⁹, A. Panneerselvam¹⁰, D. Curran¹⁰, T. Choueiri⁹, N. Agarwal¹¹, ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²Mount Sinai Hospital, New York, US, ³Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, ES, ⁴Thomas Jefferson University, Philadelphia, US, ⁵Mayo Clinic, Rochester, US, ⁶Michigan Medicine University of Michigan, Ann Arbor, US, ⁷Institut Gustave Roussy, Villejuif, FR, ⁸Stanford University Medical Center,, Palo Alto, US, ⁹Dana Farber Cancer Institute, Boston, US, ¹⁰Exelixis, Inc., Alameda, US, ¹¹Huntsman Cancer Hospital, Salt Lake City, US
- 17:16 - 17:28 **LBA25 - Results from the phase 2 BIOMarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR tyrosine Kinase inhibitor (TKI) in naïve metastatic**

Kidney cancer (m-ccRCC) patients (pts): the BIONIKK trial.

Y. Vano¹, R. Elaidi², M. Bennamoun³, C. Chevreau⁴, D. Borchiellini⁵, D. Pannier⁶, D. Maillet⁷, M. Gross-Goupil⁸, C. Tournigand⁹, B. Laguerre¹⁰, P. Barthélémy¹¹, F. Joly¹², G. Gravis¹³, S. Caruso¹⁴, C.-M. Sun¹⁴, V. Verkarre¹⁵, W.-H. Fridman¹⁶, J. Zucman-Rossi¹⁷, C. Sautès-Fridman¹⁶, S. Oudard¹, ¹Hopital European George Pompidou, Paris, FR, ²ARTIC - Association pour la Recherche de Thérapeutiques Innovantes en Cancérologie, Paris, FR, ³Institute Mutualiste Montsouris, Paris, FR, ⁴Institut Universitaire du Cancer -Toulouse-Oncopole, Toulouse, FR, ⁵Centre Anticancer Antoine Lacassagne, Nice, FR, ⁶Centre Oscar Lambret, Lille, FR, ⁷Lyon Sud Hospital Center - HCL, Pierre Benite, FR, ⁸CHU Bordeaux Hopital St. André, Bordeaux, FR, ⁹Centre hospitalier universitaire Henri-Mondor, Créteil, FR, ¹⁰Centre Eugene - Marquis, Rennes, FR, ¹¹Les Hôpitaux Universitaires de Strasbourg/ Institut de Cancérologie Strasbourg Europe, Strasbourg, FR, ¹²Centre François Baclesse, Caen, FR, ¹³Institute Paoli Calmettes, Marseille, FR, ¹⁴Centre de Recherche des Cordeliers, INSERM, Université de Paris, Sorbonne Université, Paris, France, Paris, FR, ¹⁵Hôpital Européen Georges Pompidou, APHP.Centre - Université de Paris; Immunotherapy and anti-angiogenic therapy in oncology, Université de Paris, INSERM, PARCC, Paris, France, Paris, FR, ¹⁶Centre de Recherche des Cordeliers, Paris, FR, ¹⁷Université Paris Descartes, Paris, FR

17:28 - 17:38 **Invited Discussant 7020 and LBA25**

L. Albiges, Institut Gustave Roussy, Villejuif, FR

17:38 - 17:48 **Q&A and live discussion**

16:20 - 18:00 Type: Proffered Paper session Channel 3
Title: Proffered Paper - Gynaecological cancers 2
Chair(s): Isabelle Ray-Coquard, FR; Remy Nout, NL

16:20 - 16:32 **LBA31 - Primary results from IMagyn050/GOG 3015/ENGOT-OV39, a double-blind placebo (pbo)-controlled randomised phase 3 trial of bevacizumab (bev)-containing therapy +/- atezolizumab (atezo) for newly diagnosed stage III/IV ovarian cancer (OC)**

K. Moore¹, M. Bookman², J. Sehouli³, A. Miller⁴, C. Anderson⁵, G. Scambia⁶, T. Myers⁷, C. Taskiran⁸, K. Robison⁹, J. Maenpaa¹⁰, L. Willmott¹¹, N. Colombo¹², J. Thomes-Pepin¹³, M. Gold¹⁴, C. Aghajanian¹⁵, F. Wu¹⁶, L. Molinero¹⁶, V. Khor¹⁶, Y. Lin¹⁶, S. Pignata¹⁷, ¹Stephenson Cancer Center/University of Oklahoma, Oklahoma City, US, ²University of Arizona Health Sciences, Tucson, US, ³Universitätsklinik Charité, Campus Virchow Klinikum, Berlin, DE, ⁴Roswell Park Comprehensive Cancer Center, Buffalo, US, ⁵Willamette Valley Cancer Institute, Eugene, US, ⁶Policlinico Universitario A. Gemelli, Roma, IT, ⁷Baystate Medical Center, Springfield, US, ⁸American Hospital, Istanbul, TR, ⁹Women and Infants Hospital, Providence, US, ¹⁰Tampere University Hospital (Tays), Tampere, FI, ¹¹Arizona Oncology (US Oncology Network), Phoenix, US, ¹²IEO - Istituto Europeo di Oncologia, Milan, IT, ¹³Minnesota Oncology, Maplewood, US, ¹⁴Oklahoma Cancer Specialists, Tulsa, US, ¹⁵Memorial Sloan-Kettering Cancer Center, New York, US, ¹⁶Genentech, Inc., South San Francisco, US, ¹⁷Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

16:32 - 16:44 **8050 - ICON8: Overall survival results in a GCIG phase III randomised controlled trial of weekly dose-dense chemotherapy in first line epithelial ovarian, fallopian tube or primary peritoneal carcinoma treatment**

A. Clamp¹, E. James², I. Mcneish³, A. Dean⁴, J.-W. Kim⁵, D. O'Donnell⁶, J. Hook⁷, D. Gallardo-Rincon⁸, C. Coyle², S. Blagden⁹, J. Brenton¹⁰, R. Naik¹¹, T. Perren¹², S. Sundar¹³, A. Cook¹⁴, J. Badrock², A.M. Swart¹⁵, M. Parmar¹⁴, R. Kaplan¹⁶, J. Ledermann¹⁷, ¹The Christie NHS Foundation Trust, Manchester, GB, ²Institute for Clinical Trials and Methodology, London, GB, ³Imperial College London - Hammersmith Hospital, London, GB, ⁴St John of God Subiaco Hospital, Sydney, AU, ⁵Seoul National University Hospital, Seoul, KR, ⁶St James's Hospital, Dublin, IE, ⁷St James' University Hospital, Leeds, GB, ⁸Instituto Nacional de Cancerologia, Mexico City, MX, ⁹Churchill Hospital - Oxford University Hospitals NHS Foundation Trust, Oxford, GB, ¹⁰Cancer Research UK Cambridge Institute, Cambridge, GB, ¹¹Queen Elizabeth Hospital, Gateshead, GB, ¹²St. James's University Hospital - Leeds Teaching Hospitals NHS Trust, Leeds, GB, ¹³University of Birmingham, Birmingham, GB, ¹⁴Institute of Clinical Trials and Methodology-UCL, London, GB, ¹⁵University of East Anglia, Norwich, GB, ¹⁶MRC Clinical Trials Unit-University College London, London, GB, ¹⁷UCL Cancer Institute - UCL - London's Global University, London, GB

16:44 - 16:54 **Invited Discussant LBA31 and 8050**

I. Ray-Coquard, Centre Léon Bérard, Lyon, FR

16:54 - 17:04 **Q&A and live discussion**

17:04 - 17:16 **LBA32 - Tisotumab vedotin in previously treated recurrent or metastatic cervical cancer: results from the phase 2 innovaTV 204/GOG-3023/ENGOT-cx6 study**

R. Coleman¹, D. Lorusso², C. Gennigens³, A. González-Martín⁴, L. Randall⁵, D. Cibula⁶, B. Lund⁷, L. Woelber⁸, S. Pignata⁹, F. Forget¹⁰, A. Redondo¹¹, R. Rangwala¹², S. Vindeløv¹³, M. Chen¹², J. Harris¹², L. Nicacio¹⁴, M.S.L. Teng¹⁴, M. Smith¹², B. Monk¹⁵, I. Vergote¹⁶, ¹US Oncology Research, The Woodlands, US, ²Fondazione Policlinico Universitario Agostino Gemelli - IRCCS Rome, Rome, IT, ³Centre Hospitalier Universitaire Sart Tilman, Liège, BE, ⁴Grupo Español de Investigación en Cáncer de Ovario (GEICO) and Department of Medical Oncology, Clínica Universidad de Navarra, Madrid, ES, ⁵University of California Irvine School of Medicine, Orange, US, ⁶Charles University First Faculty of Medicine, Prague, CZ, ⁷Nordic Society of Gynaecological Oncology (NSGO-CTU) and Aalborg university hospital, Aalborg, DK, ⁸Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Study Group and University Medical Center Hamburg-Eppendorf, Hamburg, DE, ⁹Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT, ¹⁰Centre Hospitalier de l'Ardenne, Libramont, BE, ¹¹Hospital Universitario La Paz, Madrid, ES, ¹²Genmab US, Inc., Princeton, US, ¹³Genmab A/S, Copenhagen, DK, ¹⁴Seattle Genetics, Inc., Bothell, US, ¹⁵Arizona Oncology (US Oncology Network), Phoenix, US, ¹⁶University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

17:16 - 17:28 **8070 - Nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant (advanced or recurrent) ovarian cancer: Open-label, randomized trial in Japan (NINJA trial)**

K. Omatsu¹, J. Hamanishi², N. Katsumata³, S. Nishio⁴, K. Sawada⁵, S. Takeuchi⁶, D.

Aoki⁷, K. Fujiwara⁸, T. Sugiyama⁹, I. Konishi¹⁰, ¹The Cancer Institute Hospital of JFCR, Tokyo, JP, ²Kyoto University-Graduate school of medicine, Kyoto, JP, ³Nippon Medical School Musashikosugi Hospital, Kanagawa, JP, ⁴Kurume University, Kurume, JP, ⁵Osaka University Graduate School of Medicine, Osaka, JP, ⁶Kobe Tokushukai Hospital, Kobe, JP, ⁷Keio University School of Medicine, Tokyo, JP, ⁸Saitama Medical University International Medical Center, Saitama, JP, ⁹St. Mary's Hospital, Fukuoka, JP, ¹⁰Kyoto Medical Center, Kyoto, JP

17:28 - 17:38 **Invited Discussant LBA32 and 8070**

A. Oaknin, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

17:38 - 17:48 **Q&A and live discussion**

18:30 - 20:10 Type: Proffered Paper session Channel 1
Title: Presidential Symposium III
Chair(s): Andres Cervantes, ES

18:30 - 18:42 **LBA6_PR - Nivolumab (NIVO) Plus Chemotherapy (Chemo) Versus Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC)/Esophageal Adenocarcinoma (EAC): First Results of the CheckMate 649 Study**

M. Moehler¹, K. Shitara², M. Garrido³, P. Salman⁴, L. Shen⁵, L. Wyrwicz⁶, K. Yamaguchi⁷, T. Skoczylas⁸, A. Campos Bragagnoli⁹, T. Liu¹⁰, M. Schenker¹¹, P. Yanez¹², M. Tehfe¹³, V. Poulart¹⁴, D. Cullen¹⁵, M. Lei¹⁴, K. Kondo¹⁶, M. Li¹⁴, J. Ajani¹⁷, Y. Janjigian¹⁸, ¹Universitätsmedizin Mainz, Mainz, DE, ²National Cancer Center Hospital East, Kashiwa, JP, ³Pontificia Universidad Católica de Chile, Santiago, CL, ⁴Fundacion Arturo Lopez Perez, Providencia, CL, ⁵Peking University Cancer Hospital & Institute, Beijing, CN, ⁶Centrum Onkologii-Instytut im. Marii Skłodowskiej-Curie, Warsaw, PL, ⁷The Cancer Institute Hospital of JFCR, Koto-ku, JP, ⁸II Klinika Chirurgii Ogólnej, Gastroenterologicznej i Nowotworów Układu Pokarmowego, Medical University of Lublin, Lublin, PL, ⁹Barretos Cancer Hospital, Barretos, BR, ¹⁰Zhong Shan Hospital, Fudan University, Shanghai, CN, ¹¹Sf. Nectarie Oncology Center, Craiova, RO, ¹²Universidad de La Frontera, Temuco, CL, ¹³Centre Hospitalier de l'Université de Montreal, Montréal, CA, ¹⁴Bristol Myers Squibb, Princeton, US, ¹⁵Bristol-Myers Squibb, Princeton, US, ¹⁶Bristol-Myers Squibb Company, Lawrenceville, US, ¹⁷The University of Texas MD Anderson Cancer Center, Houston, US, ¹⁸Memorial Sloan-Kettering Cancer Center, New York, US

18:42 - 18:54 **LBA7_PR - Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study**

N. Boku¹, M.H. Ryu², D.-Y. Oh³, S.C. Oh⁴, H.C. Chung⁵, K.-W. Lee⁶, T. Omori⁷, K. Shitara⁸, S. Sakuramoto⁹, I.J. Chung¹⁰, K. Yamaguchi¹¹, K. Kato¹², S.J. Sym¹³, S. Kadowaki¹⁴, K. Tsuji¹⁵, J.-S. Chen¹⁶, L.-Y. Bai¹⁷, L.-T. Chen¹⁸, Y.-K. Kang², ¹St. Marianna University School of Medicine, Tokyo, JP, ²Asan Medical Center - University of Ulsan College of Medicine, Seoul, KR, ³Seoul National University Hospital, Seoul, KR, ⁴Korea University Guro Hospital, Seoul, KR, ⁵Yonsei University, Seoul, KR, ⁶Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam,

Gyeonggi-do, KR, ⁷Osaka International Cancer Institute, Osaka, JP, ⁸National Cancer Center Hospital East, Kashiwa, JP, ⁹Saitama Medical University, International Cancer Center, Saitama, JP, ¹⁰Chonnam National University Hwasun Hospital, Hwasun, KR, ¹¹Cancer Institute Hospital of JFCR, Tokyo, JP, ¹²National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, ¹³Gachon University Gil Medical Center, Incheon, KR, ¹⁴Aichi Cancer Center Hospital, Nagoya, JP, ¹⁵Ishikawa Prefectural Central Hospital, Ishikawa, JP, ¹⁶Chang Gung Memorial Hospital at Linkou, Taoyuan City, TW, ¹⁷China Medical University Hospital, Taichung, TW, ¹⁸National Institute of Cancer Research, Tainan, TW

18:54 - 19:04 **Invited Discussant LBA6_PR and LBA7_PR**

E. Smyth, Addenbrooke's Hospital - Cambridge University Hospitals NHS Foundation Trust, Cambridge, GB

19:04 - 19:19 **Q&A and live discussion**

19:19 - 19:31 **LBA8_PR - Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients With Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study**

K. Kato¹, J.-M. Sun², M. Shah³, P. Enzinger⁴, A. Adenis⁵, T. Doi⁶, T. Kojima⁶, J.-P. Metges⁷, Z. Li⁸, S.-B. Kim⁹, B. Chul Cho¹⁰, W. Mansoor¹¹, S.-H. Li¹², P. Sunpaweravong¹³, M.A. Maqueda¹⁴, E. Goekkurt¹⁵, Q. Liu¹⁶, S. Shah¹⁶, P. Bhagia¹⁶, L. Shen¹⁷, ¹National Cancer Center Research Institute - Tsukiji Campus, Chuo-ku, JP, ²Samsung Medical Center Sungkyunkwan University School of Medicine, Seoul, KR, ³Meyer Cancer Center at Weill Cornell Medical College, New York, US, ⁴Dana Farber Cancer Institute, Boston, US, ⁵ICM Regional Cancer Institute of Montpellier, Montpellier, FR, ⁶National Cancer Center Hospital East, Kashiwa, JP, ⁷CHU Morvan - Institut de Cancerologie et d'Hematologie, Brest, FR, ⁸Shanghai Chest Hospital, Shanghai, CN, ⁹Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ¹⁰Yonsei University College of Medicine, Seoul, KR, ¹¹The Christie NHS Foundation Trust, Manchester, GB, ¹²Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TW, ¹³Prince of Songkhla University Hospital, Songkhla, TH, ¹⁴Hospital Universitari Vall d'Hebron - Vall d'Hebron Institut d'Oncologia (VHIO), Barcelona, ES, ¹⁵Facharztzentrum Eppendorf, Hamburg, DE, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Peking University Cancer Hospital & Institute, Beijing, CN

19:31 - 19:43 **LBA9_PR - Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer (EC/GEJC) Following Neoadjuvant Chemoradiation Therapy (CRT): First Results of the CheckMate 577 Study**

R. Kelly¹, J. Ajani², J. Kuzdzal³, T. Zander⁴, E. Van Cutsem⁵, G. Piessen⁶, G. Mendez⁷, J. Feliciano⁸, S. Motoyama⁹, A. Lièvre¹⁰, H. Uronis¹¹, E. Elimova¹², C. Grootsholten¹³, K. Geboes¹⁴, J. Zhang¹⁵, L. Zhu¹⁵, M. Lei¹⁵, K. Kondo¹⁶, J. Cleary¹⁷, M. Moehler¹⁸, ¹The Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, US, ²The University of Texas MD Anderson Cancer Center, Houston, US, ³Szpital Specjalistyczny im. Jana Pawla II, Krakow, PL, ⁴Uniklinik Köln, Cologne, DE, ⁵University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE, ⁶C.H.U. Claude Huriez, Lille, FR, ⁷Productos Roche S.A. Quimica e Industrial, Ricardo Rojas, AR, ⁸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, US, ⁹Akita University Hospital, Akita,

JP, ¹⁰CHU Pontchaillou, Rennes, FR, ¹¹Duke Cancer Institute, Durham, US, ¹²UHN - Princess Margaret Cancer Centre, Toronto, CA, ¹³Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ¹⁴UZ Gent - Universitair Ziekenhuis Gent, Gent, BE, ¹⁵Bristol Myers Squibb, Princeton, US, ¹⁶Bristol-Myers Squibb Company, Lawrenceville, US, ¹⁷Dana Farber Cancer Institute, Boston, US, ¹⁸Universitätsmedizin Mainz, Mainz, DE

19:43 - 19:53 **Invited Discussant LBA8_PR and LBA9_PR**

A. Cervantes, Hospital Clinico Universitario de Valencia, Valencia, ES

19:53 - 20:08 **Q&A and live discussion**

12.10.2020

13:00 - 14:30 **Type: Special session** **Channel 1**
Title: Practising Oncologist Session 1

15:00 - 15:30 **Type: Special session** **Channel 1**
Title: ESMO Award

Chair(s): Giuseppe Curigliano, IT

15:00 - 15:05 **Introduction**
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

15:05 - 15:30 **The treatment of locally advanced and disseminated colon- and rectal cancer in the last decades: A paradigm for a personalized approach**
H.J. Schmoll, Martin Luther University of Halle, Halle (Saale), DE

13.10.2020

13:00 - 14:30	Type: Special session Title: Practising Oncologist Session 2	Channel 1
15:00 - 15:30	Type: Special session Title: ESMO Translational Research Award Chair(s): Giuseppe Curigliano, IT	Channel 1

15:00 - 15:05 **Introduction**
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

15:05 - 15:30 **The fine specificity of immune responses to cancer**
A. Ribas, Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, US

14.10.2020

13:00 - 14:30 **Type: Special session** **Channel 1**
 Title: Practising Oncologist Session 3

15:00 - 15:30 **Type: Special session** **Channel 1**
 Title: ESMO Women for Oncology Award
 Chair(s): Giuseppe Curigliano, IT

15:00 - 15:05 **Introduction**
 G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

15:05 - 15:30 **Melanoma treatment: A door opened but not a closed case**
 C. Robert, Institut Gustave Roussy, Villejuif, FR

15.10.2020

13:00 - 14:30 **Type: Special session** **Channel 1**
Title: Practising Oncologist Session 4

15:00 - 15:30 **Type: Special session** **Channel 1**
Title: ESMO Lifetime Achievement Award
Chair(s): Giuseppe Curigliano, IT

15:00 - 15:05 **Introduction**
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

15:05 - 15:30 **Tumour biology-guided breast cancer therapy: Less can be more**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

16.10.2020

10:30 - 11:50 **Type: Special symposium** **Channel 1**
Title: Dissecting the heterogeneity of breast cancer
Chair(s): Giuseppe Curigliano, IT; Nadia Harbeck, DE

10:30 - 10:45 **The complexity of triple negative breast cancer**
M. Kok, Netherlands Cancer Institute, Amsterdam, NL

10:45 - 11:00 **HR+ vs HR- in patients with HER2+ breast cancer**
N. Harbeck, Ludwig Maximilians University - Grosshadern, Munich, DE

11:00 - 11:15 **HR+ breast cancers: Are they all the same?**
W. Zwart, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

11:15 - 11:30 **Future research priorities**
G. Curigliano, IEO - Istituto Europeo di Oncologia, Milan, IT

11:30 - 11:41 **Q&A and live discussion**

10:30 - 11:50 **Type: Educational session** **Channel 2**
Title: Advances in mesothelioma
Chair(s): Michael Thomas, DE

10:30 - 10:45 **Histology and biomarkers**
K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB

10:45 - 11:00 **Progress in immunotherapy**
M. Thomas, Thoraxklinik Heidelberg, Heidelberg, DE

11:00 - 11:15 **Surgical strategies**
I. Opitz, University Hospital Zürich, Zurich, CH

11:15 - 11:30 **Advances in radiotherapy for mesothelioma**
M. Trovò, Udine Academic Hospital, Udine, IT

11:30 - 11:41 **Q&A and live discussion**

10:30 - 11:50 **Type: Educational session** **Channel 3**
Title: The role of ctDNA in colorectal cancer in 2020
 Chair(s): Clara Montagut Viladot, ES; Timothy Price, AU

10:30 - 10:50 **Technology options, best methods**
N. Pallisgaard, University Hospital Zealand, Roskilde, DK

10:50 - 11:10 **ctDNA in adjuvant therapy: Where to from here?**
J. Tie, Peter MacCallum Cancer Centre, Melbourne, AU

11:10 - 11:30 **ctDNA in advanced disease monitoring: Can it predict therapy change?**
C. Montagut Viladot, Hospital del Mar, Barcelona, ES

11:30 - 11:42 **Q&A and live discussion**

10:30 - 11:50 **Type: Special symposium** **Channel 4**
Title: Maximising the quality of short life
 Chair(s): Roger Henriksson, SE; Kathy Oliver, GB

10:30 - 10:30 **DOI session**

10:30 - 10:45 **Hope and shared decision-making**
L. Sharp, RCC Stockholm-Gotland, HSF, Stockholm, SE

10:45 - 11:00 **The health care perspective**
R. Grant, NHS Lothian, Edinburgh, GB

11:00 - 11:15 **Clinical trial design**
L. Dirven, Leids Universitair Medisch Centrum (LUMC), Leiden, NL

11:15 - 11:30 **Ethical issues in the perspective of short life and in patients with cognitive deficits**
O. Chinot, AP-HM - CHU La Timone Enfants, Marseille, FR

11:30 - 11:41 **Q&A and live discussion**

12:10 - 13:30 **Type: Educational session** **Channel 1**
Title: New horizons in the treatment of pancreatic cancer

12:10 - 12:10 **DOI session**

12:10 - 12:30 **Genomic profiling and early detection in the diagnosis and treatment of pancreatic cancer**

K. Ryan, University of Glasgow, Glasgow, GB

12:30 - 12:50 **Increasing cure rate: (Neo)-adjuvant treatment strategies**

T. Conroy, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre-lès-Nancy, FR

12:50 - 13:10 **Modern therapy algorithms for metastatic and recurrent stage**

J. Trojan, Universitätsklinikum Frankfurt(Johannes-Wolfgang Goethe Institute), Frankfurt am Main, DE

13:10 - 13:22 **Q&A and live discussion**

12:10 - 13:30 **Type: Educational session** **Channel 2**
Title: Individualised therapy in advanced urothelial cancer: Prime time?

Chair(s): Alison Birtle, GB; Aristotelis Bamias, GR

12:10 - 12:10 **DOI session**

12:10 - 12:30 **Molecular characterisation of urothelial cancer**

H. Moch, Universitätsspital Zürich Pathologie, Zurich, CH

12:30 - 12:50 **Chemotherapy, immunotherapy or combinations: What is the best option in the face of new evidence?**

A. Birtle, Royal Preston Hospital-Lancashire Teaching Hospitals NHS Foundation Trust, Preston, GB

12:50 - 13:10 **What to do if immunotherapy fails?**

A. Bamias, Attikon University Hospital, Athens, GR

13:10 - 13:22 **Q&A and live discussion**

12:10 - 13:30 **Type: Special symposium** **Channel 3**
Title: Bone and soft tissue tumours in young adult patients
Chair(s): Eleni Tomazou, AT

12:10 - 12:10 **DOI session**

12:10 - 12:25 **Desmoid tumors: New paradigms**
N. Penel, Centre Oscar Lambret, Lille, FR

12:25 - 12:40 **Recent discoveries in genetic abnormalities in young adult sarcomas**
E. Wardelmann, University Hospital Muenster-Gerhard Domagk Institute of Pathology, Münster, DE

12:40 - 12:55 **New treatment options in Ewing sarcoma**
M. McCabe, The University of Manchester, Manchester, GB

12:55 - 13:10 **Rhabdomyosarcoma at young adult age: The way forward**
W. Van Der Graaf, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

13:10 - 13:21 **Q&A and live discussion**

12:10 - 13:30 **Type: Educational session** **Channel 4**
Title: Where are we and where are we going in early breast cancer? Better approaches to cure more patients
 Chair(s): Antonio Llombart Cussac, ES; Gul Basaran, TR

12:10 - 12:10 **DOI session**

12:10 - 12:30 **Can we treat TNBC better?**
P. Schmid, Barts Cancer Institute-Queen Mary University of London, London, GB

12:30 - 12:50 **HER2+ breast cancer: Is there anything else to do?**
G. Basaran, Acibadem University School of Medicine, Istanbul, TR

12:50 - 13:10 **HR+ HER2- cancers: Can we do better?**
M. Arnedos, Institut Gustave Roussy, Villejuif, FR

13:10 - 13:22 **Q&A and live discussion**

12:10 - 13:30 **Type: Special session** **Channel 5**
Title: The WHO Report on Cancer: What cancer policies are missing in your country? (in collaboration with WHO)
 Chair(s): Rosa Giuliani, GB

12:10 - 12:25 **Applying the recommendations of the WHO Report on Cancer**

12:25 - 12:40 **Quality cancer services: A WHO-IARC cancer control priority-setting and costing tool that calculates the impact and investment requirements for quality cancer services**

12:40 - 12:55 **Building cancer services from the ground up: Basic, moderate and advanced health service packages**
D. Trapani, Istituto Europeo di Oncologia, Milan, IT

12:55 - 13:10 **Where is the money for cancer services coming from?**
F. Meheus, IARC - International Agency for Research on Cancer, Lyon, FR

13:10 - 13:21 **Q&A and live discussion**
R. Giuliani, The Clatterbridge Cancer Centre, Liverpool, GB

13:45 - 14:15	Type: Keynote lecture Title: The microbiome and its impact on molecular treatment decisions in cancer Chair(s): Michel Ducreux, FR	Channel 1
13:45 - 13:45	DOI session	
13:45 - 14:15	The microbiome and its impact on molecular treatment decisions in cancer <u>J. Wargo</u> , The University of Texas MD Anderson Cancer Center, Houston, US	
14:30 - 15:50	Type: Educational session Title: CNS metastasis: Optimising local therapy, improving systemic control Chair(s): Nancy Lin, US	Channel 1
14:30 - 14:30	DOI session	
14:30 - 14:50	Surgery and radiation: Who, when and how? <u>R. Soffiatti</u> , University of Turin, Torino, IT	
14:50 - 15:10	Systemic management of CNS progression <u>N. Lin</u> , Dana-Farber Cancer Institute, Boston, US	
15:10 - 15:30	Leptomeningeal disease: An unmet challenge <u>E. Le Rhun</u> , University Hospital Zürich, Zurich, CH	
15:30 - 15:42	Q&A and live discussion	

14:30 - 15:50	Type: Educational session Title: GIST, a single acronym for multiple diseases and paradigms: Time to reset Chair(s): Suzanne George, US	Channel 2
14:30 - 14:30	DOI session	
14:30 - 14:50	New drugs, new horizons <u>S. George</u> , Dana Farber Cancer Institute, Boston, US	
14:50 - 15:10	How to guide and scan patients on long-term TKI treatment <u>N. Steeghs</u> , Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL	
15:10 - 15:30	Age and gender aspects: Do we need to take them into account? <u>A. Le Cesne</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
15:30 - 15:42	Q&A and live discussion	

14:30 - 15:50	<p>Type: Educational session Title: Management paradigms for metastatic castration-sensitive prostate cancer Chair(s): Karim Fizazi, FR; Tapio Visakorpi, FI</p>	Channel 3
14:30 - 14:30	DOI session	
14:30 - 14:45	<p>Treatment of the primary in metastatic prostate patients <u>B. Tombal</u>, Cliniques Universitaires St. Luc - Université Catholique de Louvain, Brussels, BE</p>	
14:45 - 15:00	<p>Current and future systemic treatments of mCSPC <u>K. Fizazi</u>, Institut Gustave Roussy, Villejuif, FR</p>	
15:00 - 15:15	<p>How does the clinician use quality of life data to decide between chemotherapy and hormonal therapy? <u>A. Morgans</u>, Northwestern University Feinberg School of Medicine, Chicago, US</p>	
15:15 - 15:30	<p>Genetic counselling for patients diagnosed with metastatic disease <u>E. Castro Marcos</u>, CNIO - Centro Nacional de Investigaciones Oncologicas, Madrid, ES</p>	
15:30 - 15:42	Q&A and live discussion	

14:30 - 15:50 **Type: Special symposium** **Channel 4**
Title: Immunometabolism as target for immunotherapy of cancer
Chair(s): Thales Papagiannakopoulos, US

14:30 - 14:30 **DOI session**

14:30 - 14:45 **Glutaminolysis**

C. Van Dang, Ludwig Insitute for Cancer Research, New York, US

14:45 - 15:00 **Metabolic regulation in the tumour microenvironment**

P.-C. Ho, Ludwig Center for Cancer Research of the UNIL (LICR@UNIL), Epalinges, CH

15:00 - 15:15 **Metabolic regulation of T-cells differentiation and function**

T. Papagiannakopoulos, NYU School of Medicine, New York, US

15:15 - 15:30 **Autophagy**

G. Kroemer, Université Paris Descartes, Paris, FR

15:30 - 15:41 **Q&A and live discussion**

14:30 - 15:50 **Type: Educational session** **Channel 5**
Title: Classification and management of GEP NEN patients
Chair(s): Nicola Fazio, IT; Rocio Garcia-Carbonero, ES

14:30 - 14:30 **DOI session**

14:30 - 14:50 **Terminology, classification and staging of GEP NENs**

J.-Y. Scoazec, Institut Gustave Roussy, Villejuif, FR

14:50 - 15:10 **Clinical management of patients with low/intermediate grade GEP NETs**

J. Strosberg, H. Lee Moffitt Cancer Center University of South Florida, Tampa, US

15:10 - 15:30 **Clinical management of patients with NET G3/NECs**

H. Sorbye, Haukeland Universitetssykehus, Bergen, NO

15:30 - 15:42 **Q&A and live discussion**

16:10 - 17:30	Type: Educational session Title: Lung cancer diagnosis in 2020: State of the art Chair(s): Daniel Shao Weng Tan, SG	Channel 1
16:10 - 16:10	DOI session	
16:10 - 16:25	NSCLC diagnostics in tissue <u>A. Stenzinger</u> , University Hospital Heidelberg, Institute of Pathology, Heidelberg, DE	
16:25 - 16:40	NSCLC and SCLC diagnostics in blood: Are we ready? <u>F. Blackhall</u> , The Christie NHS Foundation Trust, Manchester, GB	
16:40 - 16:55	Changing the paradigm of SCLC diagnosis <u>C. Rudin</u> , Memorial Sloan-Kettering Cancer Center, New York, US	
16:55 - 17:10	What's next? Emerging diagnostic technologies <u>D.S.W. Tan</u> , NCCS - National Cancer Centre Singapore, Singapore, SG	
17:10 - 17:21	Q&A and live discussion	

16:10 - 17:30	Type: Educational session Title: Future directions of supportive and palliative care in a changing landscape Chair(s): Camilla Zimmermann, CA; Karin Jordan, DE	Channel 2
16:10 - 16:10	DOI session	
16:10 - 16:25	Many cancer patients are living active lives with cancer: Who are they and what are the challenges? <u>O. Mir</u> , Institut Gustave Roussy, Villejuif, FR	
16:25 - 16:40	How can palliative and supportive care be organised in order to contribute to optimise patients QoL? <u>S. Kaasa</u> , Oslo University Hospital - The Norwegian Radium Hospital, Oslo, NO	
16:40 - 16:55	Clinical guidelines to treat symptoms and maintain functions <u>D. Hui</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
16:55 - 17:10	Competence needed for an oncologist in palliative and supportive care: How is the training performed and formalised? <u>C. Zimmermann</u> , University Health Network - Princess Margaret Cancer Center, Toronto, CA	
17:10 - 17:21	Q&A and live discussion	

16:10 - 17:30	Type: Special symposium Title: Immunotherapy in haematological malignancies Chair(s): Christian Chabannon, FR; Markus Manz, CH	Channel 3
16:10 - 16:10	DOI session	
16:10 - 16:25	Engineered antibodies <u>R.C. Bargou</u> , University of Würzburg, Würzburg, DE	
16:25 - 16:40	Checkpoint inhibition in adaptive and innate immunity <u>M. Shipp</u> , Dana Farber Cancer Institute - Longwood Center, Boston, US	
16:40 - 16:55	Cellular therapies in 2020 <u>C. Chabannon</u> , Institute Paoli Calmettes, Marseille, FR	
16:55 - 17:10	Emerging concepts and combinations <u>Q. Waseem</u> , UCL Great Ormond Street Institute of Child Health, London, GB	
17:10 - 17:21	Q&A and live discussion	

16:10 - 17:30 **Type: Special symposium** **Channel 4**
Title: Cancer evolution
 Chair(s): Samra Turajlic, GB; Robert Gatenby, US

16:10 - 16:10 **DOI session**

16:10 - 16:25 **Evolutionary routes in pancreatic cancers**
R. Rad, Technical University of Munich-TUM, Munich, DE

16:25 - 16:40 **Evolutionary therapy**
R. Gatenby, H. Lee Moffitt Cancer Center University of South Florida, Tampa, US

16:40 - 16:55 **Negative selection in tumour genome evolution acts on essential cellular functions and the immunopeptidome**
M. Schaefer, European Institute of Oncology, Milan, IT

16:55 - 17:10 **Evolution of metastatic melanoma: Results from post-mortem studies**
S. Turajlic, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

17:10 - 17:21 **Q&A and live discussion**
R. Gatenby, H. Lee Moffitt Cancer Center University of South Florida, Tampa, US

17.10.2020

10:30 - 11:50	<p>Type: Educational session Title: First-line therapy in ovarian cancer: Where do we stand and how do we move forwards? Chair(s): Isabelle Ray-Coquard, FR; Nicole Concin, AT</p>	<p>Channel 1</p>
10:30 - 10:30	DOI session	
10:30 - 10:50	<p>How molecular biology influences radical surgical treatment in first-line ovarian cancer <u>N. Concin</u>, Medical University of Innsbruck, Innsbruck, AT</p>	
10:50 - 11:10	<p>Current systemic treatment for first-line <u>A. González Martín</u>, Clinica Universidad de Navarra, Madrid, ES</p>	
11:10 - 11:30	<p>Future options <u>I. Ray-Coquard</u>, Centre Léon Bérard, Lyon, FR</p>	
11:30 - 11:42	Q&A and live discussion	

10:30 - 11:50 **Type: Special symposium** **Channel 2**
Title: The opioid crisis
Chair(s): Carla Ripamonti, IT

10:30 - 10:30 **DOI session**

10:30 - 10:45 **The opioid epidemic: How to start and when to stop**
P. Sjøgren, Rigshospitalet, Copenhagen, DK

10:45 - 11:00 **Towards safer opioids: New concepts and mechanisms**
C. Stein, Charité - Universitätsmedizin Berlin, Berlin, DE

11:00 - 11:15 **Strong versus weak opioids**
M. Fallon, Cancer Research UK Edinburgh Centre, Edinburgh, GB

11:15 - 11:30 **Opioid availability in low and middle-income countries**
N. Cherny, Shaare Zedek Medical Center, Jerusalem, IL

11:30 - 11:41 **Q&A and live discussion**

10:30 - 11:50 **Type: Educational session** **Channel 3**
Title: Myelodysplastic syndromes in 2020
Chair(s): Charles Craddock, GB; Uwe Platzbecker, DE

10:30 - 10:30 **DOI session**

10:30 - 10:50 **Biology, diagnosis and classification of MDS**
L. Malcovati, Fondazione IRCCS Policlinico San Matteo, Pavia, IT

10:50 - 11:10 **Treatment approaches in low-risk MDS patients**
C. Craddock, Queen Elizabeth Hospital - University Hospitals Birmingham NHS Foundation Trust, Birmingham, GB

11:10 - 11:30 **Treatment approaches in high-risk MDS patients**
U. Platzbecker, Universitätsklinikum Dresden, Dresden, DE

11:30 - 11:42 **Q&A and live discussion**

12:10 - 13:30	<p>Type: Special symposium Title: What other immunotherapy options are there in recurrent metastatic disease?</p>	<p>Channel 1</p>
<p>Chair(s): Ana Martins Ferreira Castro, PT; Anthony T.C. Chan, HK</p>		
12:10 - 12:10	<p>DOI session</p>	
12:10 - 12:25	<p>Current overview and how to select patients in first-line <u>J.-P. Machiels</u>, Cliniques Universitaires Saint-Luc (UCLouvain Saint-Luc), Woluwe-Saint-Lambert, BE</p>	
12:25 - 12:40	<p>Beyond the use of checkpoint inhibitor <u>E. Cohen</u>, Moores Cancer Center - UC San Diego Health, La Jolla, US</p>	
12:40 - 12:55	<p>Direct intratumoral therapies <u>A. Dietz</u>, University of Leipzig, Leipzig, DE</p>	
12:55 - 13:10	<p>Immunotherapy in NPC <u>B. Ma</u>, The Chinese University of Hong Kong, Shatin, HK</p>	
13:10 - 13:21	<p>Q&A and live discussion</p>	

12:10 - 13:30	Type: Special symposium Title: Tumour heterogeneity and its influence on cancer and immune therapy responses Chair(s): Nicholas McGranahan, GB; Marisol Soengas, ES	Channel 2
12:10 - 12:10	DOI session	
12:10 - 12:25	Tumour micro-environmental and systemic barriers to T-cell immunotherapy <u>D. Hanahan</u> , Swiss Institute of Experimental Cancer Research, EPFL, Lausanne, CH	
12:25 - 12:40	Genomic determinants and tumour heterogeneity of checkpoint inhibitor response <u>N. Mcgranahan</u> , UCL Cancer Institute/Paul O'Gorman Building, London, GB	
12:40 - 12:55	Neutrophils in cancer <u>M. Soengas</u> , CNIO- Spanish National Cancer Center, Madrid, ES	
12:55 - 13:10	Intratumour heterogeneity and its influence on immune response <u>Y. Samuels</u> , Weizmann Institute of Science, Rehovot, IL	
13:10 - 13:21	Q&A and live discussion	

12:10 - 13:30 **Type: Special session** **Channel 3**
Title: Established and new treatments, old and new toxicities (in collaboration with MASCC)
 Chair(s): Karin Jordan, DE; Florian Scotté, FR

12:10 - 12:10 **DOI session**

12:10 - 12:25 **Gastrointestinal toxicity: From the top to the bottom**
P. Bossi, Azienda Ospedaliera Spedali Civili di Brescia, Brescia, IT

12:25 - 12:40 **Skin toxicity: More than just a rash**
V. Sibaud, Institut Universitaire du Cancer -Toulouse- Oncopole, Toulouse, FR

12:40 - 12:55 **Neurotoxicity: From the head to the toes**
K. Jordan, University of Heidelberg, Heidelberg, DE

12:55 - 13:10 **Integrating PROMs for adverse effects into clinical practice**
C. Van Den Hurk, Netherlands Comprehensive Cancer Organisation (IKNL), Utrecht, NL

13:10 - 13:21 **Q&A and live discussion**
F. Scotté, Institut Gustave Roussy, Villejuif, FR

13:45 - 14:15 **Type: Keynote lecture** **Channel 1**
Title: Present and future of cancer immunotherapy
 Chair(s): Samra Turajlic, GB

13:45 - 14:15 **Present and future of cancer immunotherapy**
L. Chen, Yale Center for Medical Informatics, New Haven, US

14:30 - 15:50 **Type: Special symposium** **Channel 1**
Title: Targeted treatment in 2020
 Chair(s): Lecia Sequist, US; Alona Zer, IL

14:30 - 14:30 **DOI session**

14:30 - 14:45 **EGFR**
P. Jänne, Dana Farber Cancer Institute, Boston, US

14:45 - 15:00 **ALK and ROS1**
T.S.K. Mok, Prince of Wales Hospital, Shatin, HK

15:00 - 15:15 **HER2, NRG1, NTRK**
E. Felip, Vall d'Hebron University Hospital, Barcelona, ES

15:15 - 15:30 **BRAF, RAS, RET, etc.**
B. Besse, Institut Gustave Roussy, Villejuif, FR

15:30 - 15:41 **Q&A and live discussion**
A. Zer, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, Petah Tikva, IL

14:30 - 15:50 **Type: Educational session** **Channel 2**
Title: Adjuvant and neo-adjuvant therapy for stage III melanoma: Who, what and when?
 Chair(s): Christian Blank, NL

14:30 - 14:30 **DOI session**

14:30 - 14:50 **Controversies in the surgical management of stage III melanoma**
M. Ross, MD Anderson Cancer Center, Houston, US

14:50 - 15:10 **Adjuvant and neo-adjuvant therapy**
G. Long, Melanoma Institute Australia, Wollstonecraft, AU

15:10 - 15:30 **Translational research: Ready for patient selection?**
C. Blank, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

15:30 - 15:42 **Q&A and live discussion**

14:30 - 15:50 **Type: Special symposium** **Channel 3**
Title: Immunotherapy in colorectal cancer: Present and future
Chair(s): Dung Le, US

14:30 - 14:30 **DOI session**

14:30 - 14:45 **Colorectal tumour immunology: Update**
J. Galon, Laboratory of Integrative Cancer Immunology, Paris, FR

14:45 - 15:00 **Immune parameters and other potential biomarkers for treatment selection**
G. Argiles Martinez, Vall d'Hebron University Hospital, Barcelona, ES

15:00 - 15:15 **The next generation immune targets and possible combinations**
M. Chalabi, Het Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI-AVL), Amsterdam, NL

15:15 - 15:30 **Practical use of immunotherapy in colorectal cancer in 2020**
D. Le, Johns Hopkins University, Baltimore, US

15:30 - 15:41 **Q&A and live discussion**

14:30 - 15:50 **Type: Educational session** **Channel 5**
Title: Techniques of the future
Chair(s): Zuhir Bodalal, NL

14:30 - 14:30 **DOI session**

14:30 - 14:50 **Nanotechnology in cancer research**
K. Kostarelos, The University of Manchester, Manchester, GB

14:50 - 15:10 **Radiomics: A critical step towards integrated healthcare**
Z. Bodalal, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

15:10 - 15:30 **3D analysis in breast cancer**

15:30 - 15:42 **Q&A and live discussion**

16:10 - 17:30	Type: Special symposium Title: Maximising the benefit of immuno-oncology Chair(s): Marina Garassino, IT; Natasha Leighl, CA	Channel 1
16:10 - 16:10	DOI session	
16:10 - 16:25	Who should get an I-O combination? <u>M. Garassino</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
16:25 - 16:40	Biomarkers <u>N. Rizvi</u> , Columbia University Medical Center College of Physicians & Surgeons - New York Presbyterian Hospital, New York, US	
16:40 - 16:55	What to do post-IO failure <u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	
16:55 - 17:10	Emerging targets in immunotherapy <u>S. Peters</u> , Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH	
17:10 - 17:21	Q&A and live discussion <u>M. Garassino</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	

16:10 - 17:30	Type: Educational session Title: Liquid biopsy: Beyond targeted panel sequencing in cancer research and therapy Chair(s): Dan Landau, US	Channel 2
16:10 - 16:10	DOI session	
16:10 - 16:25	cfDNA in CNS tumours <u>J. Seoane</u> , Vall d'Hebron Institute of Oncology (VHIO)-Cellex Center, Barcelona, ES	
16:25 - 16:40	Cell-free DNA methylomes and early-stage cancers <u>D. De Carvalho</u> , Princess Margaret Cancer Centre, Toronto, CA	
16:40 - 16:55	High-sensitivity ctDNA assays to detect low-burden disease <u>N. Rosenfeld</u> , Cancer Research UK Cambridge Institute, Cambridge, GB	
16:55 - 17:10	Leveraging mutational signatures for mutational calling in cell-free tumour DNA <u>D. Landau</u> , New York Genome Center, New York, US	
17:10 - 17:21	Q&A and live discussion	

16:10 - 17:30 **Type: Special symposium** **Channel 3**
Title: New drugs in development: What will be approved in 2025?
 Chair(s): Jordi Rodon, US; Jayesh Desai, AU

16:10 - 16:10 **DOI session**

16:10 - 16:25 **FGFR inhibitors**
Y. Loriot, Institut Gustave Roussy, Villejuif, FR

16:25 - 16:40 **Antibody Drug Conjugate (ADC)**
V. Moreno Garcia, University Hospital Fundacion Jimenez Diaz, Madrid, ES

16:40 - 16:55 **Epigenetic drugs: EZH2, BET and LSD1**

16:55 - 17:10 **Future strategies of using radiotherapy as an immune-stimulating agent**
F. Herrera, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

17:10 - 17:21 **Q&A and live discussion**

16:10 - 17:30 **Type: Special session** **Channel 4**
Title: How can we reduce cancer numbers? (in collaboration with ASCO)
 Chair(s): Lori Pierce, US

16:10 - 16:25 **Cancer burden and prevention initiatives around the world: What are the preventable diseases?**
F. Bray, International Agency for Research on Cancer, Lyon, FR

16:25 - 16:40 **Evidence-based screening interventions: State-of-the-art**
D. Trapani, Istituto Europeo di Oncologia, Milan, IT

16:40 - 16:55 **Genetic susceptibility and cancer predisposition**
S. Domchek, Private Practice - Domchek, Philadelphia, US

16:55 - 17:10 **Lifestyle factors: From doctor recommendations to daily life**
J. Ligibel, Dana Farber Cancer Institute, Boston, US

17:10 - 17:21 **Q&A and live discussion**

18.10.2020

10:30 - 11:50 **Type: Educational session** **Channel 1**
Title: Recent updates in treatment strategies
Chair(s): Rebecca Dent, SG

10:30 - 10:30 **DOI session**

10:30 - 10:50 **New targeted therapies for ER positive breast cancer**
C. Saura Manich, Vall d`Hebron University Hospital Institut d'Oncologia, Barcelona, ES

10:50 - 11:10 **The next generation of HER2 targeting therapies**
V. Dieras, Centre Eugene - Marquis, Rennes, FR

11:10 - 11:30 **New approaches for triple negative breast cancer (non-IO approaches)**
R. Dent, NCCS - National Cancer Centre Singapore, Singapore, SG

11:30 - 11:42 **Q&A and live discussion**

10:30 - 11:50 **Type: Educational session** **Channel 2**
Title: Blood-brain barrier
Chair(s): Rolf Bjerkvig, NO

10:30 - 10:30 **DOI session**

10:30 - 10:50 **Biology and patho-physiology of the blood-brain barrier**
R. Bjerkvig, UiB - University of Bergen, Bergen, NO

10:50 - 11:10 **Pharmacological determinants of the ability to penetrate the blood-brain barrier**

11:10 - 11:30 **Clinical relevance**
R. Rudà, AOU Città della Salute e della Scienza Torino, Torino, IT

11:30 - 11:42 **Q&A and live discussion**

10:30 - 11:50 **Type: Special symposium** **Channel 3**
Title: Checkpoint inhibitors and beyond in gynaecological cancers
Chair(s): Mansoor Raza Mirza, DK

10:30 - 10:30 **DOI session**

10:30 - 10:45 **Biomarkers**

I. Mcneish, Imperial College London - Hammersmith Hospital, London, GB

10:45 - 11:00 **Immune therapy combinations**

S. Pignata, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

11:00 - 11:15 **T cells and related treatments**

G. Coukos, Ludwig Institute for Cancer Research - Lausanne Branch, Epalinges, CH

11:15 - 11:30 **Antibody Drug Conjugates (ADCs)**

S. Banerjee, Royal Marsden Hospital NHS Foundation Trust, London, GB

11:30 - 11:41 **Q&A and live discussion**

10:30 - 11:50	<p>Type: Educational session Title: Applications of artificial intelligence (AI) in oncology drug development Chair(s): Emiliano Calvo, ES; Christophe Massard, FR</p>	Channel 4
10:30 - 10:30	DOI session	
10:30 - 10:50	<p>Artificial intelligence in cancer imaging: Clinical challenges and applications E. <u>Deutsch</u>, Institut Gustave Roussy, Villejuif, FR</p>	
10:50 - 11:10	<p>Multidisciplinary computation techniques for drug discovery and clinical application in oncology B. <u>Al-Lazikani</u>, The Institute of Cancer Research (Sutton Site), Sutton, GB</p>	
11:10 - 11:30	<p>AI, big data and machine learning in clinical drug development in oncology: A new paradigm? E. <u>Calvo</u>, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES</p>	
11:30 - 11:42	Q&A and live discussion	

10:30 - 11:50	Type: Special symposium Title: Peptide Receptor Radionuclide Therapy (PRRT) integration with other therapies Chair(s): Jonathan Strosberg, US; Ulrich-Frank Pape, DE	Channel 5
10:30 - 10:30	DOI session	
10:30 - 10:45	PRRT: New insights <u>A. Kjaer</u> , Rigshospitalet, Copenhagen, DK	
10:45 - 11:00	PRRT for NEN: How and in whom? <u>S. Singh</u> , Sunnybrook Odette Cancer Center, Sunnybrook HSC, Toronto, CA	
11:00 - 11:15	PRRT and surgery <u>E. Bertani</u> , European Institute of Oncology, Milan, IT	
11:15 - 11:30	PRRT and chemo <u>N. Pavlakis</u> , RNSH - Royal North Shore Hospital, St Leonards, AU	
11:30 - 11:41	Q&A and live discussion	

12:10 - 13:30	Type: Special symposium Title: Are we ready for another big step in kidney and bladder cancer? Chair(s): Thomas Powles, GB; Manuela Schmidinger, AT	Channel 1
12:10 - 12:10	DOI session	
12:10 - 12:25	From bench to bedside: Future perspectives of immunotherapy combinations in mRCC <u>V. Gruenwald</u> , University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE	
12:25 - 12:40	Which trials are missing in mRCC? <u>B. Escudier</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
12:40 - 12:55	From bench to bedside: Future perspectives of immunotherapy combinations in bladder cancer <u>A. Necchi</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
12:55 - 13:10	Which trials are missing in bladder cancer? <u>T. Powles</u> , St. Bartholomew's Hospital, London, GB	
13:10 - 13:21	Q&A and live discussion	

12:10 - 13:30	Type: Educational session Title: What to do with patients who attend appointments with a next generation sequencing (NGS) platform dataset Chair(s): Kevin Harrington, GB	Channel 2
12:10 - 12:10	DOI session	
12:10 - 12:30	Introduction and HPV- <u>K. Harrington</u> , ICR - Institute of Cancer Research - Chester Beatty Laboratories, London, GB	
12:30 - 12:50	HPV+ <u>A. Psyrri</u> , Attikon University Hospital, Athens, GR	
12:50 - 13:10	Nasal, para-nasal and skull base tumours <u>L. Licitra</u> , Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
13:10 - 13:22	Q&A and live discussion	

12:10 - 13:30	Type: Special symposium Title: Targeting DNA damage response pathways in cancer Chair(s): Serena Nik-Zainal, GB; Thanos Halazonetis, CH	Channel 3
12:10 - 12:10	DOI session	
12:10 - 12:25	Synthetic lethality screens to identify genes that control the response of cancer cells to DNA damaging agents <u>T. Halazonetis</u> , University of Geneva - Fondation Pour Recherches Medicales, Geneva, CH	
12:25 - 12:40	Mutation signatures as biomarkers for selecting treatment options <u>S. Nik-Zainal</u> , University of Cambridge-Wellcome Trust Centre for Stem Cell Research, Cambridge, GB	
12:40 - 12:55	ATR inhibitors in preclinical models <u>O. Fernandez-Capetillo</u> , CNIO- Spanish National Cancer Center, Madrid, ES	
12:55 - 13:10	Clinical efficacy of agents targeting DNA replication stress in cancer <u>D.S. Tan</u> , NUS-National University of Singapore-National University Health System (NUHS), Singapore, SG	
13:10 - 13:21	Q&A and live discussion	

12:10 - 13:30 **Type: Educational session** **Channel 4**
Title: Management of soft tissue sarcomas in 2020: Digital developments and tempting treatments
 Chair(s): Christina Messiou, GB

12:10 - 12:10 **DOI session**

12:10 - 12:30 **Integration of morphology and molecular profiling into digital pathology for sarcoma diagnostics**
H.-U. Schildhaus, University Hospital of Essen, Essen, DE

12:30 - 12:50 **Imaging response in localized sarcoma: The promise of artificial intelligence**
C. Messiou, The Royal Marsden Hospital - NHS Foundation Trust, London, GB

12:50 - 13:10 **Metastatic soft tissue sarcoma: The need for novel trial designs**
B. Kasper, UMM - Universitaetsklinikum Mannheim, Mannheim, DE

13:10 - 13:22 **Q&A and live discussion**

13:45 - 14:15 **Type: Keynote lecture** **Channel 1**
Title: Linking genetic alterations to dependencies for new cancer therapeutics
 Chair(s): Daniel Peeper, NL

13:45 - 13:45 **DOI session**

13:45 - 14:15 **Linking genetic alterations to dependencies for new cancer therapeut**
W. Seller, Broad Institute, Cambridge, US

14:30 - 15:50	Type: Special symposium Title: Treatment of upper GI tumours in the time of precision oncology Chair(s): Silvia Giordano, IT; Yelena Janjigian, US	Channel 1
14:30 - 14:30	DOI session	
14:30 - 14:45	Update on predictive and prognostic roles of circulating tumor DNA <u>N. Van Grieken</u> , Vrije University Medical Centre (VUMC), Amsterdam, NL	
14:45 - 15:00	Immune checkpoint inhibitors: Clinical use and response prediction <u>Y. Janjigian</u> , Memorial Sloan-Kettering Cancer Center, New York, US	
15:00 - 15:15	Biomarker of gastroesophageal cancer: What's standard of care and what's on the horizon? <u>K. Muro</u> , Aichi Cancer Center Hospital, Nagoya, JP	
15:15 - 15:30	Biomarker of hepatobiliary and pancreatic cancer: Is there a standard of care and what's on the horizon? <u>A. Vogel</u> , Hannover Medical School, Hannover, DE	
15:30 - 15:41	Q&A and live discussion	

14:30 - 15:50 **Type: Educational session** **Channel 3**
Title: Abscopal and anenestic effect: Local immunotherapies with systemic potential
 Chair(s): Kevin Harrington, GB; Ignacio Melero, ES

14:30 - 14:30 **DOI session**

14:30 - 14:50 **Background on abscopal effect in I-O**
A. Marabelle, Institut Gustave Roussy, Villejuif, FR

14:50 - 15:10 **Radiotherapy with systemic effect**
S. Demaria, Weill Cornell Medical College, New York, US

15:10 - 15:30 **Oncolytic viruses and sting agonist, TLR agonists, FLT3**
C. Drake, Columbia University Irving Cancer Center, New York, US

15:30 - 15:42 **Q&A and live discussion**

14:30 - 15:50 **Type: Young Oncologist session** **Channel 3**
Title: Biggest challenges facing young oncologists in 2030: How to address the next generation of anticancer treatments

14:30 - 14:42 **Epigenome as therapeutic target**

14:42 - 14:54 **Harnessing artificial intelligence for understanding cancer evolution and delivering precision oncology**
A. Sottoriva, Royal Marsden Hospital Institute of Cancer Research, Sutton, GB

14:54 - 14:54 **The YO Boxing session: Is use of precision oncology in clinical practice mandatory or not to improve patient outcomes?**

14:54 - 15:06 **Pro**

15:06 - 15:18 **Contra**

14:30 - 15:50	Type: Special symposium Title: The microenvironment of cancer Chair(s): Itay Tirosh, IL; Leila Akkari, NL	Channel 4
14:30 - 14:30	DOI session	
14:30 - 14:45	Role of microenvironment and immune system in tumour metastases <u>V. Sanz-Moreno</u> , Barts Cancer Institute, London, GB	
14:45 - 15:00	Integrating microenvironment, tumour, and clinical features to predict immunotherapy response in metastatic melanomas <u>D. Liu</u> , Dana-Farber Cancer Institute, Harvard Medical School, Boston, US	
15:00 - 15:15	Microenvironment regulates chemosensitivity <u>L. Akkari</u> , The Netherlands Cancer Institute, Amsterdam, NL	
15:15 - 15:30	Primary and metastatic tumour ecosystems <u>I. Tirosh</u> , Weizmann Institute of Science, Rehovot, IL	
15:30 - 15:41	Q&A and live discussion	

14:30 - 15:50 **Type: Educational session** **Channel 5**
Title: How to implement screening for lung cancer
Chair(s): Nir Peled, IL

14:30 - 14:30 **DOI session**

14:30 - 14:45 **Risk stratification: Who gets screened?**

K. Nackaerts, KU Leuven, Leuven, BE

14:45 - 15:00 **Breath biopsy for lung cancer screening**

N. Peled, Soroka University Medical Center, Beer Sheva, IL

15:00 - 15:15 **Liquid biopsy for lung cancer screening**

P. Massion, Vanderbilt University Medical Center, Nashville, US

15:15 - 15:28 **How to implement screening in your country: Lessons learned from screening trials**

H. Kauczor, University Hospital Heidelberg, Heidelberg, DE

15:28 - 15:39 **Q&A and live discussion**

16:10 - 17:30	Type: Special symposium Title: Breakthroughs in immunotherapy for non-metastatic NSCLC Chair(s): Maarten Lambrecht, BE; Rafal Dziadziuszko, PL	Channel 1
16:10 - 16:10	DOI session	
16:10 - 16:25	Current status of (neo) adjuvant immunotherapy in early stage NSCLC <u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
16:25 - 16:40	Early stage NSCLC immunotherapy: Which biomarkers matter? <u>J. Brahmer</u> , Johns Hopkins Hospital, Baltimore, US	
16:40 - 16:55	Unresectable stage III NSCLC: PACIFIC and beyond <u>M. Lambrecht</u> , University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	
16:55 - 17:10	Dealing with comorbidities and toxicities in stage I-III NSCLC <u>R. Dziadziuszko</u> , Medical University of Gdansk, Gdansk, PL	
17:10 - 17:21	Q&A and live discussion <u>M. Lambrecht</u> , University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE	

16:10 - 17:30	Type: Special symposium Title: Unlocking precision medicine for metastatic prostate cancer Chair(s): Charles Ryan, US; Niven Mehra, BE	Channel 2
16:10 - 16:10	DOI session	
16:10 - 16:25	Challenges when using prostate biopsies for genomics <u>J. Mateo</u> , Vall d'Hebron University Hospital, Barcelona, ES	
16:25 - 16:40	Liquid biopsies: Challenges and opportunities for implementing into clinical practice <u>G. Attard</u> , UCL Cancer Institute - UCL - London's Global University, London, GB	
16:40 - 16:55	Emergence of neuroendocrine prostate cancer and the clinical relevance of tumour evolution <u>C. Ryan</u> , University of Minnesota, Minneapolis, US	
16:55 - 17:10	Selection strategies for immunotherapy in prostate cancer <u>S. Slovin</u> , Memorial Sloan Kettering Cancer Center, New York, US	
17:10 - 17:21	Q&A and live discussion	

16:10 - 17:30 **Type: Special symposium** **Channel 3**
Title: Management of melanoma in 2030: Toxicity, resistance, best biomarkers and next steps
 Chair(s): Olivier Michielin, CH; Caroline Robert, FR

16:10 - 16:10 **DOI session**

16:10 - 16:25 **Clinical and molecular characteristics of resistance to immunotherapy**

16:25 - 16:40 **Future combinations: Intralesional and other immunotherapy combinations**
O. Michielin, Centre Hospitalier Universitaire Vaudois - CHUV, Lausanne, CH

16:40 - 16:55 **Future strategies: Sequencing versus combinations in targeted and immune therapy**
P. Ascierto, Istituto Nazionale Tumori - IRCCS - Fondazione Pascale, Napoli, IT

16:55 - 17:10 **Management and learnings from toxicity?**
C. Robert, Institut Gustave Roussy, Villejuif, FR

17:10 - 17:21 **Q&A and live discussion**

16:10 - 17:30 **Type: Educational session** **Channel 4**
Title: Preclinical models for unanswered clinical questions
 Chair(s): Jacco van Rheenen, NL

16:10 - 16:10 **DOI session**

16:10 - 16:30 **Using humanised mice to study immune-cancer interactions**
A. Rongvaux, Fred Hutchinson Cancer Research Center, Seattle, US

16:30 - 16:50 **The role of stem cells in cancer prevention and therapies**
E. Batlle, Institute for Research in Biomedicine (IRB Barcelona), Barcelona, ES

16:50 - 17:10 **Intravital imaging for insights into cancer cell behaviour in real time**
J. Van Rheenen, Netherlands Cancer Institute/Antoni van Leeuwenhoek hospital (NKI-AVL), Amsterdam, NL

17:10 - 17:22 **Q&A and live discussion**

